ANALYSIS OF INFORMATION VALUE CHAINS FOR GOUT SELF-CARE MANAGEMENT by Russell, Maranda
University of Kentucky 
UKnowledge 
Theses and Dissertations--Communication Communication 
2020 
ANALYSIS OF INFORMATION VALUE CHAINS FOR GOUT SELF-
CARE MANAGEMENT 
Maranda Russell 
University of Kentucky, maranda.russell@uky.edu 
Author ORCID Identifier: 
https://orcid.org/0000-0001-6405-4807 
Digital Object Identifier: https://doi.org/10.13023/etd.2020.358 
Right click to open a feedback form in a new tab to let us know how this document benefits you. 
Recommended Citation 
Russell, Maranda, "ANALYSIS OF INFORMATION VALUE CHAINS FOR GOUT SELF-CARE MANAGEMENT" 
(2020). Theses and Dissertations--Communication. 96. 
https://uknowledge.uky.edu/comm_etds/96 
This Doctoral Dissertation is brought to you for free and open access by the Communication at UKnowledge. It has 
been accepted for inclusion in Theses and Dissertations--Communication by an authorized administrator of 
UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu. 
STUDENT AGREEMENT: 
I represent that my thesis or dissertation and abstract are my original work. Proper attribution 
has been given to all outside sources. I understand that I am solely responsible for obtaining 
any needed copyright permissions. I have obtained needed written permission statement(s) 
from the owner(s) of each third-party copyrighted matter to be included in my work, allowing 
electronic distribution (if such use is not permitted by the fair use doctrine) which will be 
submitted to UKnowledge as Additional File. 
I hereby grant to The University of Kentucky and its agents the irrevocable, non-exclusive, and 
royalty-free license to archive and make accessible my work in whole or in part in all forms of 
media, now or hereafter known. I agree that the document mentioned above may be made 
available immediately for worldwide access unless an embargo applies. 
I retain all other ownership rights to the copyright of my work. I also retain the right to use in 
future works (such as articles or books) all or part of my work. I understand that I am free to 
register the copyright to my work. 
REVIEW, APPROVAL AND ACCEPTANCE 
The document mentioned above has been reviewed and accepted by the student’s advisor, on 
behalf of the advisory committee, and by the Director of Graduate Studies (DGS), on behalf of 
the program; we verify that this is the final, approved version of the student’s thesis including all 
changes required by the advisory committee. The undersigned agree to abide by the statements 
above. 
Maranda Russell, Student 
Dr. Sujin Kim, Major Professor 
Dr. Anthony Limperos, Director of Graduate Studies 
ANALYSIS OF INFORMATION VALUE CHAINS FOR GOUT SELF-CARE
MANAGEMENT 
________________________________________ 
DISSERTATION 
________________________________________ 
A dissertation submitted in partial fulfillment of the 
requirements for the degree of Doctor of Philosophy in the College of Communication 
and Information at the University of Kentucky 
By 
Maranda Russell 
Lexington, Kentucky 
Director: Dr. Sujin Kim, Associate Professor of Information Science and Biomedical 
Informatics 
Lexington, Kentucky 
2020 
Copyright © Maranda Russell 2020 
https://orcid.org/0000-0001-6405-4807
     
 
 
 
 
 
 
 
ABSTRACT OF DISSERTATION 
 
 
 
ANALYSIS OF INFORMATION VALUE CHAINS FOR GOUT SELF-CARE 
MANAGEMENT 
 
 
This value chain analysis study sought to identify information needed by gout 
patients to successfully manage their disease, leading to a model for information extraction 
from patient health records. A scoping review was conducted to identify the types of 
information needed by gout patients. The findings of each included study were divided and 
analyzed according to the stages of the care delivery value chain. The results of the review 
were then used to create a gout information value chain as criteria for annotating the 
information deemed important for gout patients contained in publicly available patient 
education materials according to the stages of care delivery. The resulting annotations were 
used to develop a named entity recognition model capable of automatically labelling 
medical concepts from clinical notes by value chain stage. To identify concepts specifically 
relevant to gout patients, the concepts extracted from patient notes were used as candidate 
features in a phenotyping algorithm to identify concepts associated with gout flares. While 
this study was able to develop a model for identifying information relevant to gout flares, 
the findings suggest that there is information missing from patient education materials and 
their clinical notes that could be valuable to gout patients for self-management. 
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CHAPTER 1. INTRODUCTION 
The purpose of this study was to identify the information gout patients require to 
optimize their healthcare. Recent regulatory changes have made it impossible for health 
professionals to ignore health information technology, particularly electronic health record 
systems (EHRs) (Blavin, Ramos, Shah, & Devers, 2013). Studies have emerged indicating 
that these technologies can increase the ability of clinicians and patients to manage health 
care (Businger, et al., 2007). Initial studies on patient portals, a required feature of EHRs, 
have shown great potential for chronic disease management. These portals allow patients 
to access their health records through a secure website.  
Early research demonstrated that patients with this easy access to their health 
information are more involved in their health care and this involvement can lead to long 
term benefits, especially for low income patients (Lake Research Partners, 2010). 
However, as illustrated in later chapters, gout patients have thus far been unable to 
consistently leverage available information to adequately improve health outcomes. 
Though much research has been done on related topics, particularly regarding patient 
education for effective treatment options, what information is valuable to gout patients 
throughout the continuum of care remains largely unanswered. 
1.1 Background 
In 2012, results from the National Health Interview Survey (NHIS) indicated that 
approximately fifty percent of adults in the United States had at least one chronic 
condition. Of those, roughly half identified as having multiple chronic conditions (Ward, 
Schiller, & Goodman, 2014).  As life-long conditions, patients with chronic diseases tend 
to have multiple healthcare providers and higher consumption of health services (Centers 
for Disease Control and Prevention [CDC], 2009). 
This is especially true for gout, the most common type of inflammatory arthritis 
which affects up to 6 million Americans (Lawrence et al., 2008). The risk of developing 
gout increases with age. It is also associated with several common clinical (e.g. diuretics, 
low dose aspirin, hypertension, cardiovascular disease) (Wallace et al., 2004) and 
behavioral (e.g. consumption seafood and beef) (Choi, Liu, & Curhan, 2005) factors. 
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Further complicating matters, gout treatment requires two different medication tacks, one 
for the acute symptoms (anti-inflammatory drugs) that arise when the disease is not 
properly managed and one for chronic disease management (urate-lowering 
therapies[ULTs]) designed to prevent the deposition of monosodium urate crystals in joints 
Schlesinger, Dalbeth, & Perez-Ruiz, 2009).  
Despite being considered the best understood of the joint diseases and the only 
chronic arthritis with the potential to be ‘curable’, gout still often goes undiagnosed and 
sub-optimally treated (Doherty et al., 2012). There are myriad reasons for this, all of which 
can be traced back to a lack of appropriate information needed for education. The complex 
nature of gout requires self-management for optimal treatment which must include 
medications and lifestyle changes. This makes identifying information values throughout 
the care continuum critical to encourage patient engagement in self-care (Fields & 
Batterman, 2018). However, this endeavor is often unsuccessful because there is no 
established consensus among stakeholders as to the goals and means of patient education 
in the various stages of care (Doherty et al., 2012). 
1.2 Statement of Problem 
With an initial promise of government financial incentives and technical assistance, 
and the threat of fines and other penalties in the future, the U.S. healthcare system slowly 
but surely began adopting electronic health records (EHRs) (Adler-Milstein & Jha, 2017). 
However, the goal of the HITECH Act was never mere adoption of technologies. The 
central tenet of the Act is the improvement of healthcare through the “meaningful use” 
(MU) of certified EHRs. HITECH identifies multiple ways to improve the quality, safety, 
and efficiency of healthcare (Blavin, Ramos, Shah, & Devers, 2013). One such way is 
through patient engagement. In order to make well-informed decisions, patients must be 
active participants in the management of their healthcare. Research has demonstrated that 
failure to supply patients with adequate information can contribute to poor adherence to 
treatment (Stevenson, Cox, Britten, & Dunder, 2004). To ameliorate this, the MU 
component of the HITECH Act requires that EHRs include functionalities that allow 
patients to easily access their personal health records (PHRs) (Ahern, Woods, Lightowler, 
Finley, & Houston, 2011). PHRs can contain various types of information from multiple 
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sources. To facilitate access to these records, MU mandates that EHRs provide a patient 
portal that is designed to support the communication of accurate information between 
patients and healthcare providers. As the portal is linked directly to their electronic medical 
record (EMR), from the perspective of the patient the information is provided 
automatically and is more personalized than a generalized search for health information 
through the Internet (Arnold et al., 2013). 
 Though results have been mixed, the general consensus is that patient portals 
provide a secure means of accessing relevant health information that can lead to higher 
patient involvement and engagement. The potential beneficial health outcomes include 
increased adherence to treatment, knowledge and understanding, and patient satisfaction, 
all of which can lead to better clinical outcomes (Kruse, Argueta, Lopez, & Nair, 2015). 
Of course, patients must use the portal to reap these benefits.  Unfortunately, much of the 
initial research on patient engagement focused on deciding what patients could or should 
do rather than factors involved in actively engaging patients in their care. 
Such findings are particularly relevant to patients with rheumatic diseases. The 
chronic, life-long nature of this disease group generates a multitude of information unique 
to each patient that could aid in self-management of the disease and its symptoms. 
However, there is a paucity of research specifically looking at the effects of health 
information available via patient portals on treatment of rheumatic diseases.  The specific 
problem is that patients have access to an overwhelming amount of information without 
the knowledge or guidance to sort through, manage, or otherwise utilize said information 
to improve their health (Klerings, Weinhandl, &Thaler, 2015). A knowledge gap exists as 
to what personal health information is required to optimize care. 
Some publications offer generic educational interventions that might help increase 
knowledge and understanding of gout and its treatment options. However, these studies 
focus on one or two aspects of disease management and do not include PHRs, which 
contain information personalized to the patient. In contrast, this study will look across the 
entire care continuum. 
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1.3 Study Purpose 
Arthritis, a broad term generally used to refer to conditions in the rheumatic disease 
family, is considered to be one of the top ten chronic conditions. According to the 
European League against rheumatism (EULAR) (n.d.), rheumatism includes more than 
200 diseases which can affect the entire musculoskeletal system, making it the most 
prevalent group of diseases in the industrialized world. Treatment of these diseases is 
usually complex, involving medications and lifestyle changes to decrease pain and 
preserve mobility. As such, patients with these diseases must actively engage in self-
management to alleviate symptoms. Consequently, there is a plethora of information that 
patients must keep up with for effective self-care (Zhang et al., 2011). Much of this 
information is accessible via a PHR tethered to an EHR, making this an ideal disease group 
for cNLP research. On the other hand, each disease classed under this heading presents a 
unique set of opportunities and challenges. 
Gout is an inflammatory disease caused by high uric acid in the blood (Schlesinger, 
2004). It is the most prevalent form of inflammatory arthritis and continues to increase 
(Zhu, Pandya, & Choi, 2001). The most common symptom is gout flares which occur when 
uric acid crystalizes into needle-like formations within the joints (Suresh, 2005). 
Diagnostic codes have proven a poor source for flare identification in patients (Halpern, 
Fuldeore, Mody, Patel, & Mikuls, 2009). Furthermore, there is no standard definition for 
the symptom, leading researchers to search for better methods of identification using cNLP 
(Taylor et al., 2009).  
The purpose of this study was to use clinical natural language processing (cNLP) 
techniques to determine the prioritization of patient health information and explore ways 
that health information technologies can best be utilized to provide that information for 
gout patients. The study included gout patients with available data in the University of 
Kentucky Healthcare (UKHC) EHR system. 
The issues presented in this chapter highlight a fundamental problem with PHRs. 
In order to receive information, a user must first interact with the system. For various 
reasons, patients are not sufficiently motivated to engage with PHRs. This study sought to 
address this problem by performing a value chain analysis to identify the most relevant 
information that could be obtained through a patient's PHR and then using natural language 
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processing techniques to automatically extract information that patients could use to guide 
healthcare decisions. This is pertinent for several reasons. 
First, tethered and integrated PHRs are populated with information from EHRs 
which were designed to meet the needs of healthcare providers. The average patient neither 
needs nor understands all of this information (Wilson, 2009). Furthermore, studies have 
found that access to such an excess of information has the potential to cause information 
overload (Wynia & Dunn, 2010). 
Second, many studies focus on the effects of PHRs on health outcomes, with mixed 
results. Yet, the reasons for PHRs failing to produce the promised potential benefits largely 
remain a mystery (Giardina, Menon, Parrish, Sittig, & Singh, 2014). Health outcomes are 
the ultimate result of a complex set of processes. The value chain affords us the opportunity 
to view the entire continuum of care as a system to pinpoint where in the chain breakdowns 
are occurring.  
Finally, value chain analysis can show us where value is not being created and 
evaluate if the gap can be addressed with the information available or if there is a patient 
need that current functionalities of PHRs are not able to fulfill.  
1.4 Study Importance 
Patients have unprecedented access to their health records through patient portals. 
Such access is beneficial and necessary if patients are to be able to appropriately control 
their health care; however, the data is often offered without context or regard for individual 
background knowledge. This creates barriers to interpretation and optimal usage. This is 
especially troublesome for patients with chronic diseases who must deal with vast amounts 
of information over their lifespan. 
It is expected that gout patients might benefit the most from this study, as they will 
have direct, tangible output to aid them in managing their health. By researching the 
information necessary for patients to successfully deal with issues faced by gout patients, 
potential solutions may be discovered for providing information currently lacking, 
encouraging more patients to persist in the management of their health conditions. Several 
other stakeholder groups may also benefit from the results of this study on automatically 
extracting valuable information from patient records. Clinicians may leverage findings to 
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institute personalized education programs by adapting templated patient education 
materials that typically lack information that is relevant to specific patients. This study 
may also benefit healthcare organizations, adding tools for more effective patient care via 
HIT because better information filtering can be provided for smoother workflow, 
educational enrichment, increased productivity, higher satisfaction, and reduction of costs 
and other resources (Clarke et al., 2013). 
By understanding what information contributes to sustained engagement of patients 
in their care, leaders will be better equipped to understand the changes that are needed to 
further develop EHR systems. Lawmakers may also be encouraged to enact policy changes 
that continue to enable patients to access relevant health information, providing a platform 
for more efficient HIT tools and, in turn, paving the way for improved public health. These 
insights may also be helpful for creating strategies to close the health care gap by providing 
practical methods for incorporating information that can be used to minimize health 
disparities and target specific areas of inequity for engagement. Over time, these changes 
may impact an overall cultural change in the healthcare industry, providing an underlying 
foundation for patients to be better prepared for involvement in healthcare decision-
making. These findings may also equip gout patients with useful guidelines for topics of 
discussion with healthcare providers. Patients educated according to study findings may 
become social and community sources of information and support. Their perspectives may 
offer guidance to others navigating an often-stigmatized disease while stemming the 
perpetuation of misinformation that currently abounds. 
1.5 Research Questions 
Value chain research can identify where value is being or could potentially be 
created. In reflection of this, the research questions for this study were: 
RQ1: What are the major types of information required by gout patients according 
to the care delivery value chain? 
RQ2: What information can be identified by mapping online gout patient education 
materials to the value chain? 
RQ3: What gout information values can be identified from patient notes based on 
the value chain using cNLP techniques?  
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As there is no conclusive research for why gout patients are not getting necessary 
information, other research approaches may be too limiting. There are many layers and 
dimensions as to why gout patient outcomes remain suboptimal. A value chain analysis 
was used to try to uncover insights and develop a model for supplying gout patients with 
the best information for disease management at the most beneficial time in the care cycle. 
1.6 Research Design Overview 
This study was conducted in multiple phases, each with distinct output that feds 
into the next. In the first phase, a literature review using Porter’s care delivery value chain 
(CVDC) as a framework was performed. A value chain is a holistic approach that allows 
for looking at all stages of a process. As value is ultimately created and judged by patient 
well-being in healthcare, the CVDC essentially allows us to perform a needs assessment 
for patient information across the entire care continuum for gout. The information 
identified and categorized according to the stages of healthcare delivery served as the 
annotation guidelines for the second phase, where patient education materials were 
evaluated for information considered valuable to gout patients for managing the disease in 
each stage of care. Information chosen in this step was used to form our model for 
information extraction from clinical documents. Phase 3 saw the design and comparison 
of algorithms capable of identifying which factors included in this value chain were most 
predictive of gout flares. As the most common and often the first sign that gout is being 
poorly managed, information associated with and able to predict flares would be 
considered important and valuable (Suresh, 2005). More specific details about the design 
of the study are provided in chapter 3. 
1.7 Summary 
This study sought to understand what information helps gout patients engage in 
long-term self-management, using value chain analysis. As most previous work on gout 
patient information focuses on creating education and medication interventions for 
treatment, there is a knowledge gap as to other types of information that might aid in 
wellness goals, including what information is already available in EHRs that can be used 
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for this purpose. The results of this study may serve multiple stakeholders such as 
clinicians, healthcare policy makers, health IT developers, and most of all, gout patients.  
Four more chapters follow. Chapter 2 is a review of the literature on the theoretical 
framework and principal techniques used in this study. The primary topic discussed for the 
next chapter is the gap in the literature related to a value chain model for patients to 
optimally manage gout long-term and clarifies how this study will fill this gap. Chapter 3 
further discusses the research design and specific details of how the study was conducted. 
The remaining chapters focus on the output from the research conducted for this study. 
Results are reported in Chapter 4, followed by discussion and interpretation of the findings 
in Chapter 5. 
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CHAPTER 2. LITERATURE REVIEW 
2.1 Background 
It is widely acknowledged that the United States spends over twice as much as other 
developed nations on health care. From 2004-2006, roughly $1.8 trillion per year was spent 
on health care, about $6,000 per capita (Anderson & Frogner, 2008). By 2008, that number 
had risen to $7,681 per capita for a total of over $2.3 trillion and continues to rise. The rise 
in health care costs has exceeded the rate of inflation while seemingly having a negative 
correlation with the quality of U.S. health care (Kaiser Family Foundation, 2010). For all 
the money spent, the United States has essentially the same life expectancy and mortality 
rates as countries like Germany, Canada, and Japan, which spend far less (Murray & Frank, 
2010). This disparity between expenditures and outcomes has led to widespread analysis 
of the healthcare industry. These analyses have concluded that without some sort of major 
structural overhaul to reform healthcare, costs will continue to rise to an unsustainable 
degree (Council of Economic Advisors, 2009). This chapter will explore ways health 
information technology can turn the tide on those costs and/or offer more value for the 
money spent.  
General consensus seems to be that, along with spending the most money, the 
United States has the best research and development, the best professional training and 
development, and a myriad of other superiorities in the healthcare field. Unfortunately, 
these advantages do not add up to a superior health care system, at least when it comes to 
things like population longevity and quality of life. Because healthcare systems exist 
within societies having differing cultural expectations and values, quality indicators can 
be rather subjective, making it difficult to compare economic value with other countries. 
However, with the Institute of Medicine reporting almost 100,000 inpatient deaths and two 
million ambulatory patient injuries due to errors, it would be irresponsible to discount the 
experiences and opinions of patients and their families (Brailer, 2005).  
While the majority of businesses embraced technology-based information systems 
long ago, the medical field has been extremely reluctant to do so. This resistance continued 
in the face of numerous potential benefits until the government passed the Health 
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Technology for Economic and Clinical Health (HITECH) Act in 2009 (Blavin, Ramos, 
Shah, & Devers, 2013). This act provides monetary incentives to implement and use 
electronic health records to improve health care (Romano & Stafford, 2011).  
The National Academy of Science has long recognized that information technology 
is essential to the dual goals of improving health care quality while cutting costs (Adams 
& Corrigan, 2003). Despite the health care industries reluctance to adopt information 
technology, much research has been done on ways clinical decision support systems can 
be used to reduce cost at the individual patient level. There are a multitude of systems that 
can help clinicians make the best choices for their patients and reduce errors through the 
use of checks, reminders, and alerts. Electronic health records, specifically, further reduce 
redundancy and errors by integrating patient data from multiple sources. These tools have 
the power to eliminate duplicate or otherwise unneeded testing and treatments (Payne et 
al., 2012).  
Reducing expenses is only one side of the equation. If Americans were receiving 
equivalently superior health care to match the highly superior costs, there would not be 
such an issue. U.S health care needs to be safer, more patient-centered, more responsive, 
and much more cohesive. Research has shown that organizations that successfully manage 
costs do so through the use of information technology at the patient level and at the 
structural level to facilitate a more team like approach. Healthcare organizations 
accomplish this through technologies that allow patients to be more proactive in their care. 
This allows health care to take place in the patient’s home or another lower cost location 
when possible. Health information technologies also provide more efficient 
communication allowing health care workers access to experts at any distance and the 
ability to share data with such experts quickly for consultations (Payne et al., 2012). There 
are multiple other ways technology can and does benefit health care such as maintaining 
records and making billing easier. However, there are reasons the industry has not 
embraced technology for health care purposes.  
Cost reduction is the easiest way to prove a system's economic value. Dollar values 
can be placed on expenses that will be reduced over time and used to offset the cost to 
implement the new system. These numbers are based on estimates, which is risky, but is 
done in the business world all the time. Many healthcare organizations do not have the 
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capital to invest in an expensive system and wait for a return that may never materialize. 
The HITECH Act does mitigate this somewhat, but it only applies to certain systems.  
It is much harder to put a monetary value on better health and, in actuality, better 
patient health outcomes do not directly benefit a health care organization’s bottom line. 
Nor is there a financial return on investment for technology that facilitates those outcomes. 
Theoretically, better healthcare leads to repeat patronage and more patients. However, due 
to the current fee for use system, when an organization looks at its revenue, all it sees is 
less income from less testing and other services.  
Information technology is essential to reducing health care costs while 
simultaneously improving quality. However, their benefits are not guaranteed. An 
organization must carefully choose system designs and functionality when adopting a new 
system and then successfully implement with an eye toward improving workflow and 
operations.  
2.1.1 Personal Health Records 
In 2003, the Institute of Medicine (IOM) issued a report identifying the key features 
that an optimal electronic health records (EHR) system should have. Chief among them 
were that it provides knowledge and decision support to enhance patient care. To that end, 
the system should allow access of information to the proper users immediately. Two 
component systems considered integral to optimization are the electronic medical record 
(EMR) and the personal health record (PHR) (Tang, 2003). When PHRs are linked to an 
EHR in this manner, they are considered “tethered,” as the information comes directly 
from the patient's EMR. This connectedness has many potential benefits.  
Due to frequent usage for health and disease management, the majority of PHR 
research has focused on patients with chronic conditions (Bronwyn et al., 2018). In 2012, 
results from the National Health Interview Survey (NHIS) indicated that approximately 
fifty percent of adults in the United States had at least one chronic condition. Of those, 
roughly half identified as having multiple chronic conditions (Ward, Schiller, & Goodman, 
2014).  As life-long conditions, patients with chronic diseases tend to have multiple 
healthcare providers and higher consumption of health services (Centers for Disease 
Control and Prevention [CDC], 2009). Because PHRs provide patient access to 
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information along with tools for self-management and additional communication channels 
to healthcare providers, they are ideally situated to help with this process (Tenforde, Jain, 
& Hickner, 2011).  However, PHRs are not a panacea and still have room for improvement. 
Many patients are still reluctant to adopt PHRs. Current barriers to effective PHR usage 
include low perceived value and usability, privacy and security concerns (Dontje, Corser, 
& Holzmer, 2014), and low health and technology literacy, especially in elderly 
populations (Lober et al., 2006). Prior research has made great strides, but these and other 
complex issues still must be dealt with in order to optimize patient education and care, 
particularly for those with chronic conditions. 
2.1.2 Health Literacy 
Advances in information and communication technologies (ICT) have made it 
possible to store and access the large amounts of data necessary for PHRs. However, PHRs 
demand that patients be able to adequately access, understand, and use the provided 
information to make appropriate health decisions in order to reap these benefits, making 
health literacy (HL) essential to improving healthcare (Bronwyn, Rollo, Georgiou, 
Balandin, & Hill, 2018). This requires a diverse set of literacy skills (cumulatively referred 
to as health literacy (HL)) that enable a patient to complete multiple tasks that involve 
reading and calculation, such as reading prescription labels and measuring medication 
dosages (Nielsen-Bohlman, Panzer, & Kindig, 2004). Lower HL is not only associated 
with adverse health outcomes, but also, specifically, less active self-management (Dewalt, 
et al., 2004).  
In the case of musculoskeletal disorders, patients must have knowledge of their 
specific disease for optimal management and self-care. However, previous studies have 
demonstrated that many patients only know that they have arthritis and are unaware of any 
subtype (e.g. rheumatoid arthritis, osteoarthritis). Furthermore, patients often inaccurately 
self-report musculoskeletal diagnoses (e.g. gout, osteoporosis). While the diseases in this 
category require significant participation on the part of the patient for self-management, 
each has its own combination of medication and lifestyle intervention guidelines (Hill et 
al., 2015). This, coupled with the fact that most adults do not have the HL skills to 
accurately or consistently make use of health-related information, causes a disparity in the 
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self-management tasks patients are able to do and those that are required for optimal health 
outcomes (Kutner, et al., 2006). For gout patients specifically, health literacy is 
particularly low for medications, often leading to non-adherence. Encouragingly, patients 
seem to be aware of their knowledge gaps and want more information, especially about 
the whys and wherefores of treatment regimens (van Onna et al., 2015). 
2.1.3 cNLP Methods 
The HITECH Act of 2009 caused an upsurge in the adoption of electronic health 
records and researchers rapidly moved to take advantage of this data source (Blumenthal, 
2010). Early studies largely focused on usability (Ellsworth, Dziadzko, O’Horo, Farrell, 
Zhang, & Herasevich, 2017) or using structured data for risk prediction modeling 
(Goldstein, Navar, Pencina, & Ioannidis, 2017). However, the data that is most useful for 
documentation and communication is usually in an unstructured, free-text format (Jensen 
et al., 2017). Yet, clinical natural language processing (cNLP) techniques for information 
extraction (IE) remain underutilized for clinical and translational research (Wang et al., 
2018). Because the purpose of this study is to identify and examine the information 
contained in clinical notes, cNLP techniques of IE are the most appropriate choice. 
2.1.3.1 Pipelines/Algorithms 
A natural language processing pipeline is simply a chain of processes to complete 
a task where each subtask feeds into the next. In other words, the output from one process 
becomes the input for the one directly following it. Different algorithms can be applied to 
each component of the pipeline (Nadkarni, Ohno-Machado, & Chapman, 2011).  
In order to deal with the complexities inherent to rheumatic diseases, researchers 
have employed a variety of pipelines and algorithms sometimes within the same study. Lin 
et al. (2013) first used the clinical Text Analysis and Knowledge Extraction System to 
discover named entities with their accompanying concept unique identifier (CUI) from 
UMLS, assertion status, and context. The output was then fed into a pipeline that was 
designed to select optimal features using a three-step process comprising frequency cutoff, 
chi-squared, and correlation-based feature selection (CFS) which utilized the genetic 
algorithm. Erythrocyte sedimentation rate (ERS) and C-reactive protein (CRP) lab values 
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were then added to this output to create a data set for algorithm development which process 
utilized Weka to implement several classification algorithms: logistic regression, Naïve 
Bayes, Multilayer perceptron, and multiple Support Vector Machines (SVMs). The 
resulting models were then tested on a document set using 10-fold validation.  
In contrast, Love et al. (2011) used a more simplified approach to feature selection 
that is not detailed in the paper. The chosen predictor variables were extracted from clinical 
notes using mySQL queries. The random forest method was then used to train three 
algorithms for testing.  
Most studies fall somewhere in between these two, though most NLP studies of 
rheumatic diseases are fairly complex and detailed. While the paper only obliquely explains 
that a dictionary-based method was used for NLP, it does explicitly state the several ML 
algorithms that were tested: naïve Bayes, SVM, neural network, and decision tree (Zheng 
et al., 2014). 
As demonstrated by these example works, while there is variation in specific 
pipelines and algorithms, rheumatology studies employing NLP tend to rely on dictionary-
based methods for named entity recognition and supervised ML techniques. Likely due to 
this, researchers also tend to use similar measurements for performance evaluation of 
models. In contrast, our entity extraction pipeline included a sentence splitter, context 
sensitive tokenizer, part-of-speech tagger, section identifier (patient history, family history, 
etc.), a named entity recognition (ner) module created using the ML algorithms and 
terminology/ontology mapping from UMLS. 
2.2 Theoretical Framework 
The concept of a value chain was first introduced by Michael Porter as the set of 
activities that an industry specific firm uses to create value in the market. Value was 
originally defined as the amount consumers are willing to pay for a product or service. 
Thus, it would be measured by revenue generated. In order to encompass total value, the 
framework employs a process view of organizations in which firms are conceptualized as 
systems composed of subsystems, each with their own sets of inputs, transformation 
processes, and outputs (Porter, 1985). 
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2.3 Overview 
Originally applied to a manufacturing context, Porter theorized the myriad activities 
that organizations must perform in order to transform inputs into outputs as primary or 
secondary activities. Primary activities are those considered essential for the creation of 
value and competitive advantage. Secondary activities are those undertaken to support and 
improve primary activities. Value activities are identified and classed according to 
technologic and strategic distinction. Thus, Porter proposed that primary activities consist 
of five generic components (inbound logistics, operations, outbound logistics, marketing 
and sales, and service) with the idea that every discrete activity that a firm engages in can 
be categorized for the purpose of identifying areas of competitive advantage. Support 
activities can be similarly classified into four broad categories (procurement, infrastructure, 
technological development, and human resources (HR) management) with the proposition 
that increased efficiency in any of the four will lead to beneficial results in at least one of 
the primary components. All activities contribute to a firm’s profit margin, which is 
determined by the extent that value exceeds costs (Porter, 1985). This is considered the 
traditional, physical value chain model. 
2.3.1 Healthcare Applications 
Porter (1985) originally posited that his generic value chain could be used to compare 
and differentiate competing businesses. While the value added by each category may vary 
by industry, each component was considered integral to some extent in distinguishing 
competitive advantage. Therefore, though the model could be applied to any industry, 
including services, it was only relevant at the business unit level. That is, value chain 
analysis should be performed on competing firms within the same industry. However, 
much work has been done to expand the model in the intervening decades, much of it by 
Porter himself. 
Porter’s (1985) original assertion that industry-level and sector-wide value chains 
would be too broad to parse out sources of competitive advantage did not deter 
researchers. Buttigieg, Schuetz, and Bezzina (2016) employed qualitative research 
methods to create and compare value chains for public and private healthcare sectors in 
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Malta. This analysis was used to evaluate the feasibility of recommendations for 
maximizing the provision of healthcare services.  
Porter (1985) similarly objected to applying the value chain to subsets of a 
business. Segmenting and analyzing a firm according to lines such as products or 
geography would not be useful. Due to the interrelated nature of an organization’s 
subsets, it would not be possible to fully understand the value chain without the view 
provided by the firm-level value chain. Nevertheless, researchers have continued to do 
so, especially in the realm of health information. Frisse (1999) believed that the 
framework provided a lens for evaluating the value of information technology (IT) for 
various stakeholders. Through this lens, the study factored in the experiences of providers 
and patients to identify the support activities made possible by IT. These activities were 
then compared to analogous activities in other industries to demonstrate how 
improvements accomplished using IT, such as “just-in-time” logistics, can be applied to 
healthcare. Fetterolf (2006) adapted the value chain model to create a “disease 
management” value chain. In this study, knowledge distribution was the ultimate goal 
with the model demonstrating the flow of processes required to do so, starting with the 
acquisition of raw data. This type of model could help demonstrate the value in creating 
comprehensive disease management (or similar) programs throughout an organization. 
Finally, Theyel (2017) presents a bit of a conundrum with a value chain for biomedical 
products. The article advocates and proposes technologies to track products throughout 
their lifespan in order to identify areas within the value chain for improvement and 
innovation. Though specific to certain products, these products are not tied to any 
particular firm. The complete value chain for biomedical products, such as drugs and 
medical devices, can span multiple industries and encompass numerous organizations and 
could potentially be considered a global value chain. Research in these areas continues 
today with no clearly accepted value chain emerging. 
The above examples highlight the complexities inherent in healthcare and 
demonstrate potential applications of the value chain to identify ways to successfully 
utilize information technologies to address that complexity. There is still much work to 
be done, not the least of which is validating previously proposed models. The Wharton 
School of business developed a value chain representative of a conventional approach to 
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value chain analysis which involves mapping the activities involved in delivering a good 
or service (Burns, 2010). From a patient perspective, however, lab tests by themselves 
have no value, even though they still must pay for them. A tests value is in being able to 
connect the patient to needed treatment. Even treatment itself is not the ultimate goal, but 
patient well-being. Thus, to analyze value in healthcare delivery, the focus must shift 
from products and services provided to outcomes achieved. In this manner, value for 
health outcomes cannot be attributed to a specific intervention at one point in time but 
must be redefined as the total outcomes achieved per costs over the total cycle of care. 
According to Kim, Farmer, and Porter (2013), primary value is created by delivering care 
for specific medical conditions and they created the care delivery value chain (CDVC), 
which emphasizes the interrelated nature of healthcare and highlights the need for 
integrated care.  
Figure 2.1: Adapted Care Delivery Value Chain 
  
 
The CDVC is divided into six categories of primary activities. The initial stage of 
the value chain (preventing/monitoring) contains information pertinent to the pre-
diagnosis phase including critical signs and symptoms and risk factors for the disease. 
For gout, this stage is more accurately called screening. If such factors are present in a 
patient, this phase is followed by Diagnosing, where diagnostics exams and tests are 
performed. In the case of a confirmatory diagnosis, a patient moves into the preparing 
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stage where they are given information for treatment options. The chosen treatment is 
then administered in the intervening stage. For gout, there is no recovering/rehabbing 
stage in the traditional sense. Instead, this phase is dedicated to fine-tuning therapies to 
minimize side effects while keeping gout symptoms in remission. Monitoring and 
managing acute gout attacks and other complications is continuous and constitutes the 
final stage of the value chain. Figure 2.1 shows the adapted model that will be used as a 
framework for this study. 
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CHAPTER 3. METHODS 
The purpose of this chapter is to introduce the research methodology for this 
exploratory study regarding what information gout patients require to optimize self-
management.  
This approach allowed for a deeper understanding of patient experiences treating 
and managing gout and provided a way to develop a conceptual framework from the data 
in order to understand what information is available to motivate patients to engage in long-
term self-care. 
The applicability of value chain analysis and natural language processing 
techniques for this study are discussed in-depth in this chapter. The research plan, including 
the methodology, study participants, procedures, and analysis methods are also primary 
components of this chapter. 
3.1.1 Research Questions 
This study sought to build a model in order to answer the following questions: 
RQ1: What are the major types of information required by gout patients according 
to the care delivery value chain? 
RQ2: What information can be identified by mapping online gout patient education 
materials to the value chain? 
RQ3: What gout information values can be identified from patient notes based on the 
value chain using cNLP techniques? 
3.2 Selected Methodology 
 This study was conducted using value chain analysis and cNLP techniques with a 
broad aim to investigate whether the value chain is suitable for application to patient health 
information, specifically as a tool to optimize gout management. This research study 
sought to develop a model using ML techniques that could automatically extract pertinent 
information from clinical notes. Using Porter’s care delivery value chain, emphasis was 
placed on the stages at which information is most useful.   
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Porter and Teisburg (2006) are adamant that value is a measure of health outcomes.  
Gout flares are the most common outcome associated with poorly controlled gout and, as 
such, are the best proxy for evaluating the value of the information provided by the 
proposed model.  Thus, this study will examine the relationship between the information 
extracted by our model from clinical notes and adequacy of disease control. 
Due to the reasons mentioned above, identifying gout flares presents a challenge that 
retrospective claims analysis alone has not been able to meet. Because the goals of this 
study include using NLP techniques to further improve this endeavor, algorithms from 
previous studies that have been used with some success were adapted for defining clinical 
surrogates for use in identifying gout flares using only structured claims codes for 
comparison to our NLP model. Hence, gout flare episodes were identified and counted 
using one of two criteria that utilize coded data available in the EHR. A gout diagnosis and 
at least one of the following within seven days: a medication commonly prescribed for 
acute gout attacks, a joint radiograph, magnetic resonance imaging of an extremity, joint 
aspiration, joint fluid evaluation, or serum urate testing qualified as a gout flare (Halpern 
et al., 2009). A diagnosis of joint pain accompanied by a prescription for colchicine within 
seven days would also qualify (Wu et al., 2012). When used together, these two algorithms 
have demonstrated high positive predictive value (PPV > 0.8) (Zheng et al., 2014). 
3.3 Phase One Methods 
3.3.1 Aim 
Despite extensive research on patient education and counseling, there is relatively 
little on the overall information requirements of healthcare consumers, especially 
regarding gout. A preliminary search yielded no systematic reviews of the comprehensive 
health information needs for those impacted by gout. Given the increasing availability of 
health information and its sources, an extensive review of the current literature seemed 
pertinent to identify relevant topics and key information for aiding in the management of 
gout. Therefore, this review aimed to identify and examine the available research 
concerning or related to the information needs of gout patients. 
Therefore, a literature review was conducted using a scoping protocol. As the aim 
was not to evaluate the quality of the available literature, but rather the span of the 
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subject knowledge and the extent of specific topic focus for a field that had not been 
widely reviewed, this seemed the ideal methodological approach (Khalil et al., 2016) 
3.3.2 Inclusion Criteria 
In accordance with previously published methods for scoping reviews (Peters et 
al., 2015), the eligibility criteria for this review included any study where health 
information was specifically or tangentially mentioned concerning patients seeking or 
receiving information for the purpose of treating and managing gout. Due to gout being 
rare in children, the minimum age for patient inclusion was 18 years. Studies that did not 
clearly distinguish between patients and non-clinical health information consumers 
seeking to aid patients, such as family members, were also included. 
 Only lay consumers of health information were of interest to the study. Thus, 
studies that only investigated the role of professionals, such as healthcare or information 
providers, in the use of gout information were excluded. Furthermore, studies 
investigating non-health related information were excluded, even if such studies explored 
or measured the health effects related to searching for, receiving, or otherwise utilizing 
that information in the context of gout treatment and management. Only studies 
published in the English language were included, however, there were no restrictions 
based on geographic area or publication date. 
3.3.3 Search Strategy 
The scoping review was conducted by performing a comprehensive search for 
relevant literature using online databases. The research team included a library and 
information science expert that was involved in the development and refinement of the 
search strategy. The strategy was designed to adhere closely to the previously mentioned 
approach (Khalil et al., 2016). The resulting search strategy steps and the information 
sources utilized are detailed below. 
1. The initial search utilized only two databases believed to be able to provide the 
broadest overview of results pertinent to the scoping review topic. PubMed was 
chosen for its range of biomedical literature and CINAHL was included for 
perspectives from the allied health professions. The results were used to modify 
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the initial search terms for the purpose of expanding the range of relevant results. 
Additional terms identified in this manner were used to create the final search 
strategy: ("gout"[MeSH Terms] OR "gout"[All Fields]) AND ("patients"[MeSH 
Terms] OR "patients"[All Fields] OR "patient"[All Fields]) AND ("Information 
(Basel)"[Journal] OR "information"[All Fields]). 
2. A targeted search was conducted on the basis of the expanded vocabulary using 
five databases chosen to provide a complete picture of gout patient information 
requirements. Boolean operators and controlled vocabulary terms were used 
whenever possible. MeSH (Medical Subject Headings) terms found in PubMed 
formed the base for controlled vocabulary equivalencies found in the other 
electronic databases. CINAHL and their Major Headings (MH terms) were 
included in this search, as well. In addition, ERIC was searched using Descriptors 
(DE terms) for patient education research and PychINFO was searched using 
Index Terms for psychology-related literature. Scopus, which does not provide a 
controlled vocabulary search option, was included for a comprehensive review of 
available research literature.  
3. A gray literature search was conducted through WorldCat using the keywords and 
phrases that had been mapped to the controlled vocabularies for the final search 
strategy. Results were limited to the English language. 
4. The reference lists of all literature that met the inclusion criteria were reviewed 
for any additional studies related to the topic. In turn, the references of each 
additional relevant article were reviewed until saturation was reached. 
3.3.4 Study Selection 
All search results were imported into EndNote, where duplicates were removed 
before a two-step screening process was conducted to determine inclusion eligibility. 
During the first stage of screening, only the titles and abstracts were read. Articles 
determined to be relevant on the basis of this screening were then read in full to assess 
their ultimate inclusion or exclusion. The diagram for this process is presented in figure 
3.1 below. 
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Figure 3.1: Flow chart of study selection process. 
 
3.3.5 Data Extraction 
The final included articles were examined according to scoping review protocol 
(Khalil et al., 2016) and summarized in tabular format according to the stage of the care 
cycle the information would be most relevant. Publication details (author surnames, 
publication date), research objectives, methods, key findings, and conclusions drawn are 
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summarized for each study. The information involved in each study was also categorized 
according to patient need to provide additional context in aid of the aims of this review. 
3.3.6 Data Synthesis 
This study utilized both tabular and narrative approaches to integrate and 
synthesize data. The great variation in research design, focus, and quality between the 
included studies lent itself to the use of narrative integration for data synthesis. Thus, 
while tables were used to summarize the extracted data, narratives were used to evaluate 
the data and explain key findings. 
3.4 Phase Two Methods 
3.4.1 Gout Data Mart 
Our research first identified potential gout cases by utilizing two distinct types of 
EHR data. First, we searched the structured data from the EHR at the University of 
Kentucky Healthcare Systems (UKHC). UKHC is a large academic tertiary referral center 
which contains the detailed records of  >1 million patients since 2004 stored in an electronic 
data warehouse with a relational database structure readily available for research purposes. 
We then screened the structured EHR data to create a highly sensitive dataset containing 
all potential patients with gout. The gout data mart consists of all patients with ≥1 ICD-9/-
10 code for gout (274.9, M10.0, M10.2, M10.3, M10.4, M10.9). Patients aged <18 years 
at the time of the first ICD-9/-10 code were excluded. Our preliminary search of UKHC’s 
EHRs yielded 5590 potential patients. This study was approved by the University of 
Kentucky Internal Review Board. 
3.4.2 Potential Gout Features 
Based on a preliminary literature reviewed, we created a comprehensive list of 
variable types for the gout flare phenotyping algorithm classified by the six divisions of 
the CDVC. Whenever possible, the list of terms was then converted to structured data 
readily available from our EHRs. Along with diagnostic codes as forms of ICD-9 or ICD 
10 claims codes, the codes include current procedural terminology codes (CPT) for 
procedural claims, national drug codes (NDC) for electronic medication prescriptions, and 
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Logical Observation Identifiers Names and Codes (LOINC) for laboratory tests. In 
addition, encounter records further identified dates of outpatient visits and inpatient stays. 
For unstructured EHR data, we obtained narrative data from all types of commonly 
available clinical notes. These included outpatient notes, rheumatology notes, discharge 
summaries, radiology, pathology reports, etc. For our purposes, a note is defined as any 
type of healthcare narrative which contained more than 500 characters. Pre-processed 
narrative data was analyzed with CLAMP cNLP software to extract clinical variables at 
the patient level for patients with more than 2 notes (~4000) to ensure they have enough 
documentation for classification. 
The entity extraction pipeline included a sentence splitter, context sensitive 
tokenizer, part-of-speech tagger, section identifier (patient history, family history, etc.), a 
named entity recognition (NER) module created using ML algorithms (Brown clustering, 
word embedding, etc.) and terminology/ontology mapping from UMLS. Thus, this pipeline 
was able to provide us with all of the information needed to further classify extracted 
concepts according to our value chain. For example, a condition extracted from the family 
history section of a document and marked as screening could be easily identified and 
included under the family history grouping of the screening/preventing stage of the value 
chain. 
3.4.3 Concept Collection 
Text articles describing gout were identified from publicly available knowledge 
sources (Wikipedia, Medscape (eMedicine), Mayo Clinic, MedlinePlus, the American 
College of Rheumatology (ACR), WebMD, and Up-to-Date). Researchers then used the 
gout value chain above as criteria for annotating the information deemed important for gout 
patients contained in each article according to the stages of care delivery. The annotated 
documents were used with the previously mentioned machine learning algorithms to create 
a named entity recognition model; however, the low number of articles included in this 
study (N=7) did not provide enough data to produce a model capable of reliably extracting 
the desired information from future documents. Therefore, after applying the poor 
performing model to the total set of articles, the extracted terms were used to develop a 
keyword dictionary. The output from this model provided us with a list of 494 terms that 
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could be used as a beta dictionary. The list was reviewed and revised to exclude overly 
generic (e.g. symptoms, effects) and non-useful terms (e.g. and, no). The resulting 450 
terms made up the final dictionary. This dictionary was then used in a pipeline as the named 
entity recognition module and applied to the same seven text articles to label the keywords 
founds. the resulting annotations were used with the same ML algorithms to create a much 
better model (Table 3.1). Terms were not case sensitive, and stemming was used to ensure 
variations of terms (such as different tenses or plurals) were included as much as possible. 
Both models were created using 5-fold cross-validation. 
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Table 3.1: Summarized results of 5-fold for gout value chain model. 
Summarized results of n-fold:         
correct predict gold P R F1 semantic 
72 84 85 0.857 0.847 0.852 Recovering 
57 62 109 0.919 0.523 0.667 Screening 
113 130 180 0.869 0.628 0.729 Diagnosing 
194 214 248 0.907 0.782 0.84 Intervening 
28 33 53 0.848 0.528 0.651 Preparing 
206 237 322 0.869 0.64 0.737 Monitoring 
 
3.4.4 Data Processing 
The final ‘gout value chain’ model was used to process all of the available clinical 
notes (310,519) for our gout cohort. Each mention of a concept per care phase was counted 
at the patient level. Because terms and their associated CUIs could appear labeled as more 
than one phase of the value chain, the CUIs for each extracted term were first aggregated 
by CDVC phase before occurrences were counted for each patient using a Perl script. For 
example, a symptom might be labeled diagnosing if it serves as diagnostic criteria for the 
disease or intervening if it is a side effect of a medication used to treat the disease. It could 
also be included in any of the other phases depending on the context in which it was used 
in the clinical note. Therefore, multiple instances of the CUI in the screening phase are 
aggregated and counted as ‘symptom CUI; screening’. The same concept appearing in 
other phases would be similarly aggregated and counted according to the number of times 
it appears for each patient with the associated phase’s label. These methods allowed for an 
easier comparison of NLP concepts extracted from patient education materials versus 
patient notes in terms of frequency, value chain stage, etc. 
3.5 Phase Three Methods 
3.5.1 Algorithm Training and Evaluation 
This study utilized a modified version of the surrogate-assisted feature extraction 
(SAFE) procedure outlined by Yu, et al. (2016). In order to train and evaluate algorithms 
to predict gout flares, this study utilized an available R package (PheCAP) that allows the 
28 
 
use of various classification methods. Using gout flares as the outcome variable, the 
PheCAP algorithm allowed us to identify which of our candidate features are most closely 
associated with flares at each stage of care delivery. 
 In addition to NLP concepts extracted from patient notes in the previous stage, we 
included frequency of codified data readily extracted from structured EHR data using 
MySQL as candidate features. These features include the phenotype for gout, competing 
diagnoses (such as rheumatoid arthritis), and medications (allopurinol, colchicine, 
febuxostat) that were determined by our clinical domain expert to be relevant to the target 
phenotype. The identified terms and concepts were then mapped to their associated 
diagnosis (ICD-9/10) and drug codes (NDC) and counted for each patient. We also counted 
the total number of unique billing codes (ICD), the total number of healthcare visits, and 
the total number of clinical documents per patient as potential measures of patient 
healthcare utilization to round out our candidate feature set. 
Gout flares were identified and counted using an adapted version of a previously 
published algorithm (Zheng et al., 2014). Using a Perl script, patients in our cohort were 
classified as having a flare if they had either a diagnosis code for gout in the system (ICD-
9: 274.xx; ICD-10: M10.0x, M10.1x, M10.2x , M10.3x, M10.4x, M10.9x) followed by at 
least one code for any medication (colchicine, nonsteroidal anti-inflammatory drugs 
(NSAIDs), corticosteroids) or procedure ( radiograph of a joint,  magnetic resonance 
imaging (mri) for any part of an extremity, joint aspiration, microscopic examination of 
joint fluid, urate testing) commonly prescribed for gout flares within seven days or a 
medical claim with a diagnosis code for joint pain (ICD-9:719.4x; ICD-10: M25.5x) 
followed by a code for colchicine within seven days. Consistent with prior studies, care for 
gout flares is expected to last for thirty days. Therefore, any codes indicating repeated flares 
within that time frame were counted as one flare, with the date associated with the first 
applicable diagnosis code being considered the flare start date. 
PheCAP relies on surrogate variables to act as “silver standard labels”. These are 
features that are believed to be highly predictive of textbook cases of a condition. For this 
study, surrogate variables were chosen using concepts identified as priority in our gout 
value chain. For instance, any concepts identified as specifying or ordering labs or tests 
will be used as surrogate variables for the diagnosing stage. This applies to both the NLP 
29 
 
concepts extracted from clinical documents and the structured codes identified as candidate 
features. These features were then used as response variables to choose potential features 
using penalized logistic regression for final algorithm training. In this manner, PheCAP 
provides an automated method for reducing uninformative variables. 
3.5.2 Metrics 
The selected features were then used to train models for each care stage using adaptive 
lasso penalized regression (ALASSO). The performance of each model was evaluated and 
compared using the area under the receiver operator characteristic (ROC) curve (AUC) 
along with false positive rate (FPR), true positive rate (TPR), positive predictive value 
(PPV), negative predictive value (NPR), and F1 scores. 
3.5.3 Summary 
This study uses several novel approaches to answer the research questions. First, in 
order to identify the types of information needed by gout patients, this is the first 
application of the value chain to patient information and the first to apply the care delivery 
value chain to gout. It is also the first to use a scoping review of previous research to 
construct the value chain.  Second, no previous studies using patient education materials to 
create a named entity recognition model were found. Using the stages of the value chain as 
named entities gives a framework for comparing the information found in patient education 
materials and patient clinical notes. The use of an NLP pipeline featuring the created NER 
model to identify information mapped to each stage of the care delivery chain allows for a 
type of automated content analysis. Third, this is the first study to use PheCAP as a 
prediction model for a health outcome rather than a disease. Whereas the value chain 
enables the identification of medical concepts over the entire continuum of care, which 
necessarily includes comorbidities and other risk factors which must be managed along 
with gout for optimal care, PheCap was utilized in this manner to identify information in 
clinical notes that could be considered more specifically associated with gout at each stage 
of care. The innovations used in this study were designed to help determine the information 
patients need and what they currently have access to. 
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CHAPTER 4. RESULTS 
This chapter contains the results of the value chain methodology study to answer the 
research questions: 
RQ1: What are the major types of information required by gout patients according 
to the care delivery value chain? 
RQ2: What information can be identified by mapping online gout patient education 
materials to the value chain? 
RQ3: What gout information values can be identified from patient notes based on the 
value chain using cNLP techniques?  
This chapter also includes discussion on how the analysis ties back to the research 
questions. Additionally, this chapter includes sample demographics, using tables to 
complement the summary. The process used to analyze the model is described in detail in 
this chapter. Included in this chapter are tables and other graphic representations used to 
present detailed theme data. 
4.1 Phase One Results 
4.1.1 Study Selection 
Overall, 1100 records were retrieved using the outlined search strategy. More 
specifically for each of the five databases, Scopus yielded the most results (n=487), 
followed by PubMed (n=297), then CINAHL (n=122), with ERIC (n=1) and PsycINFO 
(n=11) both producing far fewer results. WorldCat produced an additional 182 results. 
4.1.2 Study Characteristics 
All of the included studies were published during the 21st century, with the vast 
majority having a publication date in the current decade. Much of the literature were 
themselves literature reviews (n=13). The studies were predominately qualitative (n=17) 
with many of the more quantitative studies also including and analyzing qualitative data. 
One study did not discuss methodology. 
Well over half of the included studies with a focus on information pertaining to 
treatment, either alone or with other topics. Only the screening/preventing phase did not 
contain any articles regarding gout treatment information. In this category, Doherty et al. 
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(2012) and Richardson et al. (2015) both focused solely on information regarding 
pathophysiology. Most of the studies included several types of information, with 
information about treatment appearing the most often by itself in studies (n=9), especially 
in articles classed in the intervening stage. 
Included studies were subsequently divided into 6 groups according to the stage 
of the care delivery cycle their research most closely pertained to: screening (n=2), 
diagnosing (n=1), preparing (n=7), intervening (n=11), recovering (n=5), and monitoring 
(n=13). A study could be included in more than one group if it contained separate 
findings and conclusions relevant to more than one stage of care. 
4.1.3 Screening 
Although containing information pertinent to the pre-diagnosis phase of gout, 
neither study categorized in this stage of care specifically focused on screening. Table 4.1 
shows the results for this stage. Richardson et al. (2015) was a qualitative study of gout 
knowledge in female gout patients, while Doherty et al. (2012) was a literature review 
searching Medline with general gout terms along with more specific phrases relating to 
the treatment and management of the disease. 
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Table 4.1: Preventing/Screening literature results 
Publication Objective Methods Findings 
Information 
Type 
Conclusion 
Doherty, et al. (2012) 
Identify and address 
why a 'curable' 
disease is so poorly 
managed. 
Literature review 
searched the Medline 
database for articles 
published in English 
language using the 
search terms ‘gout’, 
‘hyperuricaemia’, 
‘hyperuricemia’, 
‘tophi’ and 
‘monosodium urate’ 
published after 1 
January 1980, 
searched keywords 
'therapy', 
'management', 'cure', 
and 'treatment' alone 
and with the previous 
terms, other materials 
judged relevant. 
Perception of gout as 
benign, humorous, 
self-inflicted disease. 
pathophysiology 
Patients need to 
understand the 
genetic and other 
risk factors of the 
disease. 
Richardson, et al. 
(2015) 
Explore and better 
understand the 
experience women 
with gout. 
Semi-structured 
interviews of female 
gout patients using a 
narrative approach 
No knowledge of 
gout before 
diagnosis, inability to 
find information 
relevant to women. 
pathophysiology 
Diagnosis is likely 
to be missed due to 
lack of knowledge 
about gout in 
women and its 
perception as a 
man's disease. 
 
4.1.4 Diagnosing 
The sole article concerned with information pertaining to gout diagnosis was 
included in a journal supplement is displayed in table 4.2. Perez-Ruiz (2009) reads like 
material for gout education that is mainly concerned with treating and curing gout and 
contains no information about methodology. Any information related to other phases of 
care is included as a means of providing understanding and support for the targeted 
treatment recommendation. 
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Table 4.2: Diagnosis stage literature review results 
Publication Objective Methods Findings 
Information 
Type 
Conclusion 
Perez-Ruiz (2009) 
Review practices for 
long-term gout 
management 
w/emphasis on MSU 
crystals in 
pathogenesis and 
treating to target 
SUA level. 
No explicit 
methodology. 
Patients need to 
understand the role of 
MSU crystal 
observation for 
definitive diagnosis and 
the need for long term 
therapy to eradicate 
these crystals. 
labs, 
pathophysiology
, treatment 
Patients need to be 
educated about 
diagnosis, the 
disease, and their 
contribution in 
long term 
treatment, 
 
4.1.5 Preparing 
The studies featured in this group (n=7) displayed the greatest variety in topics 
with all studies featuring <2 types of information as recorded in table 4.3. Lack of 
information and knowledge relating to gout pathophysiology was highlighted in all 
studies concerning patient education. Zhang et al. (2011) was the only quantitative study. 
While the qualitative studies were designed to elicit feedback from patients through 
interviews for the purpose of thematic analysis to aid understanding about gout 
perceptions and knowledge, Zhang et al. (2011) aimed to create an instrument that could 
evaluate such knowledge. Harrold et al. (2012) highlights that knowledge gaps are not 
due to a lack of desire for information on the part of the patient and Chandratre et al. 
(2015) specifies that patients want more of this type of information from their healthcare 
providers. Patients also express a desire for more time with healthcare providers with 
Khanna et al. (2012) specifying that patients want healthcare providers to spend more 
time explaining the disease progression in particular. There is also a general lack of 
knowledge concerning treatment options, especially urate-lowering therapies (ULTs).  
Lindsay et al. (2011) found a general perception among men that gout is a disease the 
must be simply endured. Similarly, Spencer et al. (2012) found that patients are unaware 
of the existence of allopurinol, a urate-lowering drug (ULD) that can prevent acute gout 
attacks. Moreover, according to Perez-Ruiz (2009) patients are unaware that ULTs 
commonly cause gout flares upon treatment initiation and have no knowledge of 
prophylactic therapy as an option to reduce this side effect. 
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Table 4.3: Preparing stage literature review results 
Publication Objective 
Methods Findings 
Information 
Type Conclusion 
Lindsay, et al. (2011) 
Explore the 
experience and 
attitudes of men 
with gout, 
especially those 
affecting outcomes 
w/emphasis on 
barriers to urate-
lowering therapy. 
Qualitative 
grounded theory 
interviews of 11 
men with gout. 
Categorized by 
themes using 
NVivo. 
Lack of understanding of 
pain severity, disease 
progression, disease 
mechanisms and causes of 
attacks (model of gout). 
Lack of knowledge about 
long term treatment. 
Perception of gout as 
something that must be 
endured.  
disease 
progression, 
pathophysiology  
Patients need a 
"pathophysiologic 
model of gout" 
that aids 
understanding and 
destigmatization.  
Khanna, et al. (2012) 
Identify conceptual 
gaps for patients 
that lead to poorly 
controlled gout. 
In-depth focus 
groups. 
"1) Patients did not have a 
clear understanding of the 
natural history of gout; 2) 
patients did not realize 
that recurrent acute flares 
resulted in chronic joint 
damage; 3) there was lack 
of knowledge regarding 
treatment options and 
duration of therapy for 
acute and chronic gout; 4) 
patients felt that 
physicians did not spend 
enough time explaining 
the progression, i.e. 
natural history of the 
disease and its long-term 
effects; 5)  patients did not 
grasp the need for chronic 
ULT to avoid 
complications and 
disability; and 6) patients 
were not aware of 
treatment goals for 
hyperuricemia, as evident 
by adherence to their gout 
medications." 
pathophysiology, 
disease 
progression, 
treatment, labs 
These are the key 
variables that need 
targeted in patient 
education 
resources. 
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Table 4.3 (continued) 
Zhang, et al. (2011) 
Design and test a 
survey to evaluate 
patient gout-
related knowledge 
and identify targets 
for patient 
education. 
Survey of gout 
knowledge in 3 
hospitals. 
Most patients know about 
too much uric acid in the 
blood but are unaware of 
actual crystals in joints. 
Poor knowledge of 
optimum SUA levels and 
duration of use for SUA 
lowering drugs. 
pathophysiology, 
disease 
progression, 
treatment, labs 
Need to design 
more effective 
educational 
materials similar 
to those for 
diabetes. 
Spencer, et al. (2012) 
Explore patient 
and provider 
perceptions of gout 
to improve 
management 
practices. 
Semi-structured 
interviews of gout 
patients between 
age 30 and 100 
analyzed using a 
grounded theory 
approach. 
Patients do not understand 
that crystals continue to 
accumulate while 
symptom free. Unaware of 
existence of allopurinol 
which can prevent gout 
attacks. 
disease 
progression, 
treatment, 
pathophysiology 
 "universal lack of 
knowledge and 
understanding 
about 
the cause and 
consequence of 
gout and the 
importance of 
making adequate 
lifestyle changes 
and adherence to 
lifelong ULT" 
Perez-Ruiz (2009) 
Review practices 
for long-term gout 
management 
w/emphasis on 
MSU crystals in 
pathogenesis and 
treating to target 
SUA level. 
No explicit 
methodology. 
Explain to patients that 
mobilization flares are 
'price to pay' for cure and 
risk can by reduced 
through prophylactic 
therapy 
 
pathophysiology, 
treatment 
Patients need to 
understand the 
importance of 
therapy adherence 
to obtain sUA 
targets and 
eradicate crystals. 
Harrold, et al. (2010) 
Explore patient 
and provider views 
of ULDs for gout 
management. 
Qualitative in-
depth phone 
interviews of gout 
patients 
Lack of details about what 
causes gout. Perception of 
gout as condition that 
must be adapted to rather 
than one that can be 
controlled through 
lifestyle and medication. 
pathophysiology, 
treatment 
Patients want 
more information 
and more time 
from providers. 
Chandratre, et al. 
(2015) 
Explore patient 
perspectives on 
how gout impacts 
HRQOL. 
Thematic analysis 
of focus group 
interviews about 
HRQOL. 
Confusion concerning role 
of diet in cause and 
treatment, lack of 'trusted' 
sources of information, 
self-discovered sources 
considered 
overwhelming/frightening. 
Gout not viewed as 
disease. 
pathophysiology, 
treatment 
Patients concerned 
about quality of 
Internet sources 
found and desire 
more information 
from healthcare 
providers. 
 
4.1.6 Intervening 
Studies included in this group (n=11) understandably focused on information 
related to disease treatment, specifically pharmacological interventions. Information 
about these studies is included in table 4.4. This phase of care featured the most 
quantitative studies and the only intervention studies. Rees et al. (2012) featured an 
36 
 
education intervention and tested SUA levels 12 months later. Two studies were follow-
ups to previous education interventions with Mikuls et al. (2017) being a randomized 
evaluation of a pharmacist-led intervention, while Abishek et al. (2016) featured a five 
year follow up questionnaire for a nurse-driven intervention. Serawate et al. (2006) was a 
retrospective claims analysis using logistic regression. Each of these studies also used 
SUA levels as outcome measures. There were two systematic literature reviews included 
in this category. Galo et al. (2014) focused exclusively on treatment, while Reach (2011) 
discussed disease progression along with treatment information as a means to understand 
why side effects occur when commencing ULT. Dalbeth et al. (2011) similarly concluded 
that patients with greater understanding of gout had higher adherence to ULTs. However, 
Robinson and Schumacher (2013) found that this type of information was missing from 
the majority of patient education materials that they analyzed. Beyond long term 
pharmacological treatments, patients are only aware of very limited treatment options for 
symptom relief during acute attacks (Lindsay et al., 2011). Likewise, only Singh (2014) 
included information pertaining to lifestyle modifications, as diet was identified as a 
concern for their target population of African Americans and women with gout. 
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Table 4.4: Intervening stage literature review results 
Publication Objective Methods Findings 
Information 
Type 
Conclusion 
Lindsay, et al. (2011) 
Explore the 
experience and 
attitudes of men 
with gout, 
especially those 
affecting outcomes 
w/emphasis on 
barriers to urate-
lowering therapy. 
Qualitative 
grounded theory 
interviews of 11 
men with gout. 
Categorized by 
themes using 
NVivo. 
Patients learn 
treatment methods 
from other family 
members with gout.  
Lack of knowledge 
about long term 
treatment. Perception 
of gout as something 
that must be endured.  
treatment 
Patients only aware 
of anti-
inflammatories and 
diet and exercise as 
symptom 
management 
options. 
Abhishek, et al. (2016) 
Explore the effects 
of nurse-led 
intervention on 
ULT adherence. 
Proof of concept 
study: 5 year 
follow up 
questionnaire to 
patients that had 
participated in a 
previous 
intervention. 
Very high proportion 
of responders had 
excellent ULT 
adherence and 
EULAR target SUA 
level. 
treatment 
Personalized 
interactive 
education can have 
long term effects on 
ULT persistence. 
Mikuls, et al. (2017) 
Examine the impact 
of pharmacist-
driven intervention 
to optimize 
allopurinol therapy. 
Randomized 
evaluation of 
pharmacist led 
intervention via 
telephone 
Intervention patients 
showed increased 
adherence and met 
SUA goals.  
treatment 
Shows that simple 
interventions can be 
effective, but most 
patients still failed 
to reach the low 
SUA levels 
generally 
recommended. 
Serawate, et al. (2006) 
Determine 
treatment patterns, 
specifically for 
allopurinol. 
Retrospective 
claims analysis 
using multivariable 
logistic regression 
for factors 
associated with 
adherence to 
allopurinol therapy. 
Previous diagnosis 
was positively 
associated with 
treatment compliance, 
while post index SUA 
flares indicated less 
compliance 
treatment 
Newly diagnosed 
and flare patients 
may require more 
education to 
promote therapy 
compliance. 
Galo, et al. (2014) 
Identify and assess 
medication 
adherence 
intervention studies 
for rheumatic 
diseases.  
Systematic 
literature review:  
"searched Medline 
(1946–June 2014), 
Embase 
(1974–June 2014) 
and International 
Pharmaceutical 
Abstracts (1970–
June 2014). We 
used Medical 
Subject Headings 
for concepts 
underlying our 
search, 
‘medication 
adherence’, 
‘intervention’ and 
‘inflammatory 
arthritis’ and 
applied keywords 
for concepts 
that did not map." 
All interventions that 
had an effect on 
adherence included an 
education component 
and were tailored to 
the patient. 
treatment 
Patients need 
personalized 
education about 
therapies including 
proper 
administration and 
risks/benefits and  
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Table 4.4 (continued) 
Dalbeth, et al (2011) 
Examine the 
relationship 
between illness 
perceptions of gout 
patients and disease 
outcomes, 
particularly 
medication 
adherence and 
musculoskeletal 
disability. 
Questionnaire for 
patients with gout 
for under 10 years.  
Patients with greater 
understanding of gout 
also reported a higher 
need for, less concern 
about, and stronger 
adherence to ULT. 
treatment 
Interventions to 
improve disease 
understanding 
may reduce 
concerns about 
ULT and increase 
adherence. 
Robinson & 
Schumacher (2013) 
Examine 
characteristics, 
including 
readability, content, 
and construction, of 
gout patient 
education materials 
from different 
countries and 
organizations.  
Analysis of written 
patient information 
content. 
"treating serum uric 
acid (SUA) to target 
and prophylaxis 
against acute flare 
during urate-lowering 
therapy 
(ULT) initiation and 
titration" were absent 
in 60% of the studied 
resources. 
treatment 
Information 
content coverage 
is generally good, 
but the most 
commonly 
missing 
information is 
important." 
Failure to 
understand that 
SUA needs to be 
below a certain 
threshold (the 
target) may 
prevent patients 
from returning to 
their doctor for 
assessment of 
their SUA and 
titration of 
their ULT. Being 
unaware of the 
importance of 
using anti-
inflammatory 
prophylaxis 
against acute 
flares could 
reduce adherence 
during ULT 
initiation and 
titration. This 
lack of such 
prophylaxis 
would allow 
more flares and 
cause patients to 
stop ULT and/or 
lose confidence 
in their doctors.: 
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Table 4.4 (continued) 
Rees, et al. (2012) 
Test effectiveness 
of nurse-led 
intervention based 
on 'best practices' 
delivered in a 
hospital-based gout 
clinic setting. 
Proof of concept 
study: education 
intervention 
followed by 
measurement of 
sUA at 12 months. 
Package of care’ that 
includes 
patient education, 
individualized 
lifestyle advice and 
slow 
upward titration of 
ULT according to 
serial SUA levels 
achieved target levels 
in over 90% of 
patients. 
pathophysiology 
including cause of 
gout, its risk 
factors and 
prognosis 
(including the risk 
of chronic joint 
damage), and 
available 
treatment 
strategies that 
can eliminate the 
crystals 
Given proper 
education, 
knowledge of 
their therapeutic 
target, and 
regular contact 
with a nurse 
specialist,  
Aung, et al. (2017) 
Review and discuss 
intervention 
strategies to 
improve ULT 
adherence and gout 
outcomes. 
Review of 
treatment 
interventions 
Patients are concerned 
about lack of 
information and 
understanding about 
treatment strategy.  
Pathogenesis, 
treatment 
Patients feel that 
healthcare visit 
time is too short 
to provide 
adequate 
information and 
discussion about 
gout, leading 
them to rely on 
Internet sources. 
Reach (2011)  
Discuss reasons for 
gout treatment 
strategies and 
review literature on 
adherence. 
Literature review 
Patients often stop 
taking medications 
because they believe 
they are not working 
or bring on attacks 
when attacks occur 
early in therapy. 
treatment, disease 
progression 
Patients need to 
be informed 
about the reasons 
for increased 
attacks upon 
treatment 
initiation and 
understand that 
long term 
adherence 
decreases the risk 
of attacks. 
Singh (2014) 
Assess barriers to 
treatment. 
NGT study of 
African Americans 
and women with 
gout diagnosis code 
about gout 
treatment. 
Patient worries about 
medication 
interactions and side 
effects. Not sure 
which medications for 
every day vs. during 
attacks. All groups 
indicated concerns 
about dietary 
modifications. 
treatment, lifestyle 
Patients need 
provider advice 
about diet. 
Medication 
concerns are 
common for 
chronic 
conditions and 
not specific to 
gout. 
 
4.1.7 Recovering 
As a chronic disease, articles included in this group (n=5) pertain to topics related 
to the fine-tuning of long-term therapies and continuous management of gout. All studies 
in table 4.5 highlight a lack of understanding regarding short-term side effects, ultimate 
goals, and expectations of treatments leading to poor adherence to long-term medications 
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and treatment plans. Most of the studies focus on ULDs, while several specifically 
mention allopurinol. Coburn et al. (2010) has the most specific target population, 
focusing on a population of VA patients that have recently initiated allopurinol therapy. 
While all studies contain information pertaining to treatment, Becker and Chohan (2008) 
offer an editorial review that contains the most variety with information relevant to 
pathophysiology, disease progression, and labs, as well. Doherty et al. (2012) is the only 
literature review in this category and the only study that refers to lifestyle advice. The 
two qualitative studies have only treatment information for this category; however, 
Chandratre et al. (2015) explores gouts impact on quality of life (QOL), while Harrold et 
al. (2010) is more concerned with general perspectives on ULDs. 
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Table 4.5: Recovering/Rehabbing literature review results 
Publication Objective Methods Findings 
Information 
Type 
Conclusion 
Harrold, et al. (2010) 
Explore patient and 
provider views of 
ULDs for gout 
management. 
Qualitative in-depth 
phone interviews of 
gout patients. 
Patients understand use 
of allopurinol for 
reducing serum uric acid 
and preventing gout 
attacks, not clear on 
planned duration of 
therapy. Belief that 
allopurinol triggers or 
worsens gout, concerns 
about side effects. 
treatment 
Patients 
unaware of 
potential for 
flares upon 
ULD 
initiation as 
short-term 
side effect. 
Coburn, et al. (2016) 
Examine patient 
knowledge of gout, 
especially SUA 
goals including 
factors associated 
with that 
knowledge and the 
effects on health 
outcomes. 
Survey of gout 
knowledge for VA 
patients over 19 that 
had started 
allopurinol in the 
previous 6 months. 
Correct knowledge was 
high in patients for all 
topics except SU goal. 
treatment, labs 
SU goal 
knowledge 
was 
associated 
with more SU 
measurements 
during the 
first 2 years 
following 
ULT 
initiation. 
Becker & Chohan 
(2008) 
Identify and discuss 
factors contributing 
to suboptimal gout 
management with 
emphasis on 
immediate 
opportunities for 
improvement. 
Editorial Review 
Education about the 
disease is key: "diagnosis 
and course, the 
distinctive therapeutic 
modalities employed, 
circumstances likely to 
promote or mark 
progression, the 
significance of comorbid 
associations, and means 
to monitor therapy and 
maximize adherence to 
therapeutic 
recommendations". 
pathophysiology, 
disease 
progression, 
treatment, labs 
Patient 
education is 
key to 
improving 
clinical 
outcomes. 
Chandratre, et al. 
(2015) 
Explore patient 
perspectives on 
how gout impacts 
HRQOL. 
Thematic analysis 
of focus group 
interviews about 
HRQOL. 
Lack of information 
about acute attacks as 
side effect of allopurinol, 
interactions between 
medications for co-
morbidities. Incorrect 
advice to discontinue 
treatment. 
treatment 
Lack of 
knowledge 
about ULT 
benefits may 
lead to poor 
HRQOL. 
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Table 4.5 (continued) 
Doherty, et al. (2012) 
Identify and 
address why a 
'curable' disease is 
so poorly managed. 
Literature review 
searched the 
Medline database 
for articles 
published in English 
language using the 
search terms ‘gout’, 
‘hyperuricaemia’, 
‘hyperuricemia’, 
‘tophi’ and 
‘monosodium urate’ 
published after 1 
January 1980, 
searched keywords 
'therapy', 
'management', 
'cure', and 
'treatment' alone and 
with the previous 
terms, other 
materials judged 
relevant. 
Belief that gout refers to 
the acute attacks. 
Lifestyle, 
treatment 
Patients 
underestimate 
the 
importance of 
long-term 
ULT. 
 
4.1.8 Monitoring 
As the largest group of articles (n=12), this phase reflects the long-term, slow build 
up which results in sudden acute attacks and other complications. This care phase has the 
most information concerning lifestyle modifications. As with all phases of care, an 
overall lack of education and understanding is highlighted by table 4.6, with a particular 
emphasis on non-pharmacological interventions and managing co-morbidities. In line 
with Perez-Ruiz’s (2009) contention that knowledge of non-pharmacological approaches 
and lifestyle modifications is essential to gout management, only Ogdie et al. (2012) does 
not include lifestyle advice, instead focusing on the long-term monitoring of SUA levels. 
The needs assessment conducted by Rifaat et al. (2016) indicates that this type of 
information, specifically dietary guidelines, is the most sought after in this phase of care, 
at least by highly educated patients. Interestingly, the patients involved in Harrold et al. 
(2010) did recall being told to avoid certain foods, but the patients involved in Harrold et 
al. (2012) were largely unaware of dietary triggers of gout attacks. In contrast, Vaccher et 
al. (2016) found that most patients do know some personal triggers for acute attacks, but 
do not recall receiving this information from their general practitioner and instead, sought 
it out online. However, Johnston et al. (2015) found that all 30 of the patient education 
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materials they reviewed contained lifestyle information, including diet, particularly foods 
to avoid. Other types of information were not included as consistently and Jimenez-Liñan 
et al. (2016), who analyzed similar resources, points to a distinct lack of emphasis on the 
importance of ULTs. This category also features the British Society for Rheumatology’s 
recommended guidelines for gout management (Hui et al, 2017) as it relates to health 
information, as well as EULAR’s patient education recommendations for inflammatory 
arthritis (Zangi et al., 2015). Both of these sources advocate for what Fields and 
Batterman call a multifaceted approach to gout patient education and management. 
Table 4.6: Monitoring/Managing literature review results 
 
Publication Objective Methods Findings 
Information 
Type 
Conclusion 
Roddy, Zhang, & 
Doherty (2007) 
Compare practices 
for chronic gout 
management in the 
UK to EULAR 
recommendations, 
including lifestyle 
advice and ULT 
therapy. 
Questionnaire mailed 
to all patients over 30 
in 2 general practices. 
Self-reported gout or 
acute arthritis attacks 
invited for clinical 
assessment. 
Infrequent 
lifestyle 
modification 
advice. 
 lifestyle advice 
regarding weight 
loss, alcohol 
reduction, diet. 
Advocates 
dissemination of 
EULAR 
recommendations for 
management.  
Harrold, et al. (2010) 
Explore patient and 
provider views of 
ULDs for gout 
management. 
Qualitative in-depth 
phone interviews of 
gout patients. 
Patients recall 
being told to 
reduce certain 
foods, suggest 
follow up after 
initiating 
treatment. 
lifestyle, 
treatment 
Patients want more 
information about 
natural remedies. 
Harrold, et al. (2012) 
Identify and 
understand patient 
gout knowledge, 
beliefs, and barriers 
to management. 
Questionnaire about 
gout knowledge and 
beliefs. 
Lack of 
knowledge 
regarding dietary 
triggers, ULT 
dosing during 
flares, risk of 
causing flares 
upon initiation. 
Deficit greater in 
those with active 
gout. 
Lifestyle, 
treatment 
Provide oral and 
written information 
regarding short- and 
long-term effects of 
ULTs and dietary 
factors throughout 
care. 
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Table 4.6 (continued) 
Hui, et al. (2017) 
Revise and update 
recommendations 
for gout 
management in the 
UK. 
The British Society 
for 
Rheumatology/Britis
h Health 
Professionals in 
Rheumatology 
guideline for the 
management of gout 
"All patients with 
gout should be 
given verbal and 
written 
information about 
the following: the 
causes and 
consequences of 
gout and 
hyperuricaemia; 
how to manage 
acute attacks; 
lifestyle advice 
about diet, 
alcohol 
consumption and 
obesity; and the 
rationale, aims 
and use of ULT 
to target urate 
levels. 
Management 
should be 
individualized 
and take into 
account co-
morbidities and 
concurrent 
medications. 
Illness 
perceptions and 
potential barriers 
to care should be 
discussed" 
treatment, 
lifestyle 
Updated 
recommendation due 
to better 
understanding of 
barriers to effective 
care 
Ogdie, et al. (2010) 
Describe key points 
of intervention and 
propose educational 
improvements. 
Review-no details  
Patients need to 
understand that 
SUA levels under 
6 mg/dl means 
unlikely to have 
gout and goal of 
therapy should be 
to maintain that 
level. 
labs 
Patient education 
may be most 
effective method to 
change physician 
behavior. Campaign 
with slogans to get 
patients to check 
their SUA levels. 
Perez-Ruiz (2009) 
Review practices for 
long-term gout 
management 
w/emphasis on 
MSU crystals in 
pathogenesis and 
treating to target 
SUA level. 
No explicit 
methodology. 
The role of 
lifestyle changes 
and non-
pharmacological 
approaches to 
gout management 
is essential 
information 
lifestyle, 
treatment 
These types of 
measures might only 
have a modest effect 
on sUA levels but are 
very beneficial for 
general health. 
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Table 4.6 (continued) 
Johnston, et al. (2015) 
Review 
internationally 
available gout 
education resources 
to investigate 
content and ease of 
reading. 
Analysis of written 
patient information 
content in 30 gout 
sources from several 
countries. 
All sources noted 
role of uric acid, 
lifestyle factors 
such as weight, 
alcohol, and diet, 
including foods to 
avoid. Other 
topics not 
covered 
consistently. 
Lifestyle, 
treatment, 
pathophysiology 
 "informing patients 
with gout of their 
increased risk of 
heart disease and 
diabetes is important 
for encouraging 
screening as well as 
modifying diet and 
lifestyle factors to 
manage risk. 
Providing patients 
with a target level for 
SUA may also prove 
important for 
tracking progress and 
maintaining 
motivation to take 
urate-lowering 
therapy during 
intercritical periods 
of gout." 
Vaccher, et al. (2016) 
Investigate gout 
understanding and 
explore barriers to 
optimum care. 
Inductive thematic 
analysis of semi-
structured interviews 
about understanding 
of gout management. 
Most patients 
have basic 
knowledge of 
gout and know 
some personal 
triggers of 
attacks, but do 
not understand 
medications or 
the earliest signs 
of an attack. 
Pathophysiology, 
lifestyle, disease 
progression, 
treatment 
Most patients do not 
recall receiving 
information about 
gout from their GP, 
leading them to 
research gout 
themselves and 
expressed a desire for 
more informative 
sources. 
Jimenez-Liñan, et al. 
(2016) 
Assess content, 
readability, and 
accuracy of free 
online patient 
education materials 
as related to current 
gout knowledge. 
Review of 30 online 
gout education 
resources 
education 
resources often 
contain no or 
inaccurate 
information about 
pathogenesis and 
fail to emphasize 
the importance of 
ULT. 
pathophysiology, 
treatment 
Not many web-based 
sources provide 
accurate and easy to 
read information 
about gout. 
Zangi, et al. (2015) 
Develop patient 
education 
recommendations 
for those with 
inflammatory 
arthritis and identify 
areas for further 
research. 
An extensive 
systematic literature 
search in Medline, 
Embase, PsycINFO, 
Cochrane Library and 
CINAHL from 
January 2003 up to 
September 2013 of 
publications in 
English, German, 
French or Spanish 
describing any kind 
of PE activities, was 
conducted  
Trend toward 
emphasis of 
behavioral, 
cognitive, and 
emotional 
processes in 
patient education 
lifestyle, 
pathophysiology, 
disease 
progression 
Eight 
recommendations 
with the overarching 
principle that patient 
education should 
enable people to 
manage their life and 
optimize health and 
well-being 
Rifaat, et al. (2016) 
Identify patient 
knowledge gaps and 
concerns for 
inclusion in 
education initiative. 
Needs assessment 
given to highly 
educated patients 
being seen by 
rheumatologists 
Information of 
most interest was 
diet guidelines. 
lifestyle 
Major gaps in 
knowledge essential 
to self-management. 
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Table 4.6 (continued) 
Abhishek & Doherty 
(2018) 
Highlight common 
knowledge gaps, 
recommend core 
knowledge for 
education, and 
review non-
pharmacological 
strategies for gout 
management. 
Systematic literature 
review: searched 
PubMed from 
inception to 28 
March 2017 
Gout patients 
have significant 
knowledge gaps. 
Lack of time to 
provide 
individualized 
education is one 
of the many 
barriers to care of 
gout. 
pathophysiology, 
disease 
progression, 
treatment, 
lifestyle 
"People with gout 
should be educated 
about the 
pathogenesis, 
associated co-
morbidities and 
management of 
gout, including both 
pharmacological and 
non-pharmacological 
management." 
Fields & Batterman 
(2018) 
Explore literature on 
gout patient 
education suggest 
future research 
directions. 
 Literature review 
Key concepts 
highlighted in the 
literature include 
genetic and 
metabolic causes 
of gout, the risk 
of progressive 
damage with 
inadequate 
treatment, goal 
serum urate levels 
and why they are 
monitored, 
rationale for 
short- and long-
term 
management, 
impact of 
comorbidities, 
and dietary 
management. 
pathophysiology, 
disease 
progression, 
treatment, 
lifestyle, labs 
Optimal patient 
education requires 
multifaceted 
approach. 
 
4.1.9 Gout Information Value Chain 
On the basis of these results, the gout information value chain (figure 4.1) was 
created to define the types of information needed by gout patients throughout the 
continuum of care. This value chain will be used throughout the remaining phases of the 
study to identify important information that is available to gout patients in both patient 
education materials and their own clinical notes. 
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Figure 4.1 Gout Information Value Chain 
 
Primary Care Cycle Screening Diagnosing Preparing Intervening Recovering/Rehabbing Monitoring
Priority signs/symptoms:
Specifying/Orderi
ng Labs/Tests:
Intervention Options 
Education: (Hui et 
al., 2017)
Ordering/Adminis
tering Drug 
Therapy: (Hui et 
al., 2017)
Therapy Fine Tuning: 
(Hui et al., 2017)
Monitoring/Manag
ing to Avoid 
Complications:
painful joints (big 
toe), redness, 
warmth, swelling 
(Ragab, 
Elshahaly, & 
Bardin, 2017)
synovial fluid 
analysis (Sivera 
et al., 2014)
side effects, 
compliance, efficacy
acute attacks ULT
acute attacks (Hui 
et al., 2017)
ULT prophylaxis
Further Details
Medical History: 
Comorbidities
Interpreting Test 
Results: serum uric 
acid levels, 
imaging:ultrasoun
ds (Hui et al., 
2017; Ragab, 
Elshahaly, & 
Bardin, 2017)
Existing 
Medications/ 
Comorbidities: 
pregnancy, renal 
insufficiency (Hui et 
al., 2017)
Treatment: (Hui et 
al., 2017)
Non-pharmacological 
Interventions: (Hui et 
al., 2017)
Complications:
kidney disease, 
cvd, obesity, 
diabetes (Khanna 
et al., 2012)
Consulting with 
Experts: (Khanna 
et al., 2012) ex.
interactions/counter 
effects
efficacy, side 
effects, 
compliance
rest
kidney stones 
(Kramer et al., 2003)
Risk Factors 
(Khanna et al., 
2012; Hui et al., 
2017)
PCP/GP
Choosing Care 
Team: (Hui et al., 
2017)
injection guidance topical ice
recurrent gout 
flares (Hui et al., 
2017)
behavioral causes: 
alcohol (beer)
Rheumatologist
rheumatologist/gout 
specialist/PCP/NP
encourage cherry/skim 
milk powder intake
advanced gout: 
tophi, joint 
deformity (Khanna 
et al., 2012)
current 
medications: 
diuretics, low 
dose aspirin, 
immunosuppressa
nt
Determing 
Treatment Plan: 
Acute vs. Chronic 
(Hui et al., 2017)
Performing 
Procedures:
increase vitamin C/ 
omega-3 fatty acids
Monitoring Therapy 
Compliance:
family history: 
gout (Kuo et al., 
2015)
NSAIDS
joint aspiration 
(hui et al., 2017)
Clinical Procedures: 
bariatric surgery
ULT (Sivera et al., 
2014)
etiology: 
hyperuricemia 
(Hui et al., 2017)
ULT (dosage)
Life Style 
Modifications: 
(Khanna et al., 
2012; Hui et al., 
2017)
genetics  (Hui et 
al., 2017; Ragab, 
Elshahaly, & 
Bardin, 2017)
Medical History: 
(Perez-Ruiz, 2009; 
Sivera et al., 2014)
reduce alcohol/red 
meat intake/soft 
drinks
confirmatory 
signs/symptoms 
(bony erosions, 
tophi)
avoid low 
temps/dehydration
Confusing 
Conditions:
psuedogout 
(Ragab, Elshahaly, 
& Bardin, 2017)
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4.2 Phase Two Results 
4.2.1 Data Collection 
The NLP concepts extracted from patient notes and patient education materials 
served as the primary source of research data. The demographics and medical claims data 
served as supporting research data. At each step of the process, output was coded according 
to the stages of the CDVC and reviewed for emerging themes. This method ensured that 
value chain analysis was embedded throughout the data collection process. The original 
PEM output used to create the keyword dictionary and the subsequent output from patient 
clinical notes using the final model are provided in Appendix A and B. 
4.2.2 Data Analysis 
All collected concepts were divided into one of two categories: medication or 
diagnosis and procedure related terms. The original dictionary and the final model output 
were then compared and analyzed for categories or themes. The model successfully 
retrieved 3892 terms and phrases that were able to be mapped to CUIs in the UMLS (512 
medication terms and 3380 diagnosis/procedure terms). 105 of these terms matched both 
CUIs and value chain phases in the keyword dictionary. An additional 51 terms matched 
CUIs appearing in the dictionary but were labeled with different value chain phases. In line 
with the proportions of all terms appearing in the PEMs, the most matching terms appear 
in monitoring (figure 4.1). The medications that were also extracted from clinical notes for 
this phase are all commonly prescribed for gout flares. Surprisingly, diagnosing has the 
second most matches. Although screening, diagnosing, and intervening are close in 
proportion, the diagnosing stage contains no medication terms in the keyword dictionary 
and only one medication related term in the clinical note output. While screening has very 
few keyword terms categorized as medication related (n=3), clinical notes produced 32 
medication terms for the stage.  The majority of keyword terms classified as medication 
appear in intervening and this is the only stage with more medication related terms than 
diagnosis/procedure terms. The terms also appearing in patient clinical notes are all 
commonly associated with gout except ‘fenofibrate’, a cholesterol medication. The 
matching terms in the screening stage largely consist of risk factors including behaviors 
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(‘beer’) and medical history (‘family history of gout’, patient comorbidities, genetic 
factors). For the diagnosis stage, terms matching the stage in the keywords and clinical 
notes consist of procedure related terms for confirmatory diagnosis (‘synovial fluid 
analysis’, ‘radiographic findings’, ‘urate crystals’), symptoms used for diagnosis (‘joint 
damage’, ‘tophi’), and similar diseases that can be confused for and must be differentiated 
from gout (‘calcium pyrophosphate disease’). 
Figure 4.2: Percentage of Words Appearing for Each Stage in Keyword Dictionary. 
 
The preparing and recovery stages have the lowest number of keywords. Preparing 
had six medication related terms, however, three were considered generic. Interestingly, 
two of the remaining three appeared in patient notes (‘blood thinners’ and ‘take NSAIDs’). 
Recovering has exactly one less concept than preparing for both medication and 
diagnosis/procedure terms. None of the medication related keywords were extracted from 
the clinical notes by the model. One concept was considered generic and four concepts 
were also found in the patient notes for each stage. The concepts common to the keywords 
list and those extracted by the model were all possibly related to the kidneys or diet. 
Although there were a high number of keywords that the model did not extract from 
patient notes (table 4.7), many of these are combinations or longer versions of concepts 
that appear separately in the NLP note output, such as ‘allopurinol and probenecid’. The 
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medications that do appear by themselves in the keyword list that were not found in the 
notes are not commonly associated with gout treatment and are often prescribed for 
comorbidities. In fact, most of the concepts that the model did not identify in any clinical 
notes are long phrases typical of the writing style found in PEMs. Thus, while we might 
expect to find phrases like ‘under a microscope’ or ‘inject a corticosteroid directly into 
your joint’ when explaining concepts to patients, they are not likely to appear in clinical 
notes under the same context. Therefore, when similar concepts appear in the clinical notes, 
they are assigned different CUIs. For example, the CUI for ‘after acute attacks’ was not 
identified in any of the patient notes by the model. However, numerous variations of ‘acute’ 
and ‘attack’ were extracted and assigned the appropriate CUI. 
Table 4.7: Keywords not Extracted from Patient Clinical Notes 
Diagnosing 
under a microscope C0395796, dual energy computed tomography 
C4055114, are most often affected C3808454, joint appears warm 
C0575034, attacks often C1867940, chalky C3267206, monosodium urate 
monohydrate C0037564, Monoarticular involvement C0427254, Posterior 
interosseous nerve syndrome C1696572, Location outside C2016008, 
Ultrasonographic C1301497, crystals within the joint space and deposition 
of crystals C1401835, too much uric acid in the blood C2029412, crystals in 
the joint fluid C0200652, in one or more of your joints C0162296 
Intervening 
or use other medicines C0678312, inject a corticosteroid directly into your 
joint C2137753, blood levels of uric acid to normal C0855643, oral 
corticosteroids plus colchicine C0775883, Lesinurad C3886073, prevent 
disease C0679698, deposition of urate crystals in the renal medulla or uric 
acid crystals C0522574, Xanthine oxidase inhibitors C0302609, 
benzbromarone C0005035, allopurinol or probenecid C2194181 
Monitoring 
meats and fish C0335766, deposit in the joints C0541866, Alcohol in excess 
C0159070, Sugary drinks and foods C0453425, but because it can help 
C3827771, uric acid levels in the blood may lead to deposits of urate 
crystals C0522574, crystals can be found in uric acid C2022384, anakinra 
C0245109, after acute attacks C3279118, inflammation are under 
C0877470, when starting these C3166682, acid in the blood C1287384, 
Secondary infections C0442886, Urate or uric acid C0851010, Increased 
susceptibility to infection C0236171, Nerve or spinal cord impingement 
C0751463, kidney stones or urate C2109382, increased overall likelihood of 
C2015876, increased risk for any vascular event C2673803, medicines are 
working and you are taking C3176475, high levels in the blood C1399735, 
skim milk C0349375, call your doctor C3476384 
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Table 4.7 (continued) 
Preparing 
Treatment choices depend on C2069130, production of uric acid C3653539, 
do not overproduce uric acid should take C3476381, inflammation in the 
joints C0574941, uric acid to break down a chemical C0041980, crystals 
form and collect in your joints and cause gout C0809978, Uric acid buildup 
also can lead to disfiguring lumps called tophi C3806613, crystals 
accumulate in the urinary C0151579 
Recovering 
on this medicine long term to prevent C2922112, eating foods that are rich 
C3898963, damage to joints C0269891, table salt C0206136, joint 
destruction C0541875, Pembrolizumab C3658706 
Screening 
painful swelling in single joints C0311222, Esidrix C0700694, and its 
complications occur more often C2073319, to run in some C3810163, run in 
C3274438, more common in men C1867966, people become older 
C3826770, Sickle cell anemia and other anemias C0029738, Leukemia and 
other blood cancers C1516238, hydrochlorothiazide and other water pills 
C3217109, Hypertriglyceridemia Hypercholesterolemia C0543517 
metabolic abnormalities C4021768, base of the big toe C0224039, high 
levels of uric acid C0948643, presenting as slight C4036274 
 
On the surface, there is little variation in the types of concepts extracted from the 
PEMs and the patient notes. The PEM output is more gout specific with the NLP output 
featuring more terms related to comorbidities. The most frequent keywords also highlight 
more technical terms, such as ‘hyperuricemia’,’ pseudogout’, and ‘urate crystals’ (figure 
4.2). 
Figure 4.3: Top 20 Terms Most Frequently Found in Gout PEMs. 
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The NLP counts show a sharper decline among the most frequently extracted terms. 
The top four terms appear in patient notes over a million times, while the remaining top 20 
terms show up at least half as frequently. The top four terms are also in the top 20 
keywords; however, they rank much lower in frequency except for ‘pain’, which is fourth 
for both sets of output. The medications featured in the keywords output were all also 
extracted from patient notes, however, ‘febuxostat’ did not make the top 20 list for clinical 
notes (figure 4.3). 
Figure 4.4: Top 20 Terms Most Frequently Found in Gout Patient Clinical Notes. 
 
The model extracted exponentially more terms in both frequency and amount from 
the patient notes. 14 terms were considered generic and not medically relevant. These terms 
were excluded from further processing. Many other terms, while potentially medically 
relevant, are not necessarily related to gout (‘history of adopted child’). Therefore, we set 
a threshold wherein a concept needed to have been extracted from the notes of at least 4 
patients to be included for final analysis. This was done to minimize noise and maximize 
sample size in the final analyses. 2020 terms appeared for only one patient. A further 521 
terms only appeared in two patient records. An additional 252 terms were removed for 
appearing in only three patient records. The remaining 1094 terms were examined for 
associations to gout flares in the next step of the project. 
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4.3 Phase Three Results 
4.3.1 Sample 
Data for 3964 patients was included for this study. The demographics presented 
represent patients that met the minimum requirements sought as described in Chapter 3. 
71% of the population was male (n=2827) and 29% female (n=1137). All but 15 patients 
had information about race available in the database. 83% of the sample was identified as 
white (n=3276), 16% as black/African American (n=627), and 1% as Asian (n=40). There 
were also two patients identified as Hawaiian/Pacific Islander and four patients as 
American Indian/Alaskan. Additionally, 98% were designated non-Hispanic/Latino. The 
median age for the study cohort is 59 with the majority of patients being between the ages 
of 55 and 69. 
4.3.2 PheCAP Analysis Results 
High-throughput phenotyping using a common automated pipeline was conducted 
using the chosen concepts combined with the structured EHR data for each patient. This 
initial complete dataset included 3964 patients with 1206 variables. 2702 patients had been 
identified with flares and 1262 patients were identified as not having had any gout flares. 
Patients were divided into a training sample (n=2378) and a validation sample (n=1586).  
As the purpose of this first analysis was to create an overall, general model for gout 
flares, surrogates were selected to be specific to the target phenotype. Subsequently, ‘gout 
flares’ was chosen for the NLP surrogate. As there is no diagnosis code for gout flares, we 
used the ICD codes for gout as an ICD surrogate. The SAFE algorithm identified the CUI, 
ICD-9 gout code 274.xx, and the ICD-10 codes M10.0, M10.2, and M10.9 for use as 
outcome variables in the training algorithm. The algorithm chose only those identified by 
SAFE to be used in the model. Though the ICD codes as a group had a strong association 
with outcomes, when considered in combination with the gout flare CUI there was a weak, 
negative association.   When considered individually, only M10.0 and M10.9 had non-zero 
beta coefficients. The training model had an AUC of .735 and the validation set AUC was 
.733 (figure 4.5). When evaluating the model over 20 different threshold values for 
determining gout flare designation, the PPV stayed high (>.85) but the NPV was fairly low 
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(<.5). The FPR was low (<.2) but the TPR was relatively low (<.6), as well. The lowest 
threshold cutoff (.698) had the highest F1 score (.671). 
In the same manner, models were created separately for each stage of the value 
chain along with a comprehensive model combining all stages to explore the differences in 
information provided in patient notes between the care stages more thoroughly and 
determine whether certain stages contain information that could be considered more 
predictive of  or closely associated with gout flares. Results for each model are similarly 
presented below and statistics for all models at a fixed FPR are included in table 4.8. 
Overall, the models have little negative predictive value and low sensitivity.  
Figure 4.5: Area Under the Curve for Training and Validation Data Sets Featuring NLP 
Variables From all stages of CDVC. 
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Table 4.8: TPR, PPV, NPV, and F1 scores for all models at FPR of .2. 
 Model TPR PPV NPV F1 
General 0.533 0.854 0.454 0.656 
Screening  0.34 0.78 0.367 0.473 
Diagnosing  0.357 0.788 0.374 0.492 
Preparing  0.376 0.797 0.381 0.51 
Intervening  0.519 0.844 0.444 0.643 
Recovering  0.361 0.79 0.375 0.496 
Monitoring  0.514 0.843 0.441 0.638 
Comprehensive  0.669 0.875 0.537 0.758 
 
4.3.3 Screening 
For the screening stage, there were 329 potential variables. The priority information 
for this stage was signs and symptoms. Therefore, ‘high fever’, ‘warm skin’, and ‘during 
the night’ were chosen as NLP surrogates. There are ICD codes associated with joint pain 
(719.4x, M25.5x). As one of the most common symptoms of gout, the general, unspecified 
versions of those codes were used as surrogates, as well. The model developed using these 
variables as surrogates did not perform well (training AUC=.632), although it did do 
slightly better on the validation dataset (AUC=.646) (figure 4.6). None of the NLP CUIs 
by themselves contributed to the model. As a group, the CUIs and ICD codes showed a 
weak association (all beta coefficients < ±.1). This models .5 F1 score (.463) occurred at 
the lowest cutoff (.743). PPV (.78) was lowest at this point. While all other metrics were 
highest at this cutoff, all were <.5. 
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Figure 4.6: AUC Plot for Training and Validation Data Sets Featuring NLP Variables 
Labeled Screening. 
 
4.3.4 Diagnosing 
The model for the diagnosing stage was developed using the CUIs and CPT codes 
used for lab tests involved in diagnosing gout. Specifically, ‘fluid analysis’ and ‘urate 
crystals’ were used as NLP surrogates and the CPT code for serum urate testing was used 
as the surrogate for coded data. In total, 238 variables were considered for diagnosing. This 
model performed similarly to the screening model (training AUC=.637, validation 
AUC=.65) (figure 4.7). However, the code for serum urate testing did demonstrate a fairly 
strong association with the outcome variables with a beta coefficient >.65. Furthermore, 
the NLP variables together had a beta coefficient >8.18. 
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Figure 4.7: AUC Plot for Validation and Training Data Sets Using NLP Variables 
Labeled Diagnosing. 
 
4.3.5 Preparing 
The preparing stage contained only eight NLP variables to choose from. The priority 
information for this stage of the value chain include all terms related to education 
concerning treatment options. Though this category can include information about side 
effects, compliance, and efficacy, it is not limited to medication or drug interventions. 
Thus, ‘red meat’, ‘taking NSAIDs’, and ‘kidney’ were chosen as NLP surrogates. Because 
NSAIDs are likely to be the first line of treatment for gout flares that patients can take 
while deciding on long-term treatment options, the NDC codes for a common over-the-
counter treatment (ibuprofen) were also designated as surrogate variables. 121 possible 
variables were considered for this model. The model performed similarly to the previous 
stages (figure 4.8). Ibuprofen demonstrated the greatest effect on the model. ‘Red meat’ 
was the only NLP variable to have an individual effect on the model. 
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Figure 4.8: AUC for Model Created Using NLP Variables Labeled as Preparing. 
 
4.3.6 Intervening 
For intervening, there were 297 total variables. Priority information for the 
intervening stage of the care cycle consists of ordering and administering drug therapies. 
The NLP concepts chosen as surrogates were all drugs commonly prescribed for gout 
treatment, both acute attacks and long-term ULTs. The NDC codes for these drugs were 
also included as surrogate outcome variables for a total of 46 surrogates for consideration 
by SAFE. This model performed better (training AUC=.729) (figure 4.9). Sulfinpyrazone 
showed a strong association in the model with a beta coefficient > 5. 
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Figure 4.9: AUC Plot for Training and Validation Sets Using NLP Concepts Labeled 
Intervening. 
 
4.3.7 Recovering 
The recovering stage only provide three NLP concepts for consideration. Priority 
information relates to fine tuning therapies. Two concepts were selected as being related 
to this designation (‘daily’ and ‘renal impairment’). ICD codes for renal disease were 
included as surrogate representation from the structured data. The model was developed 
using 111 variables. The performance metrics for this model were slightly lower than those 
presented previously (validation AUC=.639) (figure 4.10). The main variables all 
demonstrated small associations with gout flares, however, the NLP concept ‘renal 
impairment’ alone showed a beta coefficient of -96.27. 
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Figure 4.10: AUC Plot for Training and Validation Data Featuring NLP Variables from 
Recovering. 
 
4.3.8 Monitoring 
The monitoring stage presented 647 variables with which to develop a model. The 
priority for monitoring is to manage and avoid complications, especially acute attacks. 
From a coded data perspective, avoidance is handled through the continued monitoring of 
serum urate levels. Management once an acute attack occurs frequently consists of using 
colchicine to alleviate symptoms. Therefore, the respective CPT and NDC codes were used 
as surrogate variables. 19 NLP variables related to priority information for this stage were 
also selected to act as surrogates. This model performed slightly lower than the intervening 
model (training AUC=.719) (figure 4.11). The CUIs for ‘fluid intake’ and ‘fish oil’ stand 
out as showing strong associations with gout flares. 
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Figure 4.11: AUC Plot for Training and Validation Models Created from Variables 
Included in Monitoring. 
 
4.3.9 Comprehensive Model 
As a final test, a model encompassing the entire value chain was developed. Whereas 
the first model was meant to be a general model to look for associations between broadly 
defined surrogates, this model was designed to look specifically at each stage of the value 
chain as a whole. The NLP surrogates defined for use in all previous models were also 
assigned as surrogate outcomes variables in this model. For medical codes, all codes used 
in the algorithm used to count flares were included as surrogates. In total, 1207 variables 
were considered for the development of this model, 112 of which were designated as 
surrogates. The model created had improved performance metrics when compared to the 
other models (figure 4.12). 
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Figure 4.12: AUC for Training and Validation Model for Complete Value Chain. 
 
AUC for training data was .812.  At the lowest threshold value (.672), PPV was at 
its lowest value of .875. All other statistics were at their highest, including an F1 score of 
.758. 
4.4 Conclusion 
This chapter contains the results of the analyses, connects the analyses back to the 
research questions, and demonstrates consistency of the analyses with value chain theory. 
Data for 3964 patients was included in this value chain study. Structured and unstructured 
medical data was used to understand what information is readily available in patient 
education materials regarding the topic of gout and which concepts are associated with 
patient gout flares.  The majority of patients were white males in the 55-69 age range. 
Consistent with value chain analysis, each piece of data in each step of the study was 
placed in the care continuum according to the stages of the care delivery value chain where 
it is believed to contribute value. Comparative analysis was conducted to discover 
categories, themes, and relationships between and within the six value chains, leading to 
the following key findings. The key findings resulting from this study summarize the 
contributions of PEMs to the inefficacy of patient education: (a) Gout PEMs contain far 
more terms related to diagnosis or procedures than medications, except for information  
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related to the intervening stage (b) term usage varies markedly between PEMs and clinical 
notes, (c) Information related to preparing and recovering are noticeably absent from gout 
PEMs, (d) Gaps in PEM data were exacerbated in clinical note output, (e) The best 
performing models utilized the most input data. 
Neither demographic nor healthcare utilization variables contributed to any of our 
models. Additional data on the similarities and differences discovered across the different 
stages of the care delivery value chain, between PEM and clinical note NLP output, and 
how variables relate to gout flares are also found in this chapter. While great strides have 
been made in creating good patient education materials, it is evident from the research 
results that there is variability in the information patients are given to learn about gout and 
the individual health data patients must keep track of to manage their disease. Chapter 5 
includes the summary of critical analysis and discussion of these findings. 
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CHAPTER 5. DISCUSSION 
The purpose of the value chain study was to identify factors associated with gout 
flares, leading to a model for identification. This chapter includes a discussion of major 
findings as related to the literature on gout patient education and gout patient information 
requirements and what implications may be valuable for use by stakeholders. Also included 
is a discussion on connections to this study and value chain theory and healthcare policies. 
The chapter concludes with a discussion of the limitations of the study, areas for future 
research, and a brief summary. 
The information value chain created from a scoping review allowed us to identify 
important information from popular gout patient education materials. The ability to use this 
information to identify important information in the clinical notes of gout patients and 
subsequently identify associations to gout flares was hindered by the following key 
findings: (a) Gout PEMs contained far more terms related to diagnosis or procedures than 
medications, except for information  related to the intervening stage (b) term usage varied 
markedly between PEMs and clinical notes, (c) Information related to preparing and 
recovering was noticeably absent from gout PEMs, (d) Gaps in PEM data were exacerbated 
in clinical note output, (e) The best performing models utilized the most input data. Some 
issues relate primarily to PEMs, some to the clinical narratives, and some are a combination 
of the contextual relationship between the two. These issues help contribute to lack of 
understanding and self-management skills for gout patients. 
5.1 Phase One Discussion and Conclusions 
5.1.1 Discussion 
The results of this scoping review indicate that treatment and other interventions 
are the most popular topics for gout patient information related research. This is reflective 
of the confusing and complicated nature of gout treatment as both a chronic and acute 
condition. Moreover, several key findings highlight the interrelated nature of the various 
information types necessary to successfully manage gout. 
A heavy focus on treatment for a health problem is to be expected, especially for a 
chronic painful condition like gout. However, the emphasis on treatment in research 
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studies for a disease that has proven treatment protocols is indicative of a larger problem. 
Several studies highlighted that adherence to long term therapies is lacking in gout 
patients. Patients often indicated that this is due to a lack of understanding of when and 
how to take both long- and short-term medications prescribed for gout. However, many 
studies found that lack of knowledge about the causes and progression of the disease was 
a contributing factor to misunderstandings regarding adherence to treatment strategies.  
Furthermore, all of the limited research pertaining to the first two stages of care 
(n=3) identified lack of education regarding the causes and consequences of gout. Pre-
diagnosis, this lack of understanding of gout pathophysiology leads to underdiagnosis. 
The research focus on this topic throughout the care cycle indicates that this issue is not 
remediated in later stages and continues to create barriers to effective disease 
management. 
 In addition, the variety of information types identified as being necessary for 
optimal gout management is reflective of the multifaceted nature of gout. Several of the 
articles highlighted multiple information types demonstrating that the categories work 
together to enhance understanding and aid the behavioral, cognitive, and emotional 
processes necessary for treatment compliance. Specifically, patients desire more 
information regarding natural remedies and lifestyle advice. 
5.1.2 Further Research 
Despite the rich research findings provided by the relevant articles identified by 
the scoping review, the majority were only tangentially related to our aim of identifying 
the information required for improving the efficacy of treatment/management strategies. 
The existing literature is largely focused on identifying gaps in patient knowledge with 
conclusions drawn about needed information through inference from the results. More 
research needs to be done to explicitly identify the information that is required for more 
efficient education guidelines to avoid extraneous information that risks overwhelming 
the patient.   
Six studies analyzed education interventions with two being systematic literature 
reviews. All studies found the interventions to be successful for increasing treatment 
adherence, however, each study utilized different methods for implementing and 
measuring the outcomes of the chosen intervention. Limited research is available for 
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interventions outside of the treatment stage. The included studies indicate that patients 
give up on medications and treatment options when side effects occur due to 
misunderstandings, essentially leading them to skip the recovering/rehabbing phase in 
favor of treating only the symptoms of acute attacks. Furthermore, studies have identified 
that, just as gout therapies need to be fine-tuned for the individual, education is best 
tailored and personalized to each patient. Future research could focus on exploration of 
what to do for improvement, rather than what is not being done. 
5.1.3 Strengths and Limitations 
This is the first scoping review conducted for this particular topic. The broad 
search strategy and inclusion criteria contributed to the breadth of evidence uncovered 
and provided a comprehensive overview of available research. In addition, these factors 
were essential to conducting a rigorous review in adherence with published scoping 
review protocols at each step of the screening, selection, and evaluation processes.  
Despite the meticulous and robust methods utilized, the review still has 
limitations. First, in line with general scoping review protocol, the quality of the available 
research was not evaluated. As such, this review only identifies the existence of key 
findings and makes no judgement on the worth or potential benefits of said findings. 
Second, only articles published in the English language were included, meaning that 
articles relevant to the topic that could have further incites might have been excluded. 
Last, it is possible that some relevant studies were not retrieved using our search strategy. 
Though the search terms were chosen because they were believed to be sufficiently broad 
so as to encompass the majority of relevant research, it is possible that some authors 
expressed the concept of ‘gout patient information’ in an alternate way that would not be 
retrieved by our search strategy. 
5.1.4 Conclusion 
 This review highlights the limited attention that has been paid to the information 
needs of gout patients. Though interest has grown in the last two decades, there is still an 
explicit need to explore the essential information requirements for optimal care and 
patient self-management. Specifically, there is a need to determine what information is 
most beneficial at each stage of the value chain. 
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5.1.5 Practice Implications 
 This scoping review is an initial attempt to grow the field of patient education 
research through the application of value chain analysis to identify areas that need further 
exploration by highlighting where value is currently being created and where gaps still 
occur. Continuation of this type of research can aid in recognizing the extensive health 
information needs of gout patients for the purpose of ensuring the receipt of adequate 
amounts of information at the time it is most beneficial. Such research can further be used 
to develop education interventions and other solutions to address issues in patient 
education. 
5.2 Interpretation of Findings 
While individuals vary in their healthcare knowledge, skills, and experiences, each 
of the key findings identify prominent factors in encouraging patient education throughout 
the continuum of care. These issues are dynamic in nature, as what is important to each 
patient changes over time. Each issue is examined in detail in the following sections. 
5.2.1 Phase Two 
 At first glance, the lack of medication information in patient education materials 
about a disease might not seem like an egregious issue, or, in fact, an issue at all. There are 
PEMs available for specific gout and other drugs. However, when looking back over the 
gout value chain, we see that while medication information may be more important in 
certain stages, it is an important consideration in all phases of the care cycle. In the 
screening phase, it should be known that some medications can increase the risk of 
developing gout. Patients start the tests that help determine the treatment plan, including 
medication dosages, in the diagnosing phase. Medication information is especially 
important in the preparing and recovering stages where it is most absent. Patients should 
be receiving information about all of their treatment options in the preparing phase to help 
decide on the best course of treatment, taking into account interactions of medications 
currently being taken for preexisting conditions. For the recovering phase, patients need to 
know when to consult their healthcare provider about fine-tuning their medication dosages. 
Research has shown that patients that do not know the expected medication outcomes or 
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that dosage adjustments are part of the process are more likely to stop treatment (Hui et al., 
2017). This stays important throughout the monitoring phase, where patients must 
constantly deal with new and existing comorbidities, along with their associated 
medications. In contrast, the sheer number of extracted medication terms identified as 
intervening suggests that gout PEMs contain a significant amount of information related to 
gout drugs. This noted imbalance likely caused our ner model to assign most medication 
concepts to either intervening or monitoring.  
It is clear from the results that there is an overall lack of concepts extracted from 
the PEMs, and consequently from the clinical notes, for the preparing and recovering 
stages. This is indicative of a gap in the gout PEMs and gout patient education in general 
(Becker & Chohan, 2008).  Furthermore, the information that is offered for these stages 
often overlaps with concepts from the intervening and/or monitoring phase. Such terms are 
usually used in the context of intervening or monitoring much more frequently, especially 
for medication related terms. This means that the ner model is more likely to identify the 
term as one of those two phases. 
 The researchers attempted to identify all important information contained with the 
patient education texts. Due to the writing style characteristic to our set of PEMs, this 
sometimes resulted in the annotation of longer phrases and sometimes, whole sentences. 
Clinical notes are not written with patients in mind and can be written as brief notes with a 
lot of medical jargon or abbreviations, depending on the style of the healthcare provider. 
Our ner model did fairly well at extracting medically related concepts from longer phrases 
and picking up certain abbreviations, even though these were not included in the original 
keyword list. Interestingly, in many instances, the ner model assigned a different value 
chain stage than originally labeled in the keyword dictionary. This is potentially correct 
and all of the cases I reviewed were accurately labeled based on context. Even so, this still 
can cause issues beyond the fact that the model will not accurately distinguish between 
stages 100% of the time. At times, the model did not assign a new value chain stage to a 
concept in addition to the keyword label, it assigned it instead of. This suggests that the 
concept is not used within the clinical notes in the same manner that it is used in the PEMs, 
which could cause confusion for patients 
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5.2.2 Phase Three 
 . With regard to developing models with an aim toward identifying gout flares and 
associated concepts, this eliminated several potential features for some stages while 
potentially adding potential features to others. In addition, whenever a concept is included 
in more than one stage, its counts are split between the stages depending on the context in 
which it appears in the note. This is exactly what we would want the ner to do. However, 
when working with algorithms that rely on frequency counts, as does the pheCAP 
algorithm, entities with split counts are less likely to show well in the developed model. 
 In terms of the pheCAP models developed for these stages of care, this meant that 
there were very few terms to choose from. This was especially noticeable when trying to 
select NLP surrogates for the recovering model. Only six terms were extracted for this 
phase. After removing generic terms and those that did not meet the patient threshold, there 
were only three terms to choose from (‘dairy products’, ‘daily’, and ‘renal damage’). All 
concepts were included for consideration in the final model; however, per the 
methodology, surrogate variables were required to be chosen that reflected information 
designated as priority for the specific phase. In the case of recovering, priority information 
was related to the fine tuning of therapy. Thus, ‘daily’ was chosen as it could be part of a 
medication dosage change and ‘renal damage’ was selected because it could possibly be a 
reason for fine tuning therapy. ‘Dairy products’ was not chosen because it was categorized 
as a nonpharmacological intervention, which is within the purview of recovering, but not 
priority information. This was the lowest performing model. 
It is always possible that the terms simply do not appear in patient notes. This would 
go back to the textual and contextual issues previously discussed wherein information 
patients need is included in PEMs but is not of concern to clinicians. This would seem most 
likely for nonpharmacological interventions. However, terms such as ‘red meat’, and 
‘seafood’ appear under the label of alternative stages like monitoring. There are also 
frequent mentions of vitamins and other supplements such as ‘fish oil’ identified in other 
stages, as well. 
 The best performing model, in terms of both gout flare prediction and identifying 
associations, was the comprehensive model that not only included concepts from all stages 
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of the value chain, but also designated NLP concepts from every care stage as surrogate 
variables. In addition, all ICD, NDC, and CPT codes traditionally associated with gout and 
its treatment were included as surrogate outcome variables. The model for the monitoring 
phase performed second best, and it had the most concepts of all the care phases.  
Though the study was somewhat hindered by the fact that the initial model was based 
on only seven PEMs, the disparity in concepts collected for certain stages suggests that 
some types of information are missing or neglected in gout materials. While there are 
certainly more PEMs that could be used to add to the model, the ones used for this study 
are among the most popular and trusted on the web. Furthermore, the concepts are fairly 
uniform among the various PEMs. Though there are some definite differences, such as 
Wikipedia, adding more PEMs in the same vein could just lead to exponentiation of the 
current concepts. 
This issue is not limited to NLP concepts. Many of the CPT codes selected due to 
previous usage in gout studies were not useful for this project because none of our patients 
had that code anywhere in their data. This was true for some ICD codes and a few 
medication codes, as well. 
5.3 Implications for Theory and Research 
Chapter 2 included descriptions of several value chain models. These models 
included Porter’s care delivery value chain utilized for this study. How the models 
developed in this study fit with this model is discussed in the following sections. 
5.3.1 Phase One 
 The strategic framework for healthcare delivery put forth by Kim, Farmer, and 
Porter (2013) includes the suggestion that in order to optimize healthcare for equitable 
community and economic development, we must first understand the full set of activities 
involved across the entire care cycle for all medical conditions. In this study, a value chain 
for gout is presented from an information perspective. The results of this study align with 
the primary activities of the care delivery value chain as those that generate information. 
However, the secondary activities primarily deal with tasks related to managing 
information, which in the case of an information value chain seems redundant. In this sense, 
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the focus is not so much on the value of task, but the value of the information created by 
or required for the task. 
5.3.2 Phase Two 
Gout is a unique disease with a unique patient population. The rate at which NLP 
terms were extracted across multiple care stages in both PEMs and clinical notes confirm 
that the current practice of viewing medical care as a series of isolated interventions for 
symptoms is less than ideal. The number of concepts related to complications and 
comorbidities found in our patient notes gives credence to the assertion that a medical 
condition is not one disease (Kim, Farmer, & Porter, 2013). Our cohort, specifically, has a 
high number of patients that also have diagnostic codes for lupus. This is reflected in the 
NLP output where we see several lupus related terms, such as ‘lupus flares’ and ‘SLE’. 
5.3.3 Phase Three 
5.4 Implications for Practice 
The care delivery value chain touts the importance of a systemic view in order for 
patients to best evaluate information to guide care decisions. The results of this study show 
that the stages of the value chain are fluid, with patients potentially moving back and forth 
through the chain multiple times. For gout especially, it is difficult to tell which care stage 
a patient is in or which stage information is most applicable to. This is reflected throughout 
the value chain, the PEM and clinical note output, and the models created to identify gout 
flares and associated concepts. 
5.4.1 Phase One 
The gout information value chain was developed using a collection of research 
concerning the information requirements of gout patients and best practices for treatment 
and self-management. For a variety of reasons, best practices are not always implemented 
by healthcare providers. The repetition of topics throughout the value chain indicates that 
information might be best given multiple times in the care cycle. It is likely that patients 
might need slightly different information about the same topics depending on the care 
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stage. Yet, patients are usually given only one worksheet of basic gout information when 
first diagnosed with the condition. 
5.4.2 Phase Two 
Much of the information identified in the gout value chain are not included in PEMs 
or clinical notes, nor are they told the information by any of their healthcare team. The 
British Society for Rheumatology Guideline for the Management of Gout specifically 
advocates for the provision of written and verbal instructions for most of the information 
included in our value chain (Hui et al., 2017). Research routinely shows that patients do 
not recall receiving educational information (Vaccher, et al., 2016) and our study 
demonstrates that many concepts related to the necessary information are not readily 
available in PEMs or patient notes. 
5.4.3 Phase Three 
When using the concepts collected from patient notes to develop models for each 
stage of the value chain, there was a noticeable lack of available data for several care 
phases. This was discussed in our key findings, but the attempts to create models for each 
stage of care cycle revealed possible implications for clinical practice 
There were plenty of available NLP concepts for screening; however, when 
searching for priority information to use as surrogate variables it was discovered that none 
of the symptoms that are considered among the first signs gout (painful joints, redness, 
swelling) were included in the screening data. These concepts did appear in the diagnosing 
and monitoring data. The concepts were annotated as screening when creating the keyword 
dictionary, however, the concepts were used far more often in the context of diagnosing or 
monitoring within the PEMs. The NER model subsequently learned to label those signs 
and symptoms as one of those stages. As a consequence, the screening NLP was 
proliferated with and overabundance of terms related to family history and risk factors. 
Similarly, the priority information for diagnosis is related to the ordering and administering 
of lab tests used to diagnose gout. Synovial fluid analysis is considered the gold standard 
for gout diagnosis (Hui et al., 2017). There was a concept close to this (fluid analysis) 
which was used as a surrogate variable for this model, however, the diagnosing data had 
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far more data related to possible signs and symptoms. This is in line with the research, 
which states that clinicians generally use signs and symptoms for gout diagnosis and 
screening mostly takes place outside of the healthcare cycle (Kim, Farmer, & Porter, 2013).  
The lack of concepts found in the preparing stage and the abundance of terms labeled 
intervening support research that highlights the focus on treatment in healthcare with the 
preparing stage largely being skipped (Hui et al., 2017). Recovering similarly had a low 
number of concepts and research strongly indicates that this stage is mostly ignored in gout 
due to patients not realizing that ULTs can often set off flares as a side effect. This can be 
remedied by adjusting the medication; however, many patients just stop treatment (Hui et 
al., 2017). The preponderance of terms found for monitoring are likely similar to 
intervening. 
5.5 Limitations 
While this study produced numerous interesting results, the utility of the data is 
reduced due to several limitations. First, despite the relatively high number of patients and 
documents included in the study, the data was relatively sparse for the methodology. Even 
though codes and concepts might occur in the data sets, total counts could be low overall 
or spread among very few patients. As a result, the pheCAP algorithm identified very few 
associated terms for each model.  
Second, our models can only be developed using information that exists. Missing or 
rare information in PEMs and patient notes prevents a complete understanding of the 
associations between terms and care stages and may result in inaccurate information. While 
one of the goals of this study was to identify missing and misclassified information in gout 
PEMs and to a lesser extent, patient clinical narratives, using PEMs to develop an NER 
model to extract information based on a care delivery value chain is likely not the best 
method.  
Third, the researchers tasked with selecting information deemed important to patients 
are not clinicians, nor do they have the perspective of gout patients. The participation of 
either would have greatly benefited the study. Though each step in the study process was 
guided by prior research, the perspective of a rheumatologist would have been invaluable 
in variable selection, such as designating priority information for the stages of the value 
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stage or choosing surrogate variables for the phenotyping models. Having information 
about why healthcare providers sometimes do not follow best practice guideline could have 
a profound impact on the output of this study. Similarly, having patient annotations for 
PEMs would be immensely helpful in identifying valuable information.  Though the 
literature review included multiple studies featuring summaries and conclusions about 
what information gout patients want and need, without personally experiencing gout, 
researchers can only annotate with an eye toward what they think gout patients need or 
what they would want to know as a patient. 
5.6 Future Research 
There are several opportunities for future research that could add to the findings of 
this study. The NER model created to extract concepts from patient data performed well 
according to standard metrics. It did identify concepts from PEMs and learned to identify 
similar, new concepts according to the value chain in clinical notes. However, in some 
cases it overlearned. For example, researchers identified multiple instances of family 
history related concepts in the PEMs as screening. Possibly to the frequency of occurrence, 
the model learned that ‘family history’ was important and extracted every term associated 
with ‘family history’ from patient notes. Future research could be done to refine the NER 
model. Similar methods could also be applied to other diseases. Gout is a complicated 
disease as outlined throughout this study. Other medical conditions are certain to have their 
own inherent complexities, however, the application of value chain analysis could offer 
additional insights into new diseases, as well as cNLP methods. As stated in the limitations 
section, input from clinicians and patients should be sought throughout the process as much 
as possible. Additionally, there is the opportunity to go farther with the concept of value 
and attempt to quantify the importance of patient information. A more quantitative study 
could be developed to understand the contribution of information to improving patient 
health outcomes. 
5.7 Conclusion 
Having necessary information is critical to gout patient self-management. Many 
factors are involved in ensuring gout patients have the right information to make well-
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informed decisions about their healthcare. This is the first study the researcher is aware of 
that creates a value chain for gout. It is almost certainly the first study to use value chain 
analysis to develop an NER model. Though the models created in this study demonstrated 
only marginal success, the results highlighted several interesting findings: (a) Gout PEMs 
contained far more terms related to diagnosis or procedures than medications, except for 
information  related to the intervening stage, (b) term usage varied markedly between 
PEMs and clinical notes, (c) Information related to preparing and recovering was 
noticeably absent from gout PEMs, (d) Gaps in PEM data were exacerbated in clinical note 
output, (e) The best performing models utilized the most input data. 
The implications of these findings may not be immediately clear. The value chain 
developed for this study would need to be validated. The NER model performs well at 
extracting concepts, but those concepts are not necessarily gout related. The phenotyping 
algorithms identified mostly weak associations between concepts in the value chain and 
flares. The results of this study validate the gaps in information perceived by patients and 
gives us particular areas to start filling in. Deciding how to fill those gaps is another matter. 
The results of this study indicate that patient data does not necessarily have the information, 
either. The weak associations identified could be used to identify stronger connections to 
gout flares and thus, more useful information. Hopefully, someday patients will be able to 
access important information tailored to their needs to optimize their healthcare. Until then, 
future studies could focus on identifying patient information needs throughout the care 
continuum. 
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APPENDIX 1. KEYWORD DICTIONARY 
Dictionary Keywords divided into medication related and other terms for each stage of the 
value chain. Terms in italics were considered too generic and removed from the final 
dictionary. Bold items also appear in clinical note output in the same phase. 
Medication Diagnosis/Procedures 
benzbromarone C0005035 Intervening stomach or intestines C0017178 Intervening 
colchicine (Colcrys C2718494 Intervening chance C0237506 Intervening 
colchicine (tablets or injection C4048699 Intervening joint C0022417 Intervening 
colchicine-induced C3656515 Intervening 
inflammation and 
pain in joints C0003864 Intervening 
Colchicine/probenecid C0717652 Intervening 
nausea, vomiting, 
diarrhea and C0151791 Intervening 
disease, or who take drugs that 
interact C3805130 Intervening relieve pain C0002766 Intervening 
Febuxostat (Uloric C2608992 Intervening also C0238664 Intervening 
Given orally (by mouth) or by 
injection C0555966 Intervening heart and kidney C0155602 Intervening 
nonsteroidal anti-inflammatory 
drugs C0003211 Intervening 
diarrhea, nausea, 
vomiting, and C0151791 Intervening 
NSAIDs can also cause kidney 
problems in people taking 
diuretics or certain other 
medicines to C2029949 Intervening stomach upset C0235309 Intervening 
or low-dose C1542589 Intervening Vitamin C C0003968 Intervening 
Pegloticase (Krystexxa) is given 
by injection C2938134 Intervening Renal C0022646 Intervening 
Probenecid C0033209 Intervening 
blood uric acid 
levels C0373739 Intervening 
Colchicine C0009262 Intervening Low-dose C0445550 Intervening 
doctor may need to change the 
doses of your medications or 
monitor you C3476743 Intervening 
deposition of urate 
crystals in the renal 
medulla or uric acid 
crystals C0522574 Intervening 
Fenofibrate C0033228 Intervening 
ulcers or bleeding in 
the stomach C0586374 Intervening 
Nonsteroidal anti-inflammatory 
drug C0003211 Intervening 
ulcers, and bleeding 
– NSAIDs can cause 
stomach C0586374 Intervening 
ranolazine (Ranexa C1703958 Intervening prevent disease C0679698 Intervening 
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allopurinol (Aloprim C4058836 Intervening 
blood levels of uric 
acid to normal C0855643 Intervening 
Allopurinol is also sometimes 
used to treat seizures, pain 
caused by C0274778 Intervening stores C1698986 Intervening 
brand name drugs C0590778 Intervening such as C1881351 Intervening 
cause other side effects C0013679 Intervening rash; skin redness C2126375 Intervening 
Colchicine is not C1851351 Intervening attacks of gout C2712871 Intervening 
Colchicine may cause side effects C0868415 Intervening 
relieve pain and 
reduce C2940249 Intervening 
corticosteroids C0001617 Intervening 
vitamins, minerals, or 
other dietary 
supplements C4036036 Intervening 
Febuxostat C0249529 Intervening effects may be C4229333 Intervening 
ibuprofen C0020740 Intervening    
indomethacin C0021246 Intervening    
Lesinurad (Zurampic C4074452 Intervening    
Nonsteroidal anti-inflammatory 
drugs (NSAIDs C0003211 Intervening    
of your medications or monitor 
you carefully for side effects C0513367 Intervening    
oral corticosteroids plus colchicine C0775883 Intervening    
prednisone, methylprednisolone C0338362 Intervening    
Steroids – Steroids can reduce C2315131 Intervening    
sulfinpyrazone (Anturane C1578263 Intervening    
What side effects can this 
medication C3639329 Intervening    
xanthine oxidase inhibitors C0302609 Intervening    
naproxen (Naprosyn C1578052 Intervening    
allopurinol or probenecid C2194181 Intervening    
Allopurinol C0002144 Intervening    
Allopurinol may cause C0274778 Intervening    
azathioprine C0004482 Intervening    
can be taken as pills or as C3641844 Intervening    
febuxostat (brand name: Uloric C2608992 Intervening    
indomethacin (Indocin C0306458 Intervening    
ingredients in colchicine C0009262 Intervening    
inject a corticosteroid directly into 
your joint C2137753 Intervening    
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lesinurad C3886073 Intervening    
no side effects C3650791 Intervening    
nonsteroidal anti-inflammatory 
drug (NSAID C0003211 Intervening    
NSAIDs C0003211 Intervening    
NSAIDs (Nonsteroidal anti-
inflammatory drugs C0003211 Intervening    
Medication Diagnosis/Procedures 
200 mg: Initiate 1 tablet of 
lesinurad 200 
mg/allopurinol 200 mg C4073461 Monitoring meats and fish C0335766 Monitoring 
adverse effects of NSAIDs C0413722 Monitoring Nausea/vomiting C0027498 Monitoring 
doses of short?acting 
NSAIDs give the fastest 
relief of C1880956 Monitoring inflammation of the mouth C0038362 Monitoring 
79nitial79lam (Lescol), 
lovastatin (Mevacor), 
pravastatin (Pravachol), 
and simvastatin (Zocor C3173335 Monitoring allergic reactions C0020517 Monitoring 
ibuprofen (Advil, Motrin C0306865 Monitoring Alcohol in excess C0159070 Monitoring 
increase your dose C1707810 Monitoring fever, chills, and C0085594 Monitoring 
like aspirin and ibuprofen), 
ice the inflamed area and 
drink plenty of C1424457 Monitoring Drink alcohol C0001948 Monitoring 
Stevens-Johnson 
Syndrome, drug C1274933 Monitoring leukopenia C0023530 Monitoring 
tell your doctor if you are 
taking C3476385 Monitoring hypersensitivity reactions C0020517 Monitoring 
anti-inflammatory C0003209 Monitoring inflammation C0021368 Monitoring 
before taking your C3476385 Monitoring stomach cramping C0344375 Monitoring 
Colchicine is C1851351 Monitoring stones C0006736 Monitoring 
cyclophosphamide 
(Cytoxan C1605278 Monitoring wrinkled skin C0037301 Monitoring 
Do not take C3476381 Monitoring rapid or irregular heartbeat C0080203 Monitoring 
nonsteroidal anti-
inflammatory drugs 
(NSAID C0003211 Monitoring familial Mediterranean fever C0031069 Monitoring 
steroids C0038317 Monitoring seafood C0206208 Monitoring 
adverse drug reactions C0041755 Monitoring decrease fertility in C0151639 Monitoring 
aspirin) and increase the C0357297 Monitoring 
swelling of the salivary 
glands C0240925 Monitoring 
atorvastatin (Lipitor C0286650 Monitoring 
osteoarthritis or rheumatoid 
arthritis C0029408 Monitoring 
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brand names: Advil, Motrin) 
and indomethacin (brand 
name C0699203 Monitoring Renal stones C0022650 Monitoring 
brand names: Advil, 
Motrin), and naproxen 
(brand name C0699203 Monitoring 
Mediterranean fever (FMF; 
an inborn condition that 
causes episodes of fever C0031069 Monitoring 
Celecoxib (Celebrex C1593710 Monitoring degenerative arthritis C0029408 Monitoring 
Colchicine C0009262 Monitoring swelling C0038999 Monitoring 
Colchicine (Colcrys C2718494 Monitoring ulceration C0041582 Monitoring 
Colchicine comes as a 
tablet and solution C1251364 Monitoring hypomagnesemia C0151723 Monitoring 
Common adverse drug 
reactions C0414040 Monitoring breath odor C0018520 Monitoring 
CrCl C1846718 Monitoring tophi C0221248 Monitoring 
Do not stop taking C3476381 Monitoring sensitivity to light C0085636 Monitoring 
Febuxostat C0249529 Monitoring failure, kidney disease C0035078 Monitoring 
fluconazole (Diflucan), 
itraconazole C1541189 Monitoring Renal colic C0152169 Monitoring 
fosamprenavir (Lexiva C1321662 Monitoring irritation of the eyes C0235266 Monitoring 
gastrointestinal adverse 
drug reactions C0413956 Monitoring heart attack C0027051 Monitoring 
higher doses of C3639809 Monitoring within 48 hours C0150946 Monitoring 
It is taken C1881371 Monitoring acute flares of gouty arthritis C0149896 Monitoring 
lesinurad 200 mg C4074641 Monitoring pseudogout C0033802 Monitoring 
medicines are working and 
you are taking C3176475 Monitoring 
skin lesions, severe acne or 
a skin rash, sores or C0241096 Monitoring 
mg: Initiate 1 tablet of 
lesinurad 200 
mg/allopurinol 300 mg C4073461 Monitoring pain in one or more joints C0162296 Monitoring 
minders and those for eye 
drops, creams, patches, 
and inhalers) are not child C0402660 Monitoring stomach cramps C0344375 Monitoring 
nonsteroidal anti-
inflammatory drugs 
(NSAIDs C0003211 Monitoring 
blood flow and thereby 
decrease C0232342 Monitoring 
NSAID C0003211 Monitoring blurred vision C0344232 Monitoring 
NSAIDs C0003211 Monitoring dry mouth C0043352 Monitoring 
over-the-counter NSAID 
with a prescribed NSAID or 
take more than the 
recommended dose of the C2054168 Monitoring certain types of C0007832 Monitoring 
ritonavir (in Kaletra, Norvir), 
and saquinavir C1977397 Monitoring decreased interest in sexual C0011124 Monitoring 
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take by mouth C3472561 Monitoring painful or difficult urination C0013428 Monitoring 
to aspirin, other NSAIDs, 
sulfa drugs, or have nasal 
polyps (linked to a greater 
chance of NSAID allergy C0038757 Monitoring chronic C0205191 Monitoring 
warfarin (brand name: 
Coumadin) or C3827680 Monitoring antiphospholipid antibodies C0162595 Monitoring 
you are taking C3176195 Monitoring symptoms occur C0232959 Monitoring 
your doctor before taking C3476385 Monitoring kidney stones C0022650 Monitoring 
diltiazem (Cardizem C1243267 Monitoring Chronic gouty arthritis C0268108 Monitoring 
Neoral, Sandimmune C0699603 Monitoring fibrillation after cardiac C0232197 Monitoring 
prostaglandins C0033554 Monitoring 
Increased susceptibility to 
infection C0236171 Monitoring 
lesinurad C3886073 Monitoring 
numbness of the feet, hands, 
and around the mouth C0221730 Monitoring 
Long-term use of NSAIDs C2911180 Monitoring ecchymosis C0013491 Monitoring 
Nonsteroidal 
81nitial81lammatory 
drugs C0003211 Monitoring remedies C0205202 Monitoring 
Some NSAIDs need to be 
taken more often during the 
day than C3843221 Monitoring tophi occur in advanced gout C0221248 Monitoring 
acylglucuronide C0299192 Monitoring 
peripheral vascular 
disease C0085096 Monitoring 
Anakinra C0245109 Monitoring decreased appetite C0232462 Monitoring 
dose is too high C3163907 Monitoring skim milk C0349375 Monitoring 
mg/kg/day C3642190 Monitoring scaly skin C0423773 Monitoring 
reactions to allopurinol C0414017 Monitoring 
skin reactions such as 
maculopapular rash C0423791 Monitoring 
when starting these C3166682 Monitoring 
and chronic abuse of ethanol 
(especially beer and hard 
liquor C0425331 Monitoring 
   infections C0439663 Monitoring 
   deposits of crystals C0442844 Monitoring 
   Secondary infections C0442886 Monitoring 
   reactions C0443286 Monitoring 
   low doses C0445550 Monitoring 
   soft tissues of joints C0447831 Monitoring 
   Sugary drinks and foods C0453425 Monitoring 
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affected joint and apply ice 
packs or cold compresses 
(cloths soaked in ice C0508503 Monitoring 
   is working properly C0509404 Monitoring 
   
measuring device) to 
accurately measure the 
correct amount of C0512904 Monitoring 
   
uric acid levels in the blood 
may lead to deposits of urate 
crystals C0522574 Monitoring 
   deposit in the joints C0541866 Monitoring 
   kidney or liver C0545792 Monitoring 
   feeling of warmth C0549386 Monitoring 
   limiting alcohol intake C0560219 Monitoring 
   not be safe C0581563 Monitoring 
   
rashes, or other allergic 
reactions C0585186 Monitoring 
   increased/decreased C0679128 Monitoring 
   Long-term exposure C0683018 Monitoring 
   
high levels of a substance 
called uric acid in the blood C0740394 Monitoring 
   high levels of blood uric acid C0740394 Monitoring 
   
High levels of uric acid in the 
blood C0740394 Monitoring 
   high fever C0743973 Monitoring 
   
reactions are idiosyncratic 
reactions C0745213 Monitoring 
   gradual weight loss C0750418 Monitoring 
   
Nerve or spinal cord 
impingement C0751463 Monitoring 
   role in preventing C0814407 Monitoring 
   of the lips or mouth C0841473 Monitoring 
   redness of the skin C0848314 Monitoring 
   drinking too much C0848500 Monitoring 
   
crystals can attract white 
blood cells, leading to 
severe, painful gout attacks 
and chronic arthritis C0850874 Monitoring 
   Urate or uric acid C0851010 Monitoring 
   raise uric acid C0857189 Monitoring 
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paleness or grayness of the 
lips C0877384 Monitoring 
   inflammation are under C0877470 Monitoring 
   controlling weight C0920298 Monitoring 
   in the stomach C0940163 Monitoring 
   bloating from increased gas C0946092 Monitoring 
   
decreased, lymphocyte 
count decreased C0948021 Monitoring 
   High levels of uric acid C0948643 Monitoring 
   
Cherry products such as 
whole cherries or 
unsweetened cherry juice C0982074 Monitoring 
   runny nose C1260880 Monitoring 
   losing weight C1262477 Monitoring 
   weight decreased C1262477 Monitoring 
   weight loss C1262477 Monitoring 
   
risks for any coronary 
heart disease C1277690 Monitoring 
   acid in the blood C1287384 Monitoring 
   increased levels of anti C1295614 Monitoring 
   Moderate-to-severe C1299393 Monitoring 
   
attacks are typically followed 
by periods of no symptoms C1304680 Monitoring 
   cardiovascular events C1320716 Monitoring 
   
undiagnosed vascular 
disease C1385120 Monitoring 
   
cardiovascular events like 
heart attacks C1385306 Monitoring 
   
kidney disease and adverse 
cardiovascular events C1397469 Monitoring 
   high levels in the blood C1399735 Monitoring 
   Renal impairment C1565489 Monitoring 
   gout flare C1619733 Monitoring 
   Gout flares C1619733 Monitoring 
   
crystals can form tophi, or 
swollen growths C1720757 Monitoring 
   safe to use C1820984 Monitoring 
   
temperature and away from 
excess heat and moisture 
(not in the bathroom C1822194 Monitoring 
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temperature, away from light, 
and away from excess heat 
and moisture (not in the 
bathroom C1822194 Monitoring 
   
and urinary: Tubulointerstitial 
nephritis C1843273 Monitoring 
   After several months of C1858431 Monitoring 
   such as C1881351 Monitoring 
   
increased overall likelihood 
of C2015876 Monitoring 
   
crystals can be found in uric 
acid C2022384 Monitoring 
   swollen or painful glands C2032740 Monitoring 
   swollen glands in the neck C2039120 Monitoring 
   kidney stones or urate C2109382 Monitoring 
   goes away C2128638 Monitoring 
   lower back or side pain C2129277 Monitoring 
   Cut back on C2186619 Monitoring 
   under the skin C2200110 Monitoring 
   Risk for vascular disease C2584745 Monitoring 
   Increase risk of renal events C2673803 Monitoring 
   
increased risk for any 
vascular event C2673803 Monitoring 
   
irritation of the 
gastrointestinal (GI) tract C2697368 Monitoring 
   gout attacks C2712871 Monitoring 
   
osteoarthritis, and others) 
and C2893964 Monitoring 
   
irritation, upper respiratory 
tract C2939098 Monitoring 
   Urate nephropathy C2955673 Monitoring 
   
fructose (especially high 
fructose corn syrup C2981326 Monitoring 
   high-fructose corn syrup C2981326 Monitoring 
   
risk of heart attack, heart 
failure C3176375 Monitoring 
   can become C3259831 Monitoring 
   after acute attacks C3279118 Monitoring 
   call your doctor C3476384 Monitoring 
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may be increased in patients 
with decreased C3552940 Monitoring 
   flushing or redness C3641769 Monitoring 
   organ meats such as C3687641 Monitoring 
   risk of kidney disease C3697935 Monitoring 
   but because it can help C3827771 Monitoring 
   Do not C3840725 Monitoring 
   
Drink at least eight glasses 
of water or other fluids each 
day C3841851 Monitoring 
   attack or stroke C3844825 Monitoring 
   containing drinks and foods C3880948 Monitoring 
   
numbness or tingling in the 
fingers or toes C3898946 Monitoring 
   Eat too many foods rich C3898963 Monitoring 
   eating foods that are rich C3898963 Monitoring 
   
If you are overweight, losing 
weight can help C4034888 Monitoring 
   few hours C4036223 Monitoring 
   unexpected C4055646 Monitoring 
   
to treat gout in adults who 
were not treated successfully 
with or who are not able to 
take C4068173 Monitoring 
   last 3 months C4086725 Monitoring 
   effects can be C4229014 Monitoring 
   effects may be C4229333 Monitoring 
Medication Other 
tell your doctor and pharmacist 
what C4086247 Preparing 
crystals accumulate in the 
urinary C0151579 Preparing 
you are taking or plan to take C4068173 Preparing 
liver disease or heart 
failure C0085605 Preparing 
ask your doctor or pharmacist if 
you have any questions C3165542 Preparing 
uric acid to break down a 
chemical C0041980 Preparing 
blood thinners C0003280 Preparing kidney C0022646 Preparing 
take NSAIDs C2054168 Preparing breaks down C0443161 Preparing 
or non-prescription medicines, 
or you take any herbal 
medicines, ask your doctor or 
pharmacist C1978499 Preparing drinks like cola C0452444 Preparing 
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   red meat C0452848 Preparing 
   inflammation in the joints C0574941 Preparing 
   
crystals form and collect in 
your joints and cause gout C0809978 Preparing 
   dissolving C1549535 Preparing 
   uric acid (hyperuricemia C1559990 Preparing 
   
Treatment choices 
depend on C2069130 Preparing 
   kidneys remove uric acid C2109383 Preparing 
   
do not overproduce uric 
acid should take C3476381 Preparing 
   production of uric acid C3653539 Preparing 
   
Uric acid buildup also can 
lead to disfiguring lumps 
called tophi C3806613 Preparing 
   too much C3843660 Preparing 
Medication Other 
take blood thinners C2054133 Recovering table salt C0206136 Recovering 
on this medicine long term to 
prevent C2922112 Recovering daily C0332173 Recovering 
uric acid-lowering drug, your 
doctor should slowly raise C0857189 Recovering tophi C0221248 Recovering 
effects, especially diarrhea or 
allergic reactions C1546347 Recovering dairy products C0010947 Recovering 
Pembrolizumab C3658706 Recovering damage to joints C0269891 Recovering 
   
uric acid levels drop 
below 6 mg/dL (normal C0151411 Recovering 
   levels C0441889 Recovering 
   
grapefruit or drink 
grapefruit juice C0452456 Recovering 
   on a regular basis C0513554 Recovering 
   
of tophi (deposits of uric 
acid crystals C0522574 Recovering 
   joint destruction C0541875 Recovering 
   Lose weight C1262477 Recovering 
   renal damage C1408258 Recovering 
   renal impairment C1565489 Recovering 
   drinks, such as C3641919 Recovering 
   
eating foods that are 
rich C3898963 Recovering 
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Medication Other 
diuretics (water pills) 
that help with high 
blood pressure C3843190 Screening drink alcohol C0001948 Screening 
Esidrix C0700694 Screening Obesity C0028754 Screening 
hydrochlorothiazide and 
other water pills C3217109 Screening skin rash C0015230 Screening 
   
blood pressure), hyperlipidemia 
(high cholesterol and triglycerides C0242339 Screening 
   gout first attacks your big toe C0221168 Screening 
   
Sickle cell anemia and other 
anemias C0029738 Screening 
   hemochromatosis C0018995 Screening 
   serious C0205404 Screening 
   painful swelling in single joints C0311222 Screening 
   for rheumatoid arthritis C0260963 Screening 
   Gout rarely affects C0003868 Screening 
   Diabetes C0011847 Screening 
   painful urination C0013428 Screening 
   osteoarthritis C0029408 Screening 
   Kidney disease C0022658 Screening 
   family history of gout C0221613 Screening 
   
high blood pressure), 
hyperlipidemia (high cholesterol 
and triglycerides C0242339 Screening 
   pseudogout C0033802 Screening 
   base of the big toe C0224039 Screening 
   gastric bypass surgery C0192398 Screening 
   
the big toe or other part of the 
foot) and/or bouts of arthritis C0264134 Screening 
   blood uric acid levels C0373739 Screening 
   
of severe pain, most often the big 
toe C0410779 Screening 
   What should I do if I forget C0423915 Screening 
   drink beer C0425331 Screening 
   lips, mouth, tongue C0497193 Screening 
   
of redness, swelling, pain, and 
heat in one or C0513106 Screening 
   pain, redness, swelling, and heat C0513106 Screening 
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uric acid (a normal waste 
product) collects in the body, and 
needle-like urate crystals deposit C0522574 Screening 
   swollen, red, hot C0541781 Screening 
   
Hypertriglyceridemia 
Hypercholesterolemia C0543517 Screening 
   Kidney disease or C0543793 Screening 
   after menopause C0587113 Screening 
   alcohol, especially beer C0678384 Screening 
   
high levels of uric acid in the 
blood C0740394 Screening 
   hyperuricemia C0740394 Screening 
   high fever C0743973 Screening 
   genetic factors C0814299 Screening 
   
uric acid (a normal waste 
product) collects in the body, and 
needle?like urate C0851010 Screening 
   site may be red and warm C0857810 Screening 
   high levels of uric acid C0948643 Screening 
   Intensely painful C1320357 Screening 
   
Leukemia and other blood 
cancers C1516238 Screening 
   Diabetes or C1534917 Screening 
   
problems (such as bleeding, 
ulcer, and stomach upset), kidney 
problems, high blood pressure or 
heart problems C1535460 Screening 
   may also be affected C1836053 Screening 
   
last 3 to 10 days, but the first 36 
hours C1865336 Screening 
   Men outnumber women C1867966 Screening 
   more common in men C1867966 Screening 
   more often in men, women C1867966 Screening 
   
and its complications occur more 
often C2073319 Screening 
   in the feet, especially C2127235 Screening 
   
fainting, slurred speech, sudden 
blurry vision, or sudden severe 
headache C2219960 Screening 
   
Hypertension (high blood 
pressure C2240377 Screening 
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ankles, heels, knees, wrists, 
fingers, and elbows C2677764 Screening 
   Attacks are C2751362 Screening 
   may lead to C3151638 Screening 
   people don’t have another one for C3175618 Screening 
   run in C3274438 Screening 
   Pain control tends to occur C3809908 Screening 
   run in some C3810163 Screening 
   to run in some C3810163 Screening 
   people become older C3826770 Screening 
   
more at risk if you’re overweight 
and drink alcohol C3842894 Screening 
   
high blood pressure, high 
cholesterol, diabetes, or C3843079 Screening 
   
high blood pressure, kidney 
disease, or C3843080 Screening 
   during the night C3845370 Screening 
   metabolic abnormalities C4021768 Screening 
   presenting as slight C4036274 Screening 
   
What other information should I 
know C4055149 Screening 
Other 
fever C0015967 Diagnosing 
tophi C0221248 Diagnosing 
redness C0332575 Diagnosing 
chronic (lasting) arthritis C0263680 Diagnosing 
X-rays C0043309 Diagnosing 
chronic gout C0268108 Diagnosing 
Podagra C0221168 Diagnosing 
monosodium urate monohydrate C0037564 Diagnosing 
gouty arthritis C0003868 Diagnosing 
Synovial fluid analysis C0200648 Diagnosing 
around the C0151205 Diagnosing 
tophus C0221248 Diagnosing 
inflammation via multiple mechanisms C0021370 Diagnosing 
blurred vision C0344232 Diagnosing 
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pseudogout C0033802 Diagnosing 
in one or more of your joints C0162296 Diagnosing 
instep C0230472 Diagnosing 
pain C0030193 Diagnosing 
crystal-induced arthropathies C0152087 Diagnosing 
Synovial biopsy C0150887 Diagnosing 
dual energy C0085736 Diagnosing 
Migratory polyarthritis C0240344 Diagnosing 
urate crystals C0344392 Diagnosing 
fever, sore throat C0343487 Diagnosing 
crystals in the joint fluid C0200652 Diagnosing 
Gout – chronic C0268108 Diagnosing 
uric acid production increases C0041981 Diagnosing 
uric acid can build up and form needle-like crystals C0344392 Diagnosing 
Uric acid can form sharp needle-like crystals C0344392 Diagnosing 
Uric acid – blood C0373739 Diagnosing 
Uric acid levels in the blood C0373739 Diagnosing 
under a microscope C0395796 Diagnosing 
health care providers to C0420340 Diagnosing 
Monoarticular involvement C0427254 Diagnosing 
Uric acid – urine C0428286 Diagnosing 
radiographic findings C0436485 Diagnosing 
redness and swelling C0513348 Diagnosing 
calcium pyrophosphate disease C0553730 Diagnosing 
joint damage C0565874 Diagnosing 
joint appears warm C0575034 Diagnosing 
calcium pyrophosphate crystals C0729282 Diagnosing 
Hyperuricemia C0740394 Diagnosing 
Tophaceous gout C0744466 Diagnosing 
of lips, eyes or mouth C0841473 Diagnosing 
Ultrasonographic C1301497 Diagnosing 
plain radiography C1306645 Diagnosing 
radiographs C1306645 Diagnosing 
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crystals within the joint space and deposition of crystals C1401835 Diagnosing 
gout crystals time to dissolve, and that will put a stop to the flares C1619733 Diagnosing 
Posterior interosseous nerve syndrome C1696572 Diagnosing 
attacks often C1867940 Diagnosing 
joints, and knee C1969180 Diagnosing 
Location outside C2016008 Diagnosing 
too much uric acid in the blood C2029412 Diagnosing 
too much uric acid in your blood C2029412 Diagnosing 
Swelling, warmth, erythema (sometimes resembling cellulitis), and C2039039 Diagnosing 
acute gout C2062908 Diagnosing 
Gout – acute C2062908 Diagnosing 
pain starts suddenly, often during C2130139 Diagnosing 
Tophi (multiple C2144520 Diagnosing 
knee, wrist, elbow, or ankle C2677764 Diagnosing 
This usually happens C3263474 Diagnosing 
chalky C3267206 Diagnosing 
pain or discomfort in right upper stomach C3641896 Diagnosing 
gouty joint C3697115 Diagnosing 
are most often affected C3808454 Diagnosing 
can be found in deposits (called tophi) that C3841020 Diagnosing 
toe, but you also can have gout in your knee, ankle, foot, hand, wrist, or C3898946 Diagnosing 
dual energy computed tomography C4055114 Diagnosing 
92 
APPENDIX 2.  COMPLETE NLP OUTPUT 
NLP output from patient clinical notes divided into medication related and 
diagnosis/procedure terms for each stage of the value chain. 
 
Medication Other 
C0332173 daily Recovering dairy products C0010947 Recovering 
   
renal 
impairment C1565489 Recovering 
   dairy C0010948 Recovering 
   renal damage C1408258 Recovering 
 
Medication Other 
C3225726 pain pill Diagnosing pain C0030193 Diagnosing 
   Ingrown hair C0263492 Diagnosing 
   fever C0015967 Diagnosing 
   red C0332575 Diagnosing 
   chest discomfort C0235710 Diagnosing 
   redness and C0017574 Diagnosing 
   Hypogonadism C0020619 Diagnosing 
   chronic gout C0268108 Diagnosing 
   toenail C0222007 Diagnosing 
   Acute bronchitis C0149514 Diagnosing 
   otitis C0029877 Diagnosing 
   blurred vision C0344232 Diagnosing 
   podagra C0221168 Diagnosing 
   
calcium pyrophosphate 
crystals C0729282 Diagnosing 
   pain syndromes C0391976 Diagnosing 
   red blood C0086252 Diagnosing 
   Panniculitis C0030326 Diagnosing 
   redness and swelling C0513348 Diagnosing 
   aching C0001044 Diagnosing 
   pain chest C0008031 Diagnosing 
   Acute gout C2062908 Diagnosing 
   gouty arthritis C0003868 Diagnosing 
   actinic keratosis C0022602 Diagnosing 
   livedo reticularis C0085642 Diagnosing 
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   bone biopsy C0005933 Diagnosing 
   around C0750503 Diagnosing 
   Ingrown C0027343 Diagnosing 
   painful arc C0343214 Diagnosing 
   pain increases C0456441 Diagnosing 
   Otitis externa C0029878 Diagnosing 
   osteoarthritis C0029408 Diagnosing 
   Txp C1134470 Diagnosing 
   radiographic abnormality C0436485 Diagnosing 
   painful skin C0241136 Diagnosing 
   painful lump C2126145 Diagnosing 
   Steatosis C0152254 Diagnosing 
   Dysphonia C1527344 Diagnosing 
   tophus C0221248 Diagnosing 
   tophaceous gout C0744466 Diagnosing 
   hernia repair C0019328 Diagnosing 
   pain tightness C3647127 Diagnosing 
   thymic C0040113 Diagnosing 
   popping C0439820 Diagnosing 
   myofascial C0262941 Diagnosing 
   pain management C0002766 Diagnosing 
   Urticaria C0042109 Diagnosing 
   Externa C0152345 Diagnosing 
   keloid C0022548 Diagnosing 
   microhematuria C0239937 Diagnosing 
   hernia site C4087315 Diagnosing 
   Chronic gastritis C0085695 Diagnosing 
   lichen C0023643 Diagnosing 
   planus C0023646 Diagnosing 
   pain mgmt C0994210 Diagnosing 
   Epidermoid cyst C0014511 Diagnosing 
   pain radiating C0234254 Diagnosing 
   Microalbuminuria C0730345 Diagnosing 
   painful urination C0013428 Diagnosing 
   putty C0263893 Diagnosing 
   Toenail onychomycosis C1274470 Diagnosing 
   Neuropathic C0003892 Diagnosing 
   parasitic C0030498 Diagnosing 
   osteodystrophy C0264009 Diagnosing 
   fever chills C0085594 Diagnosing 
   pain muscle C0231528 Diagnosing 
94 
 
   crusty C0555957 Diagnosing 
   odynophagia C0221150 Diagnosing 
   Dysthymia C0013415 Diagnosing 
   hemarthrosis C0018924 Diagnosing 
   urate crystals C0344392 Diagnosing 
   axillary nerve palsy C2062709 Diagnosing 
   Vascular calcifications C0342649 Diagnosing 
   Disuse osteoporosis C0152256 Diagnosing 
   Phantom C0282611 Diagnosing 
   warmth C0392197 Diagnosing 
   Orchitis C0029191 Diagnosing 
   fell C1425660 Diagnosing 
   arc C0001857 Diagnosing 
   painful joints C0003862 Diagnosing 
   radiographic C1306645 Diagnosing 
   pain much C4085212 Diagnosing 
   Red streaks C2169832 Diagnosing 
   subtalar C0038593 Diagnosing 
   onychomycosis C0040261 Diagnosing 
   Testicular C0205070 Diagnosing 
   Staphylococcal C0038170 Diagnosing 
   flag C1708067 Diagnosing 
   red cell anisopoikilocytosis C3806041 Diagnosing 
   hallux valgus C0018536 Diagnosing 
   pain swelling C0745574 Diagnosing 
   cardiac amyloid C4273093 Diagnosing 
   Toenail avulsion C0851257 Diagnosing 
   Pulmonary Blastomycosis C0339964 Diagnosing 
   red cabbage C0453115 Diagnosing 
   Uric acid level C0041981 Diagnosing 
   Acute C0205178 Diagnosing 
   Spermatic cords C0037855 Diagnosing 
   Tinea corporis C0040252 Diagnosing 
   Labial abscess C0745601 Diagnosing 
   sciatic nerve palsy C0751925 Diagnosing 
   reflux esophagitis C0014869 Diagnosing 
   Hypophonia C0521007 Diagnosing 
   
pyrophosphate crystal 
arthritis C1388597 Diagnosing 
   collagenous colitis C0238067 Diagnosing 
   Axillary lymphadenitis C0919797 Diagnosing 
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   prurigo nodularis C0263353 Diagnosing 
   TMJ C0039493 Diagnosing 
   pain do C1976730 Diagnosing 
   insect bite C0021564 Diagnosing 
   joint arthritis C0158026 Diagnosing 
   red flag sx C3646161 Diagnosing 
   pain the C0004604 Diagnosing 
   Chronic conjunctivitis C0155145 Diagnosing 
   Truncal C0042275 Diagnosing 
   Homans sign C0231781 Diagnosing 
   red macular C2216370 Diagnosing 
   fever call C2051610 Diagnosing 
   Tenosynovitis C0039520 Diagnosing 
   Pilonidal cyst C0031925 Diagnosing 
   Polyarticular gout C0744464 Diagnosing 
   Acute gastritis C0149518 Diagnosing 
   Migratory arthritis C0694577 Diagnosing 
   Enthesopathy C0242490 Diagnosing 
   Sciatic nerve C0036394 Diagnosing 
   Leukocytoclastic vasculitis C2973529 Diagnosing 
   breast biopsy C0405352 Diagnosing 
   Urolithiasis C0451641 Diagnosing 
   tan C0302595 Diagnosing 
   Acute conjunctivitis C0155141 Diagnosing 
   Tonsillitis C0040421 Diagnosing 
   Chronic iritis C0008690 Diagnosing 
   uveitis C0042164 Diagnosing 
   Hemorrhoid thrombosis C0235326 Diagnosing 
   Chronic polyarthritis C1735378 Diagnosing 
   Mucinous adenocarcinoma C0007130 Diagnosing 
   turbinates C1266928 Diagnosing 
   red meats C0452848 Diagnosing 
   Chronic bronchitis C0008677 Diagnosing 
   Genital warts C0009663 Diagnosing 
   hernia C0019270 Diagnosing 
   lymphadenopathy C0497156 Diagnosing 
   Phantom limb C0031315 Diagnosing 
   Amaurosis fugax C0149793 Diagnosing 
   Seborrheic keratosis C0022603 Diagnosing 
   Proliferative C0334094 Diagnosing 
   red rubber C1874753 Diagnosing 
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   majora C0227760 Diagnosing 
   painful bruise C0301928 Diagnosing 
   along C0205154 Diagnosing 
   retina damage C0235272 Diagnosing 
   red and warm C0857810 Diagnosing 
   Actinic skin damage C1879546 Diagnosing 
   meniscal tears C0238218 Diagnosing 
   his C0019602 Diagnosing 
   loose C0205407 Diagnosing 
   red lesions C0241115 Diagnosing 
   red flag signs C4076444 Diagnosing 
   clipping C0175722 Diagnosing 
   Vascular cognitive C3805043 Diagnosing 
   gout C0018099 Diagnosing 
   Pigmented C0031911 Diagnosing 
   Kidney biopsy C0194073 Diagnosing 
   testicular masses C0241353 Diagnosing 
   catheterizable C0261558 Diagnosing 
   multicystic C0032460 Diagnosing 
   joint damage C0565874 Diagnosing 
   Painful bladder spasm C0423735 Diagnosing 
   Sicca syndrome C0086981 Diagnosing 
   pain rectal C0034886 Diagnosing 
   Subungal hematoma C0474975 Diagnosing 
   tinea cruris C1384589 Diagnosing 
   team providers C2224485 Diagnosing 
   MCL C0026691 Diagnosing 
   red warm C0200512 Diagnosing 
   rasied C1417207 Diagnosing 
   Aphthous ulcers C0038363 Diagnosing 
   Fever blister C0019345 Diagnosing 
   rosacea rosacea C0035854 Diagnosing 
   meniscus C0224498 Diagnosing 
   discomfort C2364135 Diagnosing 
   red ring appeared C2322198 Diagnosing 
   bull C0007452 Diagnosing 
   concha C0229316 Diagnosing 
   bullosa C0014527 Diagnosing 
   mouth ulcers C0149745 Diagnosing 
   ragged C1414304 Diagnosing 
   Staphylococcal bacteremia C0152965 Diagnosing 
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   fluid analysis C0200648 Diagnosing 
   much C0205393 Diagnosing 
   painful mucosal C0858804 Diagnosing 
   red plaques C2126304 Diagnosing 
   incision site C0449681 Diagnosing 
   Lateral femorotibial C0447797 Diagnosing 
   scabs C0205204 Diagnosing 
   Moyamoya disease C0026654 Diagnosing 
   around both C2016899 Diagnosing 
   resolution C0300132 Diagnosing 
   Tubulovillous adenoma C0334307 Diagnosing 
   sacroiliitis C0574960 Diagnosing 
   Acute hepatitis C0267797 Diagnosing 
   Locates C0450429 Diagnosing 
   painful neuropathy C1850383 Diagnosing 
   
Bronchopulmonary 
Aspergillosis C2350530 Diagnosing 
   Schatzki ring C0267081 Diagnosing 
   Alport syndrome C1567741 Diagnosing 
   axillary swelling C0741354 Diagnosing 
   Pneum C0032285 Diagnosing 
   Road C0442650 Diagnosing 
   red blotches C0857199 Diagnosing 
   Subclinical C0205211 Diagnosing 
   tuberculous meningitis C0041318 Diagnosing 
   cryptorchidism C0010417 Diagnosing 
   exit C0337094 Diagnosing 
   team C0871489 Diagnosing 
   Endomyocardial biopsy C0189785 Diagnosing 
   Testicular hypofunction C0271622 Diagnosing 
   Graves disease C0018213 Diagnosing 
   concha bullosa C0339821 Diagnosing 
   suspicious C0233519 Diagnosing 
   cubital tunnel C0230376 Diagnosing 
   bilat C0155516 Diagnosing 
   paraesthesias C0030554 Diagnosing 
   Nephrogenic C0391869 Diagnosing 
   around joints C0394854 Diagnosing 
   per your blood C0267596 Diagnosing 
   
Calcium pyrophosphate 
arthropathy C0856830 Diagnosing 
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   eyebrow C0015420 Diagnosing 
   
Seronegative rheumatoid 
arthritis C0409652 Diagnosing 
   excisional biopsy C0184921 Diagnosing 
   toenail infection C0749565 Diagnosing 
   synovial hypertrophy C0410574 Diagnosing 
   posterior tibiotalar joint C2182275 Diagnosing 
   midfoot osteoarthritis C3840160 Diagnosing 
   vascular abnormalities C0241657 Diagnosing 
   Myoglobinuria C0027080 Diagnosing 
   red vaginal C0241635 Diagnosing 
   Exogenous C0205228 Diagnosing 
   Sclerodactyly C0150988 Diagnosing 
   osteitis C0029400 Diagnosing 
   around site C0509447 Diagnosing 
   hairy leukoplakia C0206186 Diagnosing 
   Red River C0328125 Diagnosing 
   redness or C0327344 Diagnosing 
   pansystolic murmur C0232258 Diagnosing 
   red papules C0859044 Diagnosing 
   Chronic anxiety C0581386 Diagnosing 
   tophi elbow C3862729 Diagnosing 
   burden C2828008 Diagnosing 
   detrusor instability C1261562 Diagnosing 
   insuf C0029626 Diagnosing 
   red stool C0278012 Diagnosing 
   Atrophic C0333641 Diagnosing 
   redness swelling C2109113 Diagnosing 
   Pain scale C1504479 Diagnosing 
   toenail injury C0347575 Diagnosing 
   
Systemic lupus 
erythematosus C0024141 Diagnosing 
   peat C0030739 Diagnosing 
   numbness C0028643 Diagnosing 
   Mole C0027960 Diagnosing 
   around the facet C0394850 Diagnosing 
   ileitis C0020877 Diagnosing 
   lines along C2138577 Diagnosing 
   satellite lesions C0445304 Diagnosing 
   calcinosis C0006663 Diagnosing 
   Hemorrhoid C0019112 Diagnosing 
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   painful dysphagia C2183443 Diagnosing 
   the epiglottis C1396772 Diagnosing 
   Sjogren C1527336 Diagnosing 
   redness later C2127376 Diagnosing 
   Munchausen syndrome C0026785 Diagnosing 
   double vision C0012569 Diagnosing 
   99nitial arthritis C3829814 Diagnosing 
   pain syn C0016053 Diagnosing 
   callus C0376154 Diagnosing 
   painful muscle spasms C4023104 Diagnosing 
   red tinge C3266636 Diagnosing 
   energy C0424589 Diagnosing 
   aortitis C0003509 Diagnosing 
   fever osteomyelitis C1443896 Diagnosing 
   Red macules C2089446 Diagnosing 
   staples C0185012 Diagnosing 
   vision C0042789 Diagnosing 
   Osteitis pubis C0221010 Diagnosing 
   Migratory polyarthritis C0240344 Diagnosing 
   Seizure gout alcoholism C0586323 Diagnosing 
   
acromioclavicular joint 
arthritis C1998181 Diagnosing 
   Acute asthma C0582415 Diagnosing 
   bowel biopsy C0192611 Diagnosing 
   hernia recurrence C0281961 Diagnosing 
   Red raised patch C2674296 Diagnosing 
   pain chronically C0150055 Diagnosing 
   healed C0043240 Diagnosing 
   Epigastic C3130255 Diagnosing 
   around the vagus C0842552 Diagnosing 
   radiocarpal joint C0043265 Diagnosing 
   pain cramping C0458254 Diagnosing 
   Axillary nerve C0228885 Diagnosing 
   red brown C0381431 Diagnosing 
   red blood inhis stool C0018932 Diagnosing 
   or warm C0509768 Diagnosing 
   Ehrlichiosis C0085399 Diagnosing 
   Fever Antibody C0373883 Diagnosing 
   Asplenia C0600031 Diagnosing 
   fever hepatitis C0424776 Diagnosing 
   orthopnea C0085619 Diagnosing 
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   Meniscal C1504554 Diagnosing 
   vestibular nerve damage C0235928 Diagnosing 
   labial biopsy C0399303 Diagnosing 
   around the vulva C3670692 Diagnosing 
   lichen sclerosis C0023652 Diagnosing 
   painful vulvar C0241718 Diagnosing 
   Around the ears C2053145 Diagnosing 
   pseudotumor cerebri C0033845 Diagnosing 
   painful mass C1709448 Diagnosing 
   cadaveric C0304209 Diagnosing 
   Dieulafoy lesion C0341217 Diagnosing 
   Infective otitis externa C0021355 Diagnosing 
   clonal C1704387 Diagnosing 
   painful hemorrhoids C0744805 Diagnosing 
   hyperresonant C0231882 Diagnosing 
   red cell anisocytosis C0221278 Diagnosing 
   red mass C0086899 Diagnosing 
   pain hip C0019559 Diagnosing 
   acute cystitis C0149523 Diagnosing 
   redness increases C1512696 Diagnosing 
   pain neck C0007859 Diagnosing 
   her C0446375 Diagnosing 
   punch biopsy C0184924 Diagnosing 
   fever or any C0041466 Diagnosing 
   chronic C0205191 Diagnosing 
   otitis media C0029882 Diagnosing 
   painful burning C0234230 Diagnosing 
   these C0039828 Diagnosing 
   spondyloarthropathy C0949691 Diagnosing 
   Polymyalgia rheumatica C0032533 Diagnosing 
   acute appendicitis C0085693 Diagnosing 
   radiculopathy C0700594 Diagnosing 
   Acromegaly C0001206 Diagnosing 
   bacilli C0004587 Diagnosing 
   Hepatopulmonary syndrome C0600452 Diagnosing 
   osteogenesis imperfecta C0029434 Diagnosing 
   red site C1504570 Diagnosing 
   cheat C0683305 Diagnosing 
   around lesion C2168390 Diagnosing 
   flat C0205324 Diagnosing 
   red hot C0541781 Diagnosing 
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   synovial biopsy C0150887 Diagnosing 
   shave biopsy C0184923 Diagnosing 
   under C0542339 Diagnosing 
   
interphalangeal joint 
synovitis C0730096 Diagnosing 
   pain intensity C1320357 Diagnosing 
   pain tenderness C0234233 Diagnosing 
   pain laterality C0740543 Diagnosing 
   ophthalmoplegia C0029089 Diagnosing 
   
Prolapsed internal 
hemorrhoids C0265037 Diagnosing 
   chronic thrombocytopenia C0749393 Diagnosing 
   Latent tuberculosis C1609538 Diagnosing 
   around outside C3642088 Diagnosing 
   Toxoplasmosis C0040558 Diagnosing 
   around base C1314395 Diagnosing 
   colloid C0009361 Diagnosing 
   Red skin C0041834 Diagnosing 
   Red Dye C1509471 Diagnosing 
   osteomyelitic C0158381 Diagnosing 
   Molluscum contagiosum C0026393 Diagnosing 
   navel C0041638 Diagnosing 
   Xerosis cutis C0263465 Diagnosing 
   polyarthritis C0162323 Diagnosing 
   Inclusion cyst C0259770 Diagnosing 
   Acute otitis C0149510 Diagnosing 
   sob C0010399 Diagnosing 
   Bartholin cyst C0004767 Diagnosing 
   Painful supination C1998080 Diagnosing 
   fever break C0011311 Diagnosing 
   fibrofatty C0225350 Diagnosing 
   symphyseal C0034015 Diagnosing 
   damage C0010957 Diagnosing 
   pulsatile C0439606 Diagnosing 
   desmoid tumor C0079218 Diagnosing 
   pain diary C0451366 Diagnosing 
   polish C0220896 Diagnosing 
   strauss C0008728 Diagnosing 
   redness accompanying C2029700 Diagnosing 
   Footdrop C0085684 Diagnosing 
   Migratory C0232901 Diagnosing 
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   hypoadrenal C0001623 Diagnosing 
   cardiac cachexia C0562491 Diagnosing 
   Pigmented gallstones C3278865 Diagnosing 
   red blanching C2126289 Diagnosing 
   Acute gout wrist C0750439 Diagnosing 
   any blood C0373612 Diagnosing 
   Cardiac C0018787 Diagnosing 
   debris C0440266 Diagnosing 
   polyarteritis nodosa C0031036 Diagnosing 
   tegmen tympani C0927520 Diagnosing 
   Painful orthopedic C1393396 Diagnosing 
   snoring C0037384 Diagnosing 
   around incision C2055676 Diagnosing 
   hallux malleus C2355596 Diagnosing 
   Submucosal C1515025 Diagnosing 
   Prostate biopsy C0194804 Diagnosing 
   vascular C0042382 Diagnosing 
   sarcoid C0036202 Diagnosing 
   painful bone C0151825 Diagnosing 
   detrusor weakness C0235091 Diagnosing 
   Vascular anomaly C0158570 Diagnosing 
   Enterovirus C0014383 Diagnosing 
   fever sweats C0038992 Diagnosing 
   red blood cell morphology C0200655 Diagnosing 
   spread C0332261 Diagnosing 
   Quadriparesis C0270790 Diagnosing 
   fever cough C1277295 Diagnosing 
   warts C0347390 Diagnosing 
   Acute bronchiolitis C0001311 Diagnosing 
   Nonalcoholic steatohepatitis C3241937 Diagnosing 
   quadrantanopsia C0544680 Diagnosing 
   ILD C0206062 Diagnosing 
   thymic hyperplasia C0040115 Diagnosing 
   inflammation C0021368 Diagnosing 
   arsenic C0104238 Diagnosing 
   pain jaw C0236000 Diagnosing 
   DMI C0011685 Diagnosing 
   red mucosa C3277147 Diagnosing 
   within the C0425538 Diagnosing 
   pain AC joint arthritis C4256999 Diagnosing 
   red discoloration C2054394 Diagnosing 
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   more C0205172 Diagnosing 
   chemosis C0271298 Diagnosing 
   carpal arthritis C0741990 Diagnosing 
   Mt C0036525 Diagnosing 
   joint discomfort C3544124 Diagnosing 
   gouty joint C3697115 Diagnosing 
   Myelofibrosis C0026987 Diagnosing 
   around the ulcers C0857313 Diagnosing 
   bloating C1291077 Diagnosing 
   hardware C1523994 Diagnosing 
   pain leg C0023222 Diagnosing 
   porphyria cutanea tarda C0162566 Diagnosing 
   Mosquito bites C0417744 Diagnosing 
   NM C0203634 Diagnosing 
   instep C0230472 Diagnosing 
   
degenerative 
spondylolisthesis C0264184 Diagnosing 
   Sacrococcygeal C1550300 Diagnosing 
   Red nasal C2071372 Diagnosing 
   painful site C1718183 Diagnosing 
   hyoid bone C0020417 Diagnosing 
   infrapatellar C0224829 Diagnosing 
   midline C0549183 Diagnosing 
   margins C0205284 Diagnosing 
   Broca dysphasia C0003550 Diagnosing 
   painful red C0853395 Diagnosing 
   kinetic C0022702 Diagnosing 
   Chronic hypokalemia C0268016 Diagnosing 
   hallux C0018534 Diagnosing 
   tingling C2242996 Diagnosing 
   Polydypsia C0085602 Diagnosing 
   
Antiphospholipid antibody 
syndrome C0085278 Diagnosing 
   Cryptococcal Meningitis C0085436 Diagnosing 
   redness erythema C0497364 Diagnosing 
   Streptococcal C0038402 Diagnosing 
   Pulmonary cryptococcus C0748116 Diagnosing 
   IBD C0021390 Diagnosing 
   chondrosarcoma C0008479 Diagnosing 
   mutation analysis C0796357 Diagnosing 
   arachnoiditis chronic C0238005 Diagnosing 
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   toenail bruise C0274239 Diagnosing 
   chronic hematoma C0749095 Diagnosing 
   Coccygeal C1550233 Diagnosing 
   toenail abnormalities C1968817 Diagnosing 
   radiographic compression C0180058 Diagnosing 
   
interphalangeal joint 
arthroplasty C0187577 Diagnosing 
   Spigelian hernia repair C0198555 Diagnosing 
   Spigelian C0392508 Diagnosing 
   pulmonary biopsy C3806336 Diagnosing 
   Axillary abscess C0263115 Diagnosing 
   Acute psychosis C0281774 Diagnosing 
   painful lesion C0241091 Diagnosing 
   adb C0236504 Diagnosing 
   utd C3845665 Diagnosing 
   orthopedic screws C3826642 Diagnosing 
   orthopedic hardware C1961571 Diagnosing 
   painful within the bone C2219991 Diagnosing 
   issues C0033213 Diagnosing 
   urticaria pigmentosa C0042111 Diagnosing 
   cores C0444669 Diagnosing 
   Pyoderma gangrenosum C0085652 Diagnosing 
   solitary C0205171 Diagnosing 
   Dual energy C0085736 Diagnosing 
   Staghorn calculus C0333014 Diagnosing 
   BPPV C0155502 Diagnosing 
   red cell aplasia C0034902 Diagnosing 
   
Waldenstrom 
macroglobulinemia C0024419 Diagnosing 
   MDD C0262218 Diagnosing 
   Gastric antral biopsy C0586699 Diagnosing 
   arrythmias C0003811 Diagnosing 
   Wegeners granulomatosis C3495801 Diagnosing 
   Rectocele repair C0677487 Diagnosing 
   Acute Esophagitis C0149882 Diagnosing 
   Takayasu C0039263 Diagnosing 
   around transplanted C2220728 Diagnosing 
   Phthisis bulbi C0271007 Diagnosing 
   Gliomatosis cerebri C0334576 Diagnosing 
   panus C1093286 Diagnosing 
   Phrenic nerve palsy C1442879 Diagnosing 
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   pain postoperatively C0030201 Diagnosing 
   glans C1550261 Diagnosing 
   Pilonidal disease C2317114 Diagnosing 
   red erythematous C3845932 Diagnosing 
   pancreatis C0227579 Diagnosing 
   pain hematuria C0473234 Diagnosing 
   Pulmonary embolus C0034065 Diagnosing 
   Solar damage C0850866 Diagnosing 
   Chronic joint discomfort C0232491 Diagnosing 
   just C0442728 Diagnosing 
   pain discomfort C0237277 Diagnosing 
   sinusitis C0037199 Diagnosing 
   CF C0010674 Diagnosing 
   red spot C0376341 Diagnosing 
   pain knee C0231749 Diagnosing 
   pain stimulator C1709449 Diagnosing 
   CMC C0065772 Diagnosing 
   red blood scan C0948706 Diagnosing 
   around suprascapular C0842558 Diagnosing 
   tophi finger C2088173 Diagnosing 
   Menometrorrhagia C0232943 Diagnosing 
   hue C0678581 Diagnosing 
   acute arthritis C0263678 Diagnosing 
   Tinnitus C0040264 Diagnosing 
   chord C0344749 Diagnosing 
   PTLD C0432487 Diagnosing 
   painful pop C4038661 Diagnosing 
   hallux interphalangeal C0447828 Diagnosing 
   diagnostic biopsy C0401747 Diagnosing 
   Eisenmenger syndrome C0013743 Diagnosing 
   Streptococcal bacteremia C0152964 Diagnosing 
   psych C0229992 Diagnosing 
   radiocapitellar C1403299 Diagnosing 
   Kaposi sarcoma C0036220 Diagnosing 
   
patellofemoral compartment 
osteoarthritis C1542808 Diagnosing 
   chondrocalcinosis C0553730 Diagnosing 
   painful arthritis C0718667 Diagnosing 
   pessary C0031246 Diagnosing 
   Aseptic meningitis C0025290 Diagnosing 
   painful bleed C1533092 Diagnosing 
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   Pagets disease C1368019 Diagnosing 
   blood flow C0232338 Diagnosing 
 
Medication Other 
C0028156 NITROFURANTOIN Screening obese C0028754 Screening 
C0591139 Bactrim Screening diabetes C0011847 Screening 
C0699142 Tylenol Screening Kidney Disease C0022658 Screening 
C0876060 keppra Screening drink C0684271 Screening 
C0749139 sulfa Screening Family history of Cancer C0260515 Screening 
C0700899 Benadryl Screening 
Family history of 
Cardiomyopathy C1272241 Screening 
C0243237 Docusate sodium Screening hyperuricemia C0740394 Screening 
C3516158 Kidney Medicine Screening Lupus C0024131 Screening 
C0209368 Mycophenolate mofetil Screening hypoparathyroidism C0020626 Screening 
C1995848 
Flunisolide nostril 
inhaler Screening diabetic neuropathy C0011882 Screening 
C1692318 Docusate Screening Hypoxemia C0700292 Screening 
C0728963 lovenox Screening osteoarthritis C0029408 Screening 
C0286677 Flonase Screening 
Family history of 
Tuberculosis C0455351 Screening 
C2945755 Flonase spray Screening Family history of C0015584 Screening 
C0678143 Zithromax Screening Breast cancer C0006142 Screening 
C0585361 bid Screening 
Family history of 
Hypercholesterolemia C2732832 Screening 
C0038317 steroid Screening 
Family history of 
Hypertension C0455405 Screening 
C0161672 Yellow fever vaccine Screening 
Family history of 
Emphysema C2315858 Screening 
C0022957 Lactulose Screening 
Family history of Heart 
Disease C2186266 Screening 
C0060926 Gabapentin Screening Sinusitis C0037199 Screening 
C1636686 Byetta Screening tuberculosis C0041296 Screening 
C3224278 Benadryl pill Screening 
Family history of Lung 
Cancer C0728711 Screening 
C0085240 Lupus anticoagulant Screening rhinorrhea C1260880 Screening 
C0875967 Avandia Screening Groin discomfort C1096590 Screening 
C0003232 Antibiotics Screening Sad C0085159 Screening 
C0085758 Tca Screening 
family history of breast 
cancer C0559119 Screening 
C0002598 amiodarone Screening Family history of asthma C1261327 Screening 
C2683919 Byetta pen Screening 
Family history of 
rheumatoid arthritis C0221614 Screening 
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C0016365 fluoxetine Screening Prostate cancer C0376358 Screening 
C1319409 diabetic medicines Screening 
Family history of Alcohol 
Abuse C0476560 Screening 
C3214596 flecainide pill Screening 
Family history of 
Depression C0455383 Screening 
C3230437 diabetes pill Screening 
Family history of thyroid 
disease C0850707 Screening 
   
Family history of 
Osteoarthritis C0455444 Screening 
   PRN C0558288 Screening 
   hemochromatosis C0018995 Screening 
   hemochromatosis gene C1384665 Screening 
   during the night C3845370 Screening 
   
Family history of 
polycystic C0455422 Screening 
   warm C0687712 Screening 
   drinking alcohol C0001948 Screening 
   Kidney C0022646 Screening 
   
family history of kidney 
cancer C0700102 Screening 
   Fibromyalgia C0016053 Screening 
   
Family history of 
hyperlipidemia C4040131 Screening 
   Dyspepsia C0013395 Screening 
   Family history of Gout C0221613 Screening 
   
family history of prostate 
cancer C1532320 Screening 
   gout C0018099 Screening 
   
Family history of 
Arthritis C0221565 Screening 
   
Family history of prostate 
cancer nephrolithiasis C1563033 Screening 
   Hypertensive C0020538 Screening 
   cecal C0007531 Screening 
   history of Hemodialysis C4047993 Screening 
   
Family history of Alcohol 
addiction C3541869 Screening 
   
Osteoarthritis of 
glenohumeral C0409939 Screening 
   Quant C0695050 Screening 
   
family history of renal 
disease C2316874 Screening 
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Family history of 
Multiple Sclerosis C0455388 Screening 
   
Family history of Colon 
Cancer C0730200 Screening 
   Family history C0241889 Screening 
   Kidney Surgery C0194053 Screening 
   diabetes management C0150544 Screening 
   denies C0332319 Screening 
   diabetes complications C0342257 Screening 
   drink some juice C2136335 Screening 
   after transplant C3896643 Screening 
   diabetes disease C0085207 Screening 
   Diabetes History C0455678 Screening 
   
intertrochanteric femur 
fracture C0162385 Screening 
   hypogammaglobulinemia C0086438 Screening 
   
family history of 
dementia C2315857 Screening 
   
history of cerebrovascular 
accident C0559159 Screening 
   
Family history of 
cataracts C0455398 Screening 
   
Family history of Brain 
Cancer C1997137 Screening 
   family history of urologic C0455360 Screening 
   diabetic exam C3162295 Screening 
   diabetic gastroparesis C0267176 Screening 
   history of CABG C1842251 Screening 
   
Family history of Liver 
Cancer C1998287 Screening 
   Unspecified C0205370 Screening 
   hyperthyroidism C0020550 Screening 
   
Family history of 
Alcoholism C0559555 Screening 
   
family history of 
aneurysm C1271046 Screening 
   CAMPYLOBACTER C0006813 Screening 
   diabetes insipidus C0011848 Screening 
   numbness big toe C0587056 Screening 
   genetic factors C0814299 Screening 
   Family history of Anxiety C4061647 Screening 
   Anxiety disorder C0003469 Screening 
   kidney cancer C0740457 Screening 
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   YERSINIA C0043405 Screening 
   Family history of HIV C2584882 Screening 
   Sickle cell disease C0002895 Screening 
   Sickle cell trait C0037054 Screening 
   Debility C3714552 Screening 
   Hypoalbuminemia C0239981 Screening 
   etoh C0001962 Screening 
   
Family history of 
Cerebral Palsy C0455391 Screening 
   after surgery C0241311 Screening 
   Diabetic ulcer of toe C2183144 Screening 
   diabetic socks C3876752 Screening 
   diabetic enteropathy C0400875 Screening 
   Diabetes check C1655734 Screening 
   dysuria C0013428 Screening 
   Skin warm C0235218 Screening 
   
Family history of 
Leukemia C0260512 Screening 
   diabetic retinopathy C0011884 Screening 
   
family history of liver 
disease C0455417 Screening 
   too C0067954 Screening 
   Family history of anemia C0260528 Screening 
   history of Brain tumor C1997047 Screening 
   Family history of cardiac C3669347 Screening 
   Gluteal C1550262 Screening 
   serious C0205404 Screening 
   
neoplasm uncertain 
behavior C0154129 Screening 
   lightheadedness C0220870 Screening 
   Mold C0369241 Screening 
   Osteoarthritis of knee C0409959 Screening 
   diabetic nephropathy C0011881 Screening 
   Axillary C0004454 Screening 
   Hypophosphatemia C0085682 Screening 
   Cytomegalovirus viremia C0877635 Screening 
   cytomegalovirus disease C0010823 Screening 
   Diabetic polyneuropathy C0271680 Screening 
   polyneuropathy C0152025 Screening 
   diabetic autonomic C0271686 Screening 
   Diabetic Hypoglycemia C0865166 Screening 
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Family history of 
Hepatitis C0559141 Screening 
   
Family history of 
Pulmonary Disease C3887084 Screening 
   
Diabetic peripheral 
neuropathy C0740447 Screening 
   history of Pneumonia C0455542 Screening 
   diabetic eye C0342245 Screening 
   Kidney injury C0160420 Screening 
   Acetone C0001002 Screening 
   
Family history of 
Glaucoma C0455397 Screening 
   history of Diphtheria C1446286 Screening 
   Gastric bypass surgery C0192398 Screening 
   obesity history C0455493 Screening 
   
Family history of kidney 
disease C0260532 Screening 
   Hiccups C0019521 Screening 
   tingling C2242996 Screening 
   sarcoid C0036202 Screening 
   Stump C0002690 Screening 
   
Family history of Bladder 
Cancer C2316064 Screening 
   campylobacter ab C0945898 Screening 
   Campylobacter Jejuni C0006819 Screening 
   odynophagia C0221150 Screening 
   Neoplasm C0027651 Screening 
   
Family history of 
Cervical Cancer C1997259 Screening 
   Diabetic foot C0206172 Screening 
   
Family history of 
Coronary Arteriosclerosis C2317524 Screening 
   Kidney lesion C1402288 Screening 
   history of Heart problem C0559157 Screening 
   Family history of Hernia C3887151 Screening 
   kidney disease requiring C1719537 Screening 
   Hydrocele repair C0558336 Screening 
   diabetes post C1504532 Screening 
   
Family history of 
Alzheimer Disease C1271045 Screening 
   Kidney calculi C0022650 Screening 
   Orthopedic surgery C0162439 Screening 
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   drink water C0599638 Screening 
   
Family history of 
Cirrhosis C3887082 Screening 
   Murder C0086660 Screening 
   Constipation C0009806 Screening 
   
Family history of 
Gallbladder Disease C0559142 Screening 
   
Family history of Skin 
Cancer C1997275 Screening 
   
Family history of macular 
degeneration C0520726 Screening 
   Hypocalcemia C0020598 Screening 
   family history of blood C0455376 Screening 
   after menopause C0587113 Screening 
   
Family history of 
Hypercalcemia C0342637 Screening 
   
Family history of 
Hyperparathyroidism C3887070 Screening 
   diabetic shoes C0499344 Screening 
   Discitis C0012624 Screening 
   
Family history of 
malignant neoplasm C1261378 Screening 
   Menieres disease C0025281 Screening 
   Appendicitis C0003615 Screening 
   hyperventilation C0020578 Screening 
   kidney disease or C0543793 Screening 
   scarlet fever C0036285 Screening 
   Neurogenic bladder C0005697 Screening 
   radiculopathy C0700594 Screening 
   Labial abscess C0745601 Screening 
   
Family history of Throat 
cancer C3887008 Screening 
   
Family history of 
migraine C0455393 Screening 
   Family history of celiac C2316251 Screening 
   Diabetic ulcer C0743150 Screening 
   history of Deceased C2229976 Screening 
   drink water to C0522749 Screening 
   axillary lymphadenopathy C0578735 Screening 
   drink liquor C0425331 Screening 
   
Family history of 
Hypothyroidism C0577643 Screening 
   base of the C0225810 Screening 
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   Diabetic foot ulcer C0406526 Screening 
   again C0723612 Screening 
   at night C0240526 Screening 
   Dry cough C0850149 Screening 
   osteoarthritis of the hip C0029410 Screening 
   
Family history of 
Hyperthyroidism C2317124 Screening 
   Accidental Drowning C0867949 Screening 
   soda C0683086 Screening 
   diabetic ketoacidosis C0011880 Screening 
   
Family history of 
Ischemic stroke C0260518 Screening 
   
Family history of 
Pulmonary Embolism C2317597 Screening 
   Dry mouth C0043352 Screening 
   granulomatosis disease C0024307 Screening 
   Osteoarthritis bilateral C4081953 Screening 
   Umbilical C0041638 Screening 
   
history of Gunshot 
Wound C2169624 Screening 
   history of Hysterectomy C0438065 Screening 
   Apathetic C0085632 Screening 
   Osteopetrosis C0029454 Screening 
   
Family history of 
Parkinson Disease C0574092 Screening 
   
Family history of Thyroid 
Cancer C2316063 Screening 
   after working C0425088 Screening 
   Vitiligo C0042900 Screening 
   
Family history of 
Essential 
Hypertriglyceridemia C0559122 Screening 
   
Family history of 
Osteoporosis C2911643 Screening 
   Diabetes type C1320657 Screening 
   hypoglycemia C0020615 Screening 
   Family history of obesity C0455373 Screening 
   habitus C0013170 Screening 
   
Family history of 
Pulmonary Fibrosis C1800706 Screening 
   Colorectal cancer staging C0677947 Screening 
   after urination C1821649 Screening 
   Incontinence C0021167 Screening 
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   Lymphedema of leg C1275454 Screening 
   family history of early C0455427 Screening 
   drink sugar C0452443 Screening 
   
Family history of 
Multiple Myeloma C2317109 Screening 
   
Family history of Simple 
Goiter C2186265 Screening 
   persistent fever C0476474 Screening 
   
family history of 
autoimmune disease C0577642 Screening 
   
history of Metastatic 
Cancer C2170476 Screening 
   history of Bradycardia C4038788 Screening 
   nights sweats C0028081 Screening 
   hemoptysis C0019079 Screening 
   
Family history of 
Hydrocephalus C4038808 Screening 
   Fungus C0016832 Screening 
   after fall C2135413 Screening 
   diabetic on C0421248 Screening 
   diabetic peripheral C0011871 Screening 
   SLE C0024141 Screening 
   bursitis C0006444 Screening 
   diabetes hypertension C0543574 Screening 
   neuropathic pains C3714625 Screening 
   Metabolic bone disease C0005944 Screening 
   
Family history of 
Polycythemia Vera C1264016 Screening 
   
Family history of 
Migraine Headache C2367596 Screening 
   nephrosclerosis C0027719 Screening 
   made C0425087 Screening 
   fibroids C0023267 Screening 
   
Nonalcoholic 
Steatohepatitis C3241937 Screening 
   
Family history of 
bleeding C2186261 Screening 
   atherosclerosis C0004153 Screening 
   bipolar disease C0005587 Screening 
   ataxia C0004134 Screening 
   history of Adopted child C2367303 Screening 
   Diabetic macular C0730285 Screening 
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   AAA C0162871 Screening 
   Recurrent UTI C0262655 Screening 
   history of Dialysis C0455667 Screening 
   
family history of 
colorectal cancers C3266797 Screening 
   diabetic injury C3875503 Screening 
   
Family history of 
Supranuclear palsy C2931887 Screening 
   family history of sleep C2315516 Screening 
   drink much C0848500 Screening 
   history of Arteritis C3532493 Screening 
   Dyslipidemia C0242339 Screening 
   microalbuminuria C0730345 Screening 
   
Family history of 
Pancreatic C1997382 Screening 
   Family history of Allergy C0455453 Screening 
   
Family history of 
Paranoid Schizophrenia C0455382 Screening 
   Diabetic diet C0011878 Screening 
   
infraclavicular 
lymphadenopathy C1264066 Screening 
   Migraine headache C0149931 Screening 
   nutritionist C0237083 Screening 
   high fever C0743973 Screening 
   
gastroesophageal reflux 
disease C0017168 Screening 
   
history of 
Adenocarcinoma C1997170 Screening 
   blood clots in C0423010 Screening 
   
Family history of 
Congenital abnormality C0496711 Screening 
   diabetes other C0011870 Screening 
   Family history of bipolar C0455384 Screening 
   amyloidosis C0002726 Screening 
   Family history of kidney C1397162 Screening 
   approximately C0332232 Screening 
   
Family history of 
Melanoma C1996990 Screening 
   Acne vulgaris C0001144 Screening 
   
Family history of Gastric 
Ulcer C0559140 Screening 
   Attacks are C2751362 Screening 
   coryza C0086066 Screening 
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   sarcoid disease C0340432 Screening 
   Lupus nephritis C0024143 Screening 
   nephritis C0027697 Screening 
   Lymphedema of arm C0730207 Screening 
   
Family history of Peptic 
Ulcer C0455415 Screening 
   Family history of Hearing C0260538 Screening 
   history of macular C3839192 Screening 
   Kidney transplant C0022671 Screening 
   Family history of Smoker C1542099 Screening 
   waist C0230097 Screening 
   kidney atrophy C0341698 Screening 
   Neuropathic C0003892 Screening 
   diabetic amyotrophy C0271685 Screening 
   Strabismus Surgery C0197981 Screening 
   drink alcohol occasionally C0556298 Screening 
   Aneuric C0049161 Screening 
   Family history of Mental C1397167 Screening 
   Family history of Thyroid C0455366 Screening 
   
Family history of 
Epilepsy C0455392 Screening 
   arthropathy C0022408 Screening 
   trended C1521798 Screening 
   any fevers C0041466 Screening 
   Ureteral C0041959 Screening 
   intense C0522510 Screening 
   nonobstructing C0264787 Screening 
   Headaches C0018681 Screening 
   hemoperitoneum C0019065 Screening 
   
family history of 
headache C2316204 Screening 
   history of Tachycardia C3887026 Screening 
   
Family history of 
Esophageal Reflux C3494804 Screening 
   Acne C0702166 Screening 
   diabetic dietary C0562216 Screening 
   
family history of 
endocrine disease C0455365 Screening 
   Kidney mass C0262613 Screening 
   
Family history of Breast 
Cyst C2315879 Screening 
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bruising or other 
abnormalities C0679314 Screening 
   Osteoarthritis hands C0263746 Screening 
   Celiac Crisis C1300681 Screening 
   
history of Aplastic 
Anemia C1997103 Screening 
   diabetic clinic C3839636 Screening 
   
hypertensive 
nephrosclerosis C0264657 Screening 
   Osteoarthritis of ankle C0409931 Screening 
   
Family history of 
Atherosclerosis C0455407 Screening 
   perforated diverticulitis C0544794 Screening 
   wound healing C0043240 Screening 
   salmonella enteritis C0036114 Screening 
   Meningioma C0025286 Screening 
   
Family history of 
Psoriasis C0455439 Screening 
   Txp C1134470 Screening 
   umbilical hernia repair C0019333 Screening 
   diabetic neuropathic C0343178 Screening 
   kidney disease III C1868148 Screening 
   Prediabetes C0362046 Screening 
   Cellulitis C0007642 Screening 
   hepatocellular disease C0023895 Screening 
   Bronchitis C0006277 Screening 
   
Family history of 
Rheumatic Fever C2315907 Screening 
   CRC C0170127 Screening 
   diabetes in C0032969 Screening 
   obesity complicates C3647716 Screening 
   Pituitary adenoma C0032000 Screening 
   
Family history of 
Essential 
Hypercholesterolemia C0020445 Screening 
   
Family history of Oxygen 
deficit C2316880 Screening 
   Chromhidrosis C0263473 Screening 
   
Family history of 
Psoriatic C2315905 Screening 
   keratoconus C0022578 Screening 
   after C0231290 Screening 
   Dysplastic nevus C0205748 Screening 
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Family history of 
Accidental death C0425043 Screening 
   Family history of Ulcer C0574097 Screening 
   Kidney tumor C0022665 Screening 
   obesity nutrition C1408387 Screening 
   Alzheimer disease C0002395 Screening 
   kidney disease stage C0022661 Screening 
   
Family history of 
Malignant Lymphoma C2315022 Screening 
   sickle cell C0221283 Screening 
   diabetic agents C0935929 Screening 
   chest discomfort C0235710 Screening 
   lupus arthritis C0541786 Screening 
   perirectal abscess C0267566 Screening 
   
Family history of 
Cerebral C2584725 Screening 
   nephrocalcinosis C0027709 Screening 
   barrier laser C0302718 Screening 
   Gastroenteritis C0017160 Screening 
   diabetic control C0421257 Screening 
   Dyspnea C0013404 Screening 
   bm C0011135 Screening 
   
Family history of Blood 
infection C0554872 Screening 
   MELAS C0162671 Screening 
   
family history of 
parathyroid C1840403 Screening 
   hyponatremia C0020625 Screening 
   kidney hydronephrosis C1385560 Screening 
   Gallstone pancreatitis C0521614 Screening 
   airway disease C0699949 Screening 
   occasional C0521114 Screening 
   
Hypocalcemia and 
hypophosphatemia C0475815 Screening 
   radiofrequency C2347883 Screening 
   adhesions C0001511 Screening 
   fever C0015967 Screening 
   278 C0075763 Screening 
   
Family history of 
systemic lupus C3887087 Screening 
   much C0205393 Screening 
   MRSA C1265292 Screening 
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Family history of 
Hyperlipoproteinemia C0700623 Screening 
   
Family history of colonic 
polyps C2911243 Screening 
   Old age C1999167 Screening 
   obese weight C0740216 Screening 
   Saturday night C0270796 Screening 
   better C0332272 Screening 
   
Family history of 
deafness C1442747 Screening 
   
Family history of 
Parkinsonism C2939151 Screening 
   Toxic C0600688 Screening 
   Breast discomfort C0877338 Screening 
   osteoarthritis in multiple C0559096 Screening 
   become C0429569 Screening 
   history of testicular C1960622 Screening 
   NASH C1092184 Screening 
   Cirrhosis C0023890 Screening 
   posttraumatic C0152086 Screening 
   hernia repair C0019328 Screening 
   diabetes poorly C0554876 Screening 
   
Family history of 
Hodgkin Disease C2316879 Screening 
   tophaceous C0744466 Screening 
   ketoacidosis C0220982 Screening 
   history of Opioid abuse C3266352 Screening 
   speech C0037817 Screening 
   
Family history of 
Backache C2316195 Screening 
   genetic abnormalities C0262496 Screening 
   
Kidney transplant 
complication C1261281 Screening 
   Chlamydia DNA PCR C1315245 Screening 
   during night C0231912 Screening 
   Meningitis C0025285 Screening 
   regimen C0040808 Screening 
   history of Current Smoker C3241966 Screening 
   
history of Abdominal 
hernia C0455548 Screening 
   family history of other C0260535 Screening 
   smoldering C0002894 Screening 
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   Overweight C0497406 Screening 
   Calcitonin C0006668 Screening 
   callouses C3841385 Screening 
   
Family history of 
Osteopenia C2315253 Screening 
   Acute myopericarditis C0265132 Screening 
   Yersinia antibodies C0523287 Screening 
   ehrlichiosis C0085399 Screening 
   after lunch C1879668 Screening 
   Cryptogenic cirrhosis C0267809 Screening 
   twisting C0231467 Screening 
   diabetic cheiroarthropathy C0406685 Screening 
   Drinks alcohol on rare C0425316 Screening 
   Family history of Seizure C3267207 Screening 
   Kidney damage C1408258 Screening 
   hematuria C0018965 Screening 
   
history of Seasonal 
allergies C2106658 Screening 
   Lupus cerebritis C0393968 Screening 
   lupus erythematous C0155180 Screening 
   Family history of Airway C3887086 Screening 
   Gall C2700230 Screening 
   hepatocellular cancer C0345904 Screening 
   rheumatoid arthritis C0003873 Screening 
   Kidney hematoma C0475022 Screening 
   Mucositis C0333355 Screening 
   myeloma C0026764 Screening 
   lupus erythematosus C0409974 Screening 
   morbid C0026538 Screening 
   HLD C0020473 Screening 
   Family history of CAD C0329472 Screening 
   parotitis C0030583 Screening 
   Family history of Bone C1997149 Screening 
   dental abnormalities C0262444 Screening 
   hyperplasia of breast C0542028 Screening 
   IBD C0021390 Screening 
   Hernia surgery C3826215 Screening 
   Family history of autism C1445919 Screening 
   
family history of 
disorders C0559550 Screening 
   COPD C0024117 Screening 
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Family history of 
Diverticulitis C2315926 Screening 
   Meniscus repair C0407887 Screening 
   
Family history of Alcohol 
dependence C2911218 Screening 
   Kidney cyst C3887499 Screening 
   Rheumatoid arteritis C0264993 Screening 
   Campylobacter enteritis C0275982 Screening 
   subj C3889670 Screening 
   
Family history of 
myocardial infarction C0455406 Screening 
   history of hypoglycemia C4039056 Screening 
   abnormalities are C3277173 Screening 
   sinusitis disease C0015029 Screening 
   uveitis C0042164 Screening 
   Cornea clear C1849214 Screening 
   vomit C0042963 Screening 
   
Family history of Tongue 
Neoplasm C0573984 Screening 
   beam radiation C3846444 Screening 
   overuse C0035127 Screening 
   dizzyness C0012833 Screening 
   history of Mesothelioma C1997977 Screening 
   Family history of Colitis C0455416 Screening 
   
Family history of 
Megaloblastic Anemia C1306856 Screening 
   Diabetic toe C0476266 Screening 
   kidney disease in C3824723 Screening 
   neuropthy C0155302 Screening 
   Neoplasm of fibula C0347341 Screening 
   angioedema C0002994 Screening 
   over C0020505 Screening 
   
history of Primary 
hyperparathyroidism C4040208 Screening 
   390 C0054370 Screening 
   drink more C3842894 Screening 
   staph C0038160 Screening 
   Family history of suicide C0455386 Screening 
   Campylobacter in stool C2020393 Screening 
   hernia repair mesh repair C0519122 Screening 
   for rheumatoid arthritis C0260963 Screening 
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Family history of 
Ichthyosis C4012361 Screening 
   
history of 
gastroesophageal reflux C4039982 Screening 
   vasculitis C0042384 Screening 
   Kidney initial C2839534 Screening 
   
family history gastric 
cancer C1708349 Screening 
   Osteoarthritis of foot C0586735 Screening 
   Diverticulosis C1510475 Screening 
   drink second bottle C2193544 Screening 
   bursa C0006441 Screening 
   Diarrhea much C4084784 Screening 
   Thrombocytopenia C0040034 Screening 
   worse C0332271 Screening 
   BOOP C0242770 Screening 
   organizing pneumonia C0264383 Screening 
   
history of retinal 
detachment C0455516 Screening 
   neurogenic claudication C0580173 Screening 
   
granulomatous 
lymphadenitis C1960596 Screening 
   Gluteal cellulitis C0263158 Screening 
   Ampullary adenoma C1332244 Screening 
   COPD bronchitis C0742809 Screening 
   
diabetic 
glomerulosclerosis C0017667 Screening 
   gastroparesis C0152020 Screening 
   hypochloremia C0085680 Screening 
   history of Adrenal C4039586 Screening 
   
Family history of 
Hypolipidemia C1857970 Screening 
   history of Morbid C3510286 Screening 
   Strabismus C0038379 Screening 
   snoring C0037384 Screening 
   
Family history of Bowel 
cancer C0559117 Screening 
   
Family history of 
Peripheral neuropathy C2316926 Screening 
   Schizoaffective disorder C0036337 Screening 
   
history of 
Hypernephroma C4047637 Screening 
   diaphragmatic C0011980 Screening 
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   Family history of alpha C4038806 Screening 
   family history as C0514034 Screening 
   Shigella C0036953 Screening 
   his C0019602 Screening 
   Drinking warm C1737350 Screening 
   lymphomatous C0024299 Screening 
   Healthy adult C0686750 Screening 
   Flaring C1517205 Screening 
   
Family history of 
Bronchiectasis C4231142 Screening 
   Gastric cancer C0024623 Screening 
   workup C0741889 Screening 
   
history of Polymyalgia 
rheumatica C3532608 Screening 
   history of Amblyopia C1272091 Screening 
   umbilical hernias C0019322 Screening 
   diabetic lotion C1169242 Screening 
   Fibrocystic breast C0016034 Screening 
   cherry juice C0982074 Screening 
   Diabetes type II C0011860 Screening 
   MT second toe C0085686 Screening 
   diabetes are C3829804 Screening 
   diabetes as C0375127 Screening 
   neoplasm of bone C0005967 Screening 
   lupus membranous C0268758 Screening 
   Paget disease of bone C0029401 Screening 
   diabetes monitoring C0422587 Screening 
   family history of tremor C2317094 Screening 
   base of the thumb C2016583 Screening 
   Falls frequently C0850703 Screening 
   avid C1510996 Screening 
   Necrotizing C0027540 Screening 
   history of Hemorrhage C0475171 Screening 
   Calcaneus fracture C0281926 Screening 
   transplant recipient C0376387 Screening 
   osteoporosis C0029456 Screening 
   may also C2678291 Screening 
   
Osteoarthritis of lumbar 
spine C1442869 Screening 
   lipo C1333906 Screening 
   base of the second toe C0224049 Screening 
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   Sad affect C2219477 Screening 
   orthotic shoes C3688926 Screening 
   Mouth droop C2237286 Screening 
   diabetes under C2062378 Screening 
   
Family history of cardiac 
disorder C0559128 Screening 
   cornea cornea C0010031 Screening 
   wheezing worse at night C2203206 Screening 
   discoid lupus C0024138 Screening 
   half C2825407 Screening 
   
Pseudoxanthoma 
elasticum C0033847 Screening 
   Scleredema C0036413 Screening 
   Alport C1567741 Screening 
   Bilateral breast cancer C0281267 Screening 
   
Seronegative rheumatoid 
arthritis C0409652 Screening 
   Quadriplegia C0034372 Screening 
   
Obesity hypoventilation 
syndrome C0031880 Screening 
   psychosis C0033975 Screening 
   Hypoglycemia rarely C4227725 Screening 
   
Family history of 
Polycythemia C3887075 Screening 
   
family history of 
cardiovascular disease C0455404 Screening 
   history of Vulva cancer C1997152 Screening 
   Axillary abscess C0263115 Screening 
   incisions well healed C2116737 Screening 
   Headaches are occipital C0231613 Screening 
   Yersinia enterocolitica C0043406 Screening 
   Amyloid C0002716 Screening 
   Bronchiolitis C0006271 Screening 
   obliterans C0040021 Screening 
   Narcotic addiction C1527402 Screening 
   base of the ulcer C2171457 Screening 
   Dermatolysis C0010495 Screening 
   nasal drainage C0746759 Screening 
   Pericarditis C0031046 Screening 
   diabetic strips C0462900 Screening 
   Functional Murmur C0232255 Screening 
   Diabetes per C3171765 Screening 
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   Solitary C0205171 Screening 
   Hodgkin disease C0019829 Screening 
   
Family history of 
congestive C2315232 Screening 
   
Family history of 
hypertrophic C0949658 Screening 
   GvHD C0018133 Screening 
   working C0043227 Screening 
   diabetic dilated retinal C1314526 Screening 
   after removal C0372646 Screening 
   neoplasm of prostate C0154009 Screening 
   Necrotizing pancreatitis C0267941 Screening 
   drink fluids C0426597 Screening 
   history of appendicitis C0455547 Screening 
   gastric bypass C0017125 Screening 
   
Family history of Urinary 
problem C0424960 Screening 
   
Family history of Black 
lung C0574101 Screening 
   osteoarthritis history C0455572 Screening 
   Kidney problems C0812426 Screening 
   family history of atopy C0455457 Screening 
   inguinal hernia repair C0021446 Screening 
   smoker C0337664 Screening 
   diabetes test C0438272 Screening 
   diabetes uncontrolled C2349362 Screening 
   
Family history of Breast 
Neoplasm C0455356 Screening 
   diabetes to C0730232 Screening 
   after sex C2126184 Screening 
   endorses C0680918 Screening 
   Phrenic nerve palsy C1442879 Screening 
   lymphedema C0024236 Screening 
   lemonade C0452446 Screening 
   Intracerebral bleed C2937358 Screening 
   possible C0332149 Screening 
   guides C0181090 Screening 
   history of Heat stroke C3887136 Screening 
   hepatocellular carcinoma C2239176 Screening 
   intense pain C1320357 Screening 
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Family history of 
Congenital 
Malformations C1261329 Screening 
   Meningitis booster C3839177 Screening 
   Carcinoid tumor C0007095 Screening 
   drink coke C0452444 Screening 
   Blastomycosis C0005716 Screening 
   Diabetic Arthropathy C0494909 Screening 
   
Family history of 
Sarcoidosis C2317266 Screening 
   hyperhomocysteinemia C0598608 Screening 
   Paronychia of toe C0311211 Screening 
   disease deceased C0747268 Screening 
   Sinusitis acute C0149512 Screening 
   
Family history of 
Duodenal C0559139 Screening 
   history of Accidental fall C2242910 Screening 
   Hypervolemia C0546817 Screening 
   diabetic dermopathy C0406682 Screening 
   history of some C3645919 Screening 
   pulmonary sarcoid C0340199 Screening 
   quiet C0439654 Screening 
   will also be C0425262 Screening 
   reports C0700287 Screening 
   Uremia C0041948 Screening 
   Midline incision C0456276 Screening 
   Kaposi sarcoma C0036220 Screening 
   malaise C0231218 Screening 
   night shift C1660631 Screening 
   hypodensities C0742093 Screening 
   Moyamoya disease C0026654 Screening 
   
Family history of 
Nephropathy C0403443 Screening 
   Miracle C0996776 Screening 
   cites C1264695 Screening 
 
Medication Other 
C2054168 
take 
NSAIDS Preparing Kidney C0022646 Preparing 
   DISSOLVE C1549535 Preparing 
   red meat C0452848 Preparing 
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   red blisters C2126355 Preparing 
   
blood 
thinners C0003280 Preparing 
   txp C1134470 Preparing 
   red C0332575 Preparing 
   break down C0443161 Preparing 
   came C0960273 Preparing 
   down C0205104 Preparing 
   disfunction C0005887 Preparing 
   red streaks C2169832 Preparing 
   
incidentalom
a C2609247 Preparing 
   trx C1336690 Preparing 
   blood C0005767 Preparing 
   take down C0189301 Preparing 
   do C1512020 Preparing 
   dissection C0012737 Preparing 
   sauce C0453357 Preparing 
   damge C0525773 Preparing 
   red violet C0763107 Preparing 
   shut down C1547200 Preparing 
   went C0796199 Preparing 
   kidney dis C0022658 Preparing 
   kidney down C0194182 Preparing 
   insufficency C0349073 Preparing 
   kidney diseas C0431705 Preparing 
 
Medication Other 
C0038317 steroids Monitoring infection C0439663 Monitoring 
C0009262 Colchicine Monitoring swelling C0038999 Monitoring 
C0030049 Oxycodone Monitoring serous effusion C0302149 Monitoring 
C0728755 Dilaudid Monitoring inflammation C0021368 Monitoring 
C0445550 low doses Monitoring Chronic C0205191 Monitoring 
C0002645 Amoxicillin Monitoring kidney injury C0160420 Monitoring 
C0003211 NSAID Monitoring weight gain C0043094 Monitoring 
C0012373 Diltiazem Monitoring Urinary tract infection C0042029 Monitoring 
C0027415 narcotics Monitoring weight loss C1262477 Monitoring 
C3889572 10mg dose Monitoring Bowel sounds C0232693 Monitoring 
C0728963 Lovenox Monitoring ulceration C0041582 Monitoring 
C1261311 steroid injection Monitoring Pulmonary fibrosis C0034069 Monitoring 
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C0700926 Ancef Monitoring 
chronic obstructive 
pulmonary C0024117 Monitoring 
C0851881 
ENTEROCOCCAL 
INFECTIONS Monitoring 
hypersensitivity 
pneumonitis C0002390 Monitoring 
C0007561 Ceftriaxone Monitoring Peripheral vascular disease C0085096 Monitoring 
C0699129 coumadin Monitoring 
Staphylococcus Aureus 
Infection C1318973 Monitoring 
C0542867 60mg Monitoring 
Increased risk for 
pancreatitis C1842408 Monitoring 
C0360714 statin Monitoring Chronic alcohol C0001973 Monitoring 
C0876068 lidoderm Monitoring CHRONIC CHEST C1740831 Monitoring 
C1962522 Amlodipine as Monitoring heart disease C0018799 Monitoring 
C0585077 steroid dose Monitoring delayed recall C0561757 Monitoring 
C0699177 Plaquenil Monitoring 
Escherichia coli urinary 
tract infection C0577708 Monitoring 
C0700899 Benadryl Monitoring immunosuppressive C0021079 Monitoring 
C0332173 qd Monitoring Ibs C0022104 Monitoring 
C3656735 
Amlodipine 
induced Monitoring chronic infection C0151317 Monitoring 
C0004259 Atropine Monitoring Wound infection C0043241 Monitoring 
C0719198 Celebrex Monitoring stone C0006736 Monitoring 
C0014563 Epinephrine Monitoring encouraging weight C2958424 Monitoring 
C0242402 opioid Monitoring Chronic back C0457949 Monitoring 
C0376196 opiate Monitoring Renal stones C0022650 Monitoring 
C1851351 Colchicine not Monitoring unintentional weight loss C2363736 Monitoring 
C0305814 debrox drops Monitoring chronic renal C0022661 Monitoring 
C0002598 amiodarone Monitoring gout flares C1619733 Monitoring 
C0022860 labetalol Monitoring 
chronic pulmonary 
embolism C0856722 Monitoring 
C0366521 labetalol dose Monitoring gout attack C2712871 Monitoring 
C0701009 bumex Monitoring Abnormal weight loss C0936227 Monitoring 
C0149783 steroid therapy Monitoring Nonpitting edema C1265804 Monitoring 
C0875968 Avelox Monitoring Allergic rhinitis C2607914 Monitoring 
C2064827 steroid topical Monitoring respiratory infections C0035243 Monitoring 
C1547581 as needed Monitoring Chronic migraine C1960870 Monitoring 
C1098080 Crestor Monitoring hemisensory loss C0234216 Monitoring 
C0006625 cachexia Monitoring chronic cough C0010201 Monitoring 
C3667576 steroid spray Monitoring weight C0043100 Monitoring 
C3663261 steroid ointment Monitoring cold intolerance C0009269 Monitoring 
C0040610 tramadol Monitoring 
chronic were kidney 
disease C1561643 Monitoring 
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C2723026 
steroid topical 
creams Monitoring Chronic anemia C0581384 Monitoring 
C0051696 Amlodipine Monitoring Chronic rhinitis C0008711 Monitoring 
C0085826 antiplatelet agents Monitoring gout C0018099 Monitoring 
C4257295 
fluticasone nasal 
spray Monitoring count C0750480 Monitoring 
C0014025 Enalapril Monitoring risk for infection C0582147 Monitoring 
C0394853 steroid inj Monitoring heart attack C0027051 Monitoring 
C0147814 Unasyn Monitoring chronic anticoagulation C0694554 Monitoring 
C0020933 imipenem Monitoring seafood C0206208 Monitoring 
C0981221 atropine drops Monitoring thrush C0006849 Monitoring 
C1619735 decreasing dose Monitoring Candida under the breast C0741706 Monitoring 
C0036557 sedatives Monitoring unexplained weight loss C1828173 Monitoring 
C1652084 
Flunisolide nasal 
spray Monitoring Incision well healed C2116737 Monitoring 
C0585361 bid Monitoring panic attacks C0086769 Monitoring 
C0020740 Ibuprofen Monitoring systemic lupus C0024141 Monitoring 
C0591139 bactrim Monitoring labia C0227759 Monitoring 
C0807726 refills Monitoring Low weight C0041667 Monitoring 
C0876060 Keppra Monitoring Not doing weight bearing C0563556 Monitoring 
C0586794 steroids not Monitoring recent weight loss C2126067 Monitoring 
C0699992 lasix Monitoring 
pneumothorax or 
pulmonary C0810019 Monitoring 
C0366596 oxycodone dosing Monitoring immune liver disease C0021053 Monitoring 
C1702177 Januvia Monitoring infection of skin C0162627 Monitoring 
C2985380 steroid creams Monitoring pulmonary infections C0876973 Monitoring 
C0593507 advil Monitoring bearing weight C0085086 Monitoring 
C1880956 such high doses Monitoring chronic knee C0451820 Monitoring 
C2065041 steroid inhalers Monitoring chronic disease C0008679 Monitoring 
C2925914 began after taking Monitoring renal cysts C0268800 Monitoring 
C0700798 Indocin Monitoring pseudogout C0033802 Monitoring 
C0366345 amiodarone doses Monitoring allergic reaction C0020517 Monitoring 
C0633854 Fioricet Monitoring Umbilical hernia repair C0019333 Monitoring 
C0376414 Paxil Monitoring Kidney or Liver C0545792 Monitoring 
C0015399 eyedrops Monitoring chronic pancreatitis C0149521 Monitoring 
C0584668 stopped taking Monitoring caffeine intake C4062719 Monitoring 
C0250482 Zosyn Monitoring Breast C0006141 Monitoring 
C0939412 novolog Monitoring BCC C0152320 Monitoring 
C2054168 
NSAIDs while 
taking Monitoring Vaccine reaction C0565653 Monitoring 
C0040341 Tobramycin Monitoring obstructing stones C0940751 Monitoring 
C0663448 viagra Monitoring prostate cancer C0376358 Monitoring 
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C0716467 2mg versed Monitoring chronic histoplasmosis C0854428 Monitoring 
C0054836 carvedilol Monitoring low levels C0151723 Monitoring 
C0032825 KCL Monitoring fungal infection C0026946 Monitoring 
C0570232 
steroid inj skin 
reaction Monitoring significant weight C3897172 Monitoring 
C1707810 increased dose Monitoring Mycoplasma C0026934 Monitoring 
C0366557 metoprolol dosing Monitoring Renal neoplasm C0022665 Monitoring 
C0569293 
Amiodarone 
pulmonary toxicity Monitoring simple cysts C0037157 Monitoring 
C0719509 Coreg Monitoring Applauded C0662157 Monitoring 
C0977190 3mg Monitoring Chronic atrial C0694539 Monitoring 
C3663260 steroid drops Monitoring lucencies C0743894 Monitoring 
C0366686 warfarin dose Monitoring weight gain or weight loss C2964349 Monitoring 
C0521900 Amoxicillin as Monitoring incision C0184898 Monitoring 
C0032143 tPa Monitoring opportunistic infections C0029118 Monitoring 
C2054130 chronic antibiotics Monitoring scleral icterus C0240962 Monitoring 
C3653411 opiods Monitoring or edema C0474434 Monitoring 
C0058829 Dyazide Monitoring purified C1998793 Monitoring 
C1879367 flexor Monitoring peripheral artery disease C1306889 Monitoring 
C0308399 Bacitracin ointment Monitoring Chronic hepatitis C0019189 Monitoring 
C2054177 steroid to take Monitoring kidney disease C0022658 Monitoring 
C1427310 steroids for Monitoring advanced liver disease C0860197 Monitoring 
C1570232 Lyrica Monitoring PRN C0558288 Monitoring 
C1439877 after 129nitial dose Monitoring serosanguineous drainage C1112519 Monitoring 
C3206494 amiodarone pills Monitoring 
supraclavicular 
lymphadenopathy C0749155 Monitoring 
C2029949 NSAID related Monitoring do as C3899344 Monitoring 
C0342269 steroid induced Monitoring chronic cholecystitis C0085694 Monitoring 
C0701042 cipro Monitoring 
incarcerated incisional 
hernia C0311271 Monitoring 
C0452115 infection or vaccine Monitoring goes away C2128638 Monitoring 
C0663241 Linezolid Monitoring dry weight C1439839 Monitoring 
C0536495 moxifloxacin Monitoring 
chronic upper respiratory 
infections C2074970 Monitoring 
C1822607 takes inhalers as Monitoring urination C0042036 Monitoring 
C1709043 missing any doses Monitoring RLE full weight bearing C2149803 Monitoring 
C0074332 senna Monitoring Vascular calcifications C0342649 Monitoring 
C0718612 apatate Monitoring adverse reaction C0559546 Monitoring 
C2702169 Stelara Monitoring healing wounds C0043240 Monitoring 
C0733815 Levophed Monitoring blood in stool C0018932 Monitoring 
C4081659 Not taking if Monitoring paraesophageal hernia C0267725 Monitoring 
C0216784 Valsartan Monitoring chronic skin C0157738 Monitoring 
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C2054160 taking otc Monitoring Honking systolic murmur C2046973 Monitoring 
C4075962 low dose chest Monitoring under the skin C2200110 Monitoring 
C0556984 tid Monitoring cognitive deficit C0009241 Monitoring 
C2936530 opioid therapy Monitoring Chronic obstructive C0333166 Monitoring 
C0568678 
Atropine without 
further event Monitoring Chronic serous otitis C0155421 Monitoring 
C3464355 
Dymista nasal 
spray Monitoring Clostridium difficile colitis C0238106 Monitoring 
C1174739 Velcade Monitoring 
Clostridium difficile 
infection C0343386 Monitoring 
C0245561 duloxetine Monitoring coffee ground emesis C1510416 Monitoring 
C0038757 sulfa allergy Monitoring 
Gastroesophageal reflux 
disease C0017168 Monitoring 
C0746949 NSAID allergy Monitoring blood loss C0019080 Monitoring 
C3209937 colchicine pills Monitoring blood clots C0302148 Monitoring 
C0750389 chronic warfarin Monitoring Carcinoid tumor C0007095 Monitoring 
C0085542 pravastatin Monitoring single gastric polyp C0940274 Monitoring 
C0393080 VORICONAZOLE Monitoring Gastric polyp C0236048 Monitoring 
C0001617 corticosteroid Monitoring anaphylactic reaction C0002792 Monitoring 
C0304586 Antibiotics for skin Monitoring Postmenopausal bleeding C0032776 Monitoring 
C0557004 when taking Monitoring blood loss anemia C0154286 Monitoring 
C0416166 events while taking Monitoring low blood C1658984 Monitoring 
C1707813 dose pak Monitoring recent weight gain C2367670 Monitoring 
C0124498 kayexalate Monitoring ventral hernia C0019326 Monitoring 
C0740157 Carafate Monitoring lumbar hernia C0401119 Monitoring 
C3642173 Renal dose Monitoring thromboembolic events C0040038 Monitoring 
C1542525 
NSAID drug 
reaction Monitoring chronic infarcts C0548844 Monitoring 
C0939400 Nexium Monitoring limiting sodium intake C1821817 Monitoring 
C0358845 
NSAIDs and opioid 
analgesics Monitoring swelling of these joints C0152031 Monitoring 
C0022209 inh Monitoring cigarette smoker C0337667 Monitoring 
C2363722 steroid psychosis Monitoring 
Staphylococcus aureus skin 
infection C1739131 Monitoring 
C0690666 150mg Monitoring pilonidal cyst C0031925 Monitoring 
C0721444 low dose asa Monitoring inguinal hernia repair C0021446 Monitoring 
C0025084 taking meds Monitoring rectal masses C0240873 Monitoring 
C0026078 midodrine Monitoring Noninsulin dependent C0011860 Monitoring 
C0570424 
adverse reaction to 
amiodarone Monitoring adenopathy C0497156 Monitoring 
C1518010 low radiation dose Monitoring arises C4019053 Monitoring 
C0973749 160mg dose Monitoring dental caries C0011334 Monitoring 
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C3251097 
ACE inhibitor beta 
blocker Monitoring hernia C0019270 Monitoring 
C0878554 
chronic opioid 
intake Monitoring 
Advised continued weight 
loss C0555962 Monitoring 
C0589598 second dose Monitoring loose C0205407 Monitoring 
C0790952 Azelastine spray Monitoring Perianal C0442158 Monitoring 
C0810782 inhaler as Monitoring chronic sinusitis C0149516 Monitoring 
C0858726 
Steroid induced 
osteoporosis Monitoring Chronic diarrhea C0401151 Monitoring 
C1736183 
NSAID 
prophylaxis Monitoring stomach ulcers C0038358 Monitoring 
C0282638 
antibiotic 
prophylaxis Monitoring under local anesthesia C1720162 Monitoring 
C1319853 NSAID induced Monitoring Periapical abscess C0031024 Monitoring 
C0936433 oxycodone tablets Monitoring yeast infections C0750466 Monitoring 
C2054156 
taking weight loss 
pills Monitoring bloating C1291077 Monitoring 
C0366482 Flecainide dose Monitoring Chronic otitis C0747083 Monitoring 
C0950902 Integrilin Monitoring sensorineural hearing loss C0018784 Monitoring 
C0444956 high doses Monitoring serositis C0036749 Monitoring 
C0001645 beta blocker Monitoring drainage or infection C3513343 Monitoring 
C0003015 ace inhibitor Monitoring microscopic colitis C0400821 Monitoring 
C0059865 etodolac Monitoring inframammary skin C0459398 Monitoring 
C1515187 takes night dose Monitoring latent infections C0872054 Monitoring 
C0980743 tobramycin drops Monitoring helminth infections C0018889 Monitoring 
C0978129 500mg Monitoring hepatic cysts C0267834 Monitoring 
C0715695 300mg Monitoring low back C0024031 Monitoring 
C0078839 zolpidem Monitoring 
Degenerative lumbar spinal 
stenosis C0410636 Monitoring 
C0406479 steroid acne Monitoring HIV infection C0019693 Monitoring 
C4053796 
NSAID 
nephropathy Monitoring chronic HIV infection C0853112 Monitoring 
C4036053 or missed doses Monitoring Internal Hernia C0178282 Monitoring 
C0043031 
warfarin 
anticoagulation Monitoring breast abscess C0151463 Monitoring 
C0359826 Betadine skin Monitoring bone loss C0029453 Monitoring 
C0853383 
Low dose 
epinephrine Monitoring infection is C2010716 Monitoring 
C1555542 Dosing weight Monitoring TOOTH ABSCESS C0518988 Monitoring 
C0178602 dose Monitoring or chest discomfort C0008031 Monitoring 
C1706103 dose as Monitoring Homans signs C0231781 Monitoring 
C0746307 
hydralazine 
induced skin lupus Monitoring Chronic systolic heart C1135194 Monitoring 
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C4075005 does not take Monitoring incision infection C0038941 Monitoring 
C1273095 single dose Monitoring Kidney working C3176738 Monitoring 
C0749009 steroid allergy Monitoring keloid C0022548 Monitoring 
C3207189 caffeine pills Monitoring BK virus infection C1096691 Monitoring 
C0003360 antihistamines Monitoring degenerative disk C2717759 Monitoring 
C0684237 Narcan Monitoring Rectal C1527425 Monitoring 
C0876226 zyvox Monitoring histoplasmosis skin C0199757 Monitoring 
C0499146 
Administer subcu 
as single dose Monitoring Cat scratch C0238909 Monitoring 
C0002771 analgesics Monitoring chronic damage C0006109 Monitoring 
C3249878 Steroid infections Monitoring Hiatus hernia C3489393 Monitoring 
C1134651 beta glucan Monitoring drink milk C0452242 Monitoring 
C2370736 dose zolpidem Monitoring DOE C0231807 Monitoring 
C2136360 
Verbalizes taking 
dose as Monitoring 
pneumothorax or pleural 
effusion C0947889 Monitoring 
C0857243 
NSAIDs cause 
mouth ulcers Monitoring friends C0079382 Monitoring 
C3528809 80mg dose Monitoring serous otitis media C0155415 Monitoring 
C3837102 steroid nasal Monitoring bowel adhesions C0267778 Monitoring 
C0749012 steroid dependent Monitoring umbilical hernia C0019322 Monitoring 
C0196394 
steroid spinal 
epidural injection Monitoring Incarcerated hernia C0740406 Monitoring 
C0270994 steroid myopathy Monitoring Chronic venous stasis C0750169 Monitoring 
   degenerative arthritis C0029408 Monitoring 
   Hyperplastic polyps C0333983 Monitoring 
   Rectal polyp C0034887 Monitoring 
   bilateral knee C0230434 Monitoring 
   superficial skin infection C0342985 Monitoring 
   high levels C0151714 Monitoring 
   Scrotal abscess C0238418 Monitoring 
   Escherichia coli C0014834 Monitoring 
   Polymyalgia rheumatica C0032533 Monitoring 
   biliary colic C0151824 Monitoring 
   Heat intolerance C0231274 Monitoring 
   Escherichia coli bacteremia C1096262 Monitoring 
   Chronic neck C0746815 Monitoring 
   ulcerations no skin C0437804 Monitoring 
   ulcerations or lesions C0275990 Monitoring 
   stopped working C0425082 Monitoring 
   anxiety attacks C0700031 Monitoring 
   LBP C0020649 Monitoring 
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   breast lump C0024103 Monitoring 
   inflammation process C1155266 Monitoring 
   inflammation or infectious C1400391 Monitoring 
   
Chronic ischemic heart 
disease C0264694 Monitoring 
   Abnormal weight C0578026 Monitoring 
   much weight loss C4084777 Monitoring 
   hemorrhagic cysts C0333145 Monitoring 
   Perianal Abscess C0031019 Monitoring 
   chronic insomnia C0751249 Monitoring 
   intentional weight loss C1563041 Monitoring 
   
Nonobstructive coronary 
artery disease C2007633 Monitoring 
   Nonocclusive coronary C4020724 Monitoring 
   GI blood loss C0041909 Monitoring 
   Renal osteodystrophy C0035086 Monitoring 
   scleroderma renal crisis C1262147 Monitoring 
   infection not C0580334 Monitoring 
   renovascular disease C1442904 Monitoring 
   sodium intake C0489645 Monitoring 
   toenail fungal infection C0749566 Monitoring 
   aortic vascular C0182556 Monitoring 
   systemic infection C0243026 Monitoring 
   skipping C0560435 Monitoring 
   black stools C0025222 Monitoring 
   invasive ductal C1134719 Monitoring 
   Breast cancer C0006142 Monitoring 
   chronic hip C0744939 Monitoring 
   
clostridium difficile 
enterocolitis C1400528 Monitoring 
   breath or chest C0423729 Monitoring 
   kidney cyst C3887499 Monitoring 
   ulcer disease C0030920 Monitoring 
   underlying C0749769 Monitoring 
   weight change C0005911 Monitoring 
   Infective otitis externa C0021355 Monitoring 
   tendinitis C0039503 Monitoring 
   HCV infection C3871345 Monitoring 
   Externa C0152345 Monitoring 
   Chronic viral hepatitis C0276623 Monitoring 
   wound C0043250 Monitoring 
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   chronic allograft C0403592 Monitoring 
   MRSA wound infection C1504508 Monitoring 
   skin rashes C0015230 Monitoring 
   Reflux Esophagitis C0014869 Monitoring 
   high levels of C0564512 Monitoring 
   chronic foot C0410418 Monitoring 
   Chronic memory loss C0746484 Monitoring 
   increasing sweats C0700590 Monitoring 
   scaling skin C0237849 Monitoring 
   nail abscess C1404693 Monitoring 
   
chronic cardiovascular 
disease C1290380 Monitoring 
   wound skin C0564444 Monitoring 
   coronary atherosclerosis C0010054 Monitoring 
   nonobstructing C0264787 Monitoring 
   inflammation or infection C0679333 Monitoring 
   Colovesical fistula C0268842 Monitoring 
   bronchogenic cysts C0006281 Monitoring 
   Rectal bleeding C0267596 Monitoring 
   biliary ductal dilatation C0842860 Monitoring 
   Gastric residuals C3665864 Monitoring 
   chronic chest wall C0742356 Monitoring 
   constipation C0009806 Monitoring 
   chest infections C0149725 Monitoring 
   Thyroid neoplasm C0040136 Monitoring 
   submental nodes C0229723 Monitoring 
   chronic dysphagia C0743317 Monitoring 
   Best C1522427 Monitoring 
   bowel gas C3670913 Monitoring 
   weight gain weight loss C3175831 Monitoring 
   hemarthrosis C0018924 Monitoring 
   bone contusion C1390461 Monitoring 
   Prostate C0033572 Monitoring 
   neuroendocrine tumor C0206754 Monitoring 
   may be C1278418 Monitoring 
   neoplasm of skin C0007114 Monitoring 
   supraumbilical hernia C0749174 Monitoring 
   abdominal distension C0000731 Monitoring 
   inguinal hernia C0019294 Monitoring 
   10lb C3364555 Monitoring 
   kidney C0022646 Monitoring 
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   Infusion Reaction C2368034 Monitoring 
   Postherpetic neuralgia C0032768 Monitoring 
   Ulceration healed C0333293 Monitoring 
   Stump C0002690 Monitoring 
   Dental Infection C0877046 Monitoring 
   
Recurrent urinary tract 
infection C0262655 Monitoring 
   Chronic Abdominal C0232491 Monitoring 
   parenchymal liver C0745745 Monitoring 
   Mycoplasma pneumoniae C0032302 Monitoring 
   stream C0442540 Monitoring 
   infection blood C0474659 Monitoring 
   ureteral calculi C1456865 Monitoring 
   Melanosis in the colon C0221391 Monitoring 
   GI losses C0473916 Monitoring 
   who C0043237 Monitoring 
   Abscess Drainage C0344096 Monitoring 
   gluteal abscess C0263118 Monitoring 
   pelvic abscess C0030785 Monitoring 
   chronic thickening C2074894 Monitoring 
   reflux nephropathy C3495566 Monitoring 
   Dependent edema C0235437 Monitoring 
   Giardia cysts C3662519 Monitoring 
   source of infection C0449426 Monitoring 
   compression or cord C0037926 Monitoring 
   chronic neuropathic C1864996 Monitoring 
   Refused rectal exam C0741701 Monitoring 
   chronic glomerulonephritis C0152451 Monitoring 
   Pfannenstiel skin incision C0457819 Monitoring 
   bowel disease C0021831 Monitoring 
   intrarenal C0226712 Monitoring 
   fish oil C0016157 Monitoring 
   stone likely urate stone C0798105 Monitoring 
   Kidney infection C0021313 Monitoring 
   Noncardiac chest C0476281 Monitoring 
   Dry cough C0850149 Monitoring 
   infectious hepatitis C0019159 Monitoring 
   ganglion cysts C1258666 Monitoring 
   chronic constipation C0401149 Monitoring 
   attack stroke C3844825 Monitoring 
   intestinal infections C0178238 Monitoring 
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   effusions C0013687 Monitoring 
   Chronic thrombocytopenia C0749393 Monitoring 
   chronic edema C0333241 Monitoring 
   as a sinus infection C0940933 Monitoring 
   Cerebral vascular disease C1410784 Monitoring 
   chronic wound C3494660 Monitoring 
   chronic lumbar C0410414 Monitoring 
   hardware C1523994 Monitoring 
   colonic polyps C0009376 Monitoring 
   flares C1517205 Monitoring 
   will become C0548520 Monitoring 
   do C1512020 Monitoring 
   tapers C0441640 Monitoring 
   chronic vascular C0559030 Monitoring 
   inconclusive C0205258 Monitoring 
   hydronephrosis C0020295 Monitoring 
   adenomatous polyps C0206677 Monitoring 
   dysuria C0013428 Monitoring 
   Night sweats C0028081 Monitoring 
   bowel obstruction C0021843 Monitoring 
   radiculopathy C0700594 Monitoring 
   low blood sugars C0020615 Monitoring 
   peritonsillar abscess C0031157 Monitoring 
   Cyst of skin C0191335 Monitoring 
   beer intake C0559430 Monitoring 
   or unusual C3166232 Monitoring 
   hypophonia C0521007 Monitoring 
   Hair loss C0002170 Monitoring 
   chronic thrombosis C2728999 Monitoring 
   Chronic elbow C0564826 Monitoring 
   chronic degenerative C0393583 Monitoring 
   chronic dvt C2728996 Monitoring 
   incisional hernia repair C0342971 Monitoring 
   chronic allergic rhinitis C0748410 Monitoring 
   senile macular retinal C0242383 Monitoring 
   sob C0010399 Monitoring 
   chronic vertigo C0750248 Monitoring 
   chronic arthritis C0263680 Monitoring 
   Abnormal weight gain C0332544 Monitoring 
   Rectal skin tag C0345890 Monitoring 
   chronic synovitis C0877521 Monitoring 
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   MDS C0265219 Monitoring 
   cardiac dilatation C0264732 Monitoring 
   hilar adenopathy C0149711 Monitoring 
   
Chronic gastrointestinal 
bleed C0266808 Monitoring 
   chronic liver C0156189 Monitoring 
   zoonotic infections C0043528 Monitoring 
   Vanc C1430966 Monitoring 
   asthma attack C0347950 Monitoring 
   
Monckeberg vascular 
calcifications C0887866 Monitoring 
   deposition of amyloid C0011560 Monitoring 
   chronic pleural effusion C0747636 Monitoring 
   ascites C0003962 Monitoring 
   fluid intake C0429791 Monitoring 
   
Adenomatous polyp of 
colon C0850572 Monitoring 
   rectal abscesses C0149770 Monitoring 
   histoplasmosis infection C0019655 Monitoring 
   chest discomfort C0235710 Monitoring 
   cardiac events C0741923 Monitoring 
   weight loss goals C0515789 Monitoring 
   or cardiovascular disease C0007222 Monitoring 
   Pruritic rash C0033771 Monitoring 
   Lumbar radiculopathy C1263855 Monitoring 
   gall stones C0242216 Monitoring 
   do think C3259568 Monitoring 
   fluctuating weight C0241729 Monitoring 
   Upper respiratory infection C0041912 Monitoring 
   fevers chills C0085594 Monitoring 
   gained some weight C4014806 Monitoring 
   wound dehiscence C0259768 Monitoring 
   chronic deformities C0744536 Monitoring 
   inside wound C0160524 Monitoring 
   hematemesis C0018926 Monitoring 
   scarlet fever C0036285 Monitoring 
   Stage IV kidney disease C1561641 Monitoring 
   Reactive airway disease C3714497 Monitoring 
   chronic prostatitis C0085696 Monitoring 
   infections requiring C3483787 Monitoring 
   renal abscess C0151465 Monitoring 
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   Neuropathic C0003892 Monitoring 
   
Cauda equina spinal cord 
injury C0854395 Monitoring 
   obstructive uropathy C0178879 Monitoring 
   stone event C0418022 Monitoring 
   Buttock wound C0741846 Monitoring 
   infection like C0745245 Monitoring 
   esophageal varices C0014867 Monitoring 
   or reflux C1535588 Monitoring 
   
Chronic membranous 
glomerulonephritis C0854414 Monitoring 
   non weight bearing C0445100 Monitoring 
   bone erosions C0587240 Monitoring 
   Perianal skin C1704244 Monitoring 
   under anesthesia C1720436 Monitoring 
   hemophilia C0684275 Monitoring 
   DVT C0149871 Monitoring 
   kidney stones or C0744261 Monitoring 
   renal masses C0262613 Monitoring 
   chronic bone C1385418 Monitoring 
   ulcer on the skin C0437803 Monitoring 
   encouraged water intake C0204697 Monitoring 
   Cardiac ascites C0341525 Monitoring 
   catheter site infections C1112210 Monitoring 
   skin infections C0037278 Monitoring 
   Endorses C0680918 Monitoring 
   bowel perforation C0021845 Monitoring 
   reaction as C0865403 Monitoring 
   infected implants C0588128 Monitoring 
   after taking C2129215 Monitoring 
   sinusitis C0037199 Monitoring 
   Postnasal drip C0032781 Monitoring 
   friends who drink C0556322 Monitoring 
   Not taking C0426599 Monitoring 
   Gastric varices C0017145 Monitoring 
   not taking any C3844558 Monitoring 
   Extensive vascular C0155094 Monitoring 
   dark stool C0474585 Monitoring 
   for weight loss C0547548 Monitoring 
   much better C3841449 Monitoring 
   swelling as C0424810 Monitoring 
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   DOS C0719635 Monitoring 
   chronic otitis externa C0151217 Monitoring 
   radiation pneumonitis C0206063 Monitoring 
   hemoptysis C0019079 Monitoring 
   she C1822717 Monitoring 
   chronic cystitis C0221763 Monitoring 
   memory loss C0751295 Monitoring 
   soa C1898571 Monitoring 
   infected knee C1400580 Monitoring 
   loose stools C2129214 Monitoring 
   chronic heel C0744717 Monitoring 
   prostate infection C0240811 Monitoring 
   saddle embolus C0023370 Monitoring 
   ureteral cysts C1696112 Monitoring 
   itching C0033774 Monitoring 
   pulmonary emboli C0034065 Monitoring 
   chronic shoulder C0264042 Monitoring 
   hepatojugular reflux C0239949 Monitoring 
   Central chest C0423634 Monitoring 
   unintended C1283932 Monitoring 
   Chronic hoarseness C0745015 Monitoring 
   chronic diastolic heart C2711480 Monitoring 
   coughing up sputum C0239134 Monitoring 
   beefy red open wound C3645725 Monitoring 
   sweats or weight C4048703 Monitoring 
   Chronic utis C0262421 Monitoring 
   chronic dyspepsia C0743312 Monitoring 
   loose bowel movements C0011991 Monitoring 
   Gastric lymphoma C0349532 Monitoring 
   Nabothian cysts C0027269 Monitoring 
   Fibroid uterus C0042133 Monitoring 
   symptoms or weight loss C1542746 Monitoring 
   neoplasm of colon C0007102 Monitoring 
   mucinous neoplasm C1334811 Monitoring 
   or rest C0682643 Monitoring 
   gallbladder stones C0947622 Monitoring 
   cat scratch disease C0007361 Monitoring 
   stones passing C0848621 Monitoring 
   thrill in the C2115906 Monitoring 
   smoking cigarettes C0700219 Monitoring 
   infection or fevers C1400815 Monitoring 
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   Salivary glands C0036098 Monitoring 
   indwelling stent C4270259 Monitoring 
   renal parenchymal disease C1841992 Monitoring 
   sharp pains C0455270 Monitoring 
   fructose corn syrup C2981326 Monitoring 
   purulent drainage C0517630 Monitoring 
   Staph infection C0038160 Monitoring 
   Incisional hernia C0267716 Monitoring 
   chronic colitis C0267375 Monitoring 
   hacking cough C0239133 Monitoring 
   further weight loss C0150869 Monitoring 
   long term C0443252 Monitoring 
   
Increased pulmonary 
vascular C1867423 Monitoring 
   Bee sting reaction C0438638 Monitoring 
   Hyperpigmentation of skin C0162834 Monitoring 
   epididymal cysts C0037859 Monitoring 
   Omega fish oil C1572282 Monitoring 
   swelling thumb C0575899 Monitoring 
   
risk of cardiovascular 
disease C3176371 Monitoring 
   frothy C4069284 Monitoring 
   lacunar infarctions C0333559 Monitoring 
   MAC C0009545 Monitoring 
   history of kidney stone C1998388 Monitoring 
   Lyme disease C0024198 Monitoring 
   breast tenderness C0262397 Monitoring 
   renal vascular disease C0268790 Monitoring 
   Simple C0205352 Monitoring 
   sliding hiatal hernia C0376710 Monitoring 
   chronic conditions C0399432 Monitoring 
   Chronic leg edema C1739409 Monitoring 
   chronic process C1827411 Monitoring 
   discomfort C2364135 Monitoring 
   hallux valgus C0018536 Monitoring 
   edema or infectious C1400819 Monitoring 
   corneal edema C0010037 Monitoring 
   corneal C0010031 Monitoring 
   corneal decompensation C0948284 Monitoring 
   pancreatic neoplasm C0030297 Monitoring 
   Breast cyst C0006144 Monitoring 
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   Diaphragmatic hernia C0019284 Monitoring 
   kid C0680063 Monitoring 
   obvious C0557880 Monitoring 
   stone disease C0947660 Monitoring 
   fungal skin infection C0011630 Monitoring 
   stone each C1535790 Monitoring 
   infected mesh C1321093 Monitoring 
   ovarian cysts C0029927 Monitoring 
   burn scar C0036280 Monitoring 
   hyperplasia C0020507 Monitoring 
   head aches C0018681 Monitoring 
   sanguinous drainage C0333271 Monitoring 
   Ulcer debridement C0730126 Monitoring 
   leg wound C1408542 Monitoring 
   after recent viral infection C2919453 Monitoring 
   chronic reflux C0743582 Monitoring 
   
rectal neuroendocrine 
tumor C1335678 Monitoring 
   stitches in the skin C1540362 Monitoring 
   hilar lymphadenopathy C0456973 Monitoring 
   environmental allergies C0282504 Monitoring 
   ankylosing spondylitis C0038013 Monitoring 
   Monilia genital infection C0006840 Monitoring 
   CMV infection C0010823 Monitoring 
   infection of the C0555971 Monitoring 
   ureteral stones C0041952 Monitoring 
   chronic stone C0267885 Monitoring 
   FHx prostate cancer C0260515 Monitoring 
   chronic iritis C0008690 Monitoring 
   it is C3174772 Monitoring 
   chronic epigastric C0743541 Monitoring 
   
chronic functional 
constipation C4060572 Monitoring 
   today C0310367 Monitoring 
   GI infections C4082764 Monitoring 
   rectal prolapse C0034888 Monitoring 
   reflux C0232483 Monitoring 
   osteoarthritic C1834973 Monitoring 
   
Mucinous carcinoma of 
skin C0346020 Monitoring 
   mucinous adenocarcinoma C0007130 Monitoring 
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   urination or pelvic C3539896 Monitoring 
   infection in the C0854706 Monitoring 
   Chronic polyarthritis C1735378 Monitoring 
   or colon C0555952 Monitoring 
   symptomatic aortic stenosis C0741183 Monitoring 
   breast skin rash C0741755 Monitoring 
   chronic leg C0263560 Monitoring 
   hoarseness of voice C0019825 Monitoring 
   degenerative disc disease C0158266 Monitoring 
   bright red C1272329 Monitoring 
   abdominal tract hematoma C0473120 Monitoring 
   scrotal edema C0151609 Monitoring 
   relapsing lung C0855002 Monitoring 
   Streptococcal infection C0038395 Monitoring 
   pulmonary vascular C0456261 Monitoring 
   chronic headaches C0151293 Monitoring 
   colostomy site C0546255 Monitoring 
   risk for cardiac event C1443393 Monitoring 
   Spinal epidural abscess C0238434 Monitoring 
   fungus C0016832 Monitoring 
   not put weight C0231246 Monitoring 
   chronic incontinence C0749938 Monitoring 
   chronic bronchitis C0008677 Monitoring 
   interstitial thickening C2750120 Monitoring 
   recent weight change C2127346 Monitoring 
   chronic residual C0270408 Monitoring 
   current infection C0588457 Monitoring 
   collagen vascular disease C0262428 Monitoring 
   psoas abscess C0085222 Monitoring 
   went C0796199 Monitoring 
   incision line C0197081 Monitoring 
   gastroparesis C0152020 Monitoring 
   Chronic osteomyelitis C0008707 Monitoring 
   dysarthria C0013362 Monitoring 
   endobronchial C0444471 Monitoring 
   venous stasis C0277919 Monitoring 
   Chronic venous C0042485 Monitoring 
   Bone Neoplasm C0005967 Monitoring 
   chronic microangiopathy C3808622 Monitoring 
   
Bone neoplasm uncertain 
behavior C0346546 Monitoring 
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   certain types of food C0566312 Monitoring 
   cerebellar ataxia C0007758 Monitoring 
   Treating as C0516188 Monitoring 
   infection per C2346550 Monitoring 
   chronic active hepatitis C0241910 Monitoring 
   
Inflammatory bowel 
disease C0021390 Monitoring 
   Chronic liver disease C0341439 Monitoring 
   within the C0425538 Monitoring 
   symptomatic C0231220 Monitoring 
   xanthine stones C1848431 Monitoring 
   stone or foreign C3879015 Monitoring 
   staghorn stone C0438018 Monitoring 
   atrial pacing C0199647 Monitoring 
   peripheral neuropathy C0031117 Monitoring 
   Psoriatic arthritis C0003872 Monitoring 
   inflammation and skin C0011603 Monitoring 
   Chronic angina C0340288 Monitoring 
   versus stasis disease C0018133 Monitoring 
   ventral incisional hernia C0750175 Monitoring 
   Adenovirus infection C0001486 Monitoring 
   Chronic nasal C0746757 Monitoring 
   Nasal polyps C0027430 Monitoring 
   
atherosclerotic vascular 
disease C0004153 Monitoring 
   high dose fish oil C0452295 Monitoring 
   abscess C0000833 Monitoring 
   dry itchy skin C3830437 Monitoring 
   renal vascular C0227622 Monitoring 
   stasis dermatitis C0011620 Monitoring 
   Calf tenderness C0238883 Monitoring 
   Anemia of kidney disease C1561828 Monitoring 
   log C0228228 Monitoring 
   in the cyst C1394327 Monitoring 
   Skin abscess C0149777 Monitoring 
   Infected sebaceous cyst C0345989 Monitoring 
   Chronic stasis skin C0748828 Monitoring 
   scaly skin C0423773 Monitoring 
   offsets C1711330 Monitoring 
   chronic proctitis C0860176 Monitoring 
   Infected graft C0349725 Monitoring 
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   infected hip C0744926 Monitoring 
   Reducible umbilical hernia C0577704 Monitoring 
   chronic anal fistula C0740978 Monitoring 
   Herbal weight loss C1572271 Monitoring 
   in skin integrity C0946387 Monitoring 
   heart valve infection C0014121 Monitoring 
   cognitive impairment C0338656 Monitoring 
   pulmonary edema C0034063 Monitoring 
   
inflammation related to 
your gallbladder C0008325 Monitoring 
   chronic interstitial C0221236 Monitoring 
   interstitial lung disease C0206062 Monitoring 
   these C0039828 Monitoring 
   rectal fistula C0034884 Monitoring 
   water intake C0013123 Monitoring 
   definite epidural abscess C0237049 Monitoring 
   chronic pelvic C0149960 Monitoring 
   remember C0034770 Monitoring 
   GI bleed C0017181 Monitoring 
   chronic hearing loss C0744663 Monitoring 
   low dose lung C4067633 Monitoring 
   sexual behavior C0036864 Monitoring 
   chronic nerve C4229567 Monitoring 
   Nevus C0027960 Monitoring 
   tonsil stones C0272388 Monitoring 
   limiting alcohol intake C0560219 Monitoring 
   Chronic laryngitis C0155836 Monitoring 
   chronic volvulus C0267195 Monitoring 
   radicular C0034543 Monitoring 
   Bochdalek hernia C0265700 Monitoring 
   carotid bruits C0007280 Monitoring 
   femoral bruits C0558799 Monitoring 
   tears C0039409 Monitoring 
   nasal drainage C0746759 Monitoring 
   
chronic childhood 
respiratory disease C1398939 Monitoring 
   thrush infection C3646468 Monitoring 
   FHx of kidney disease C0260532 Monitoring 
   numbness C0028643 Monitoring 
   or wound infection C3844442 Monitoring 
   discomfort around C0858893 Monitoring 
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   chronic asthma C0877430 Monitoring 
   emphysema or airway C1403214 Monitoring 
   chronic abscess C0333398 Monitoring 
   prostate abscess C0156290 Monitoring 
   after 48 hours C3897190 Monitoring 
   
chronic prostate toe rectal 
pains C0742666 Monitoring 
   epidermoid cysts C0014511 Monitoring 
   Norovirus infection C2712971 Monitoring 
   spinal stenosis C0037944 Monitoring 
   do become C0510415 Monitoring 
   Chronic ischemic colitis C0267413 Monitoring 
   axillary adenopathy C0578735 Monitoring 
   Metabolic bone disease C0005944 Monitoring 
   either C3844638 Monitoring 
   Low cardiac output C0007166 Monitoring 
   as food always C3900013 Monitoring 
   
infections or upper 
respiratory infections C1536805 Monitoring 
   voice loss C0003564 Monitoring 
   low fever C0239574 Monitoring 
   granulomatous disease C0740451 Monitoring 
   infection becomes C1864807 Monitoring 
   sleep disturbance C0037317 Monitoring 
   Ulcerative colitis C0009324 Monitoring 
   crypt abscess C0333374 Monitoring 
   Rectal ulcerative colitis C3509262 Monitoring 
   atrophy C0333641 Monitoring 
   infection up C0158421 Monitoring 
   stool C0015733 Monitoring 
   infections to C0157749 Monitoring 
   infected hematoma C0948087 Monitoring 
   Chronic allergic C0029543 Monitoring 
   caused neurotoxicity C0546131 Monitoring 
   chronic oral C0747051 Monitoring 
   pulmonary effusions C1608981 Monitoring 
   
atypical pulmonary 
infection C0392054 Monitoring 
   pannus C0333350 Monitoring 
   microscopic hematuria C0239937 Monitoring 
   chronic subdural hematoma C0749095 Monitoring 
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   do you C3259020 Monitoring 
   
Perirectal small cutaneous 
abscess C0267566 Monitoring 
   thyroid disease C0040128 Monitoring 
   Weight trending C0424655 Monitoring 
   Wound drainage C0694702 Monitoring 
   acute diverticulitis C0518989 Monitoring 
   Watchers weight C2067212 Monitoring 
   Surgical wound C0332803 Monitoring 
   chronic epididymitis C0238110 Monitoring 
   chest wound C0742361 Monitoring 
   incision dehiscence C0038940 Monitoring 
   heart murmur C0018808 Monitoring 
   carb intake C4255294 Monitoring 
   sarcoid pulmonary C0340199 Monitoring 
   anorexia or weight loss C1971623 Monitoring 
   Metastatic breast cancer C0278488 Monitoring 
   relief C0564405 Monitoring 
   urination or bloody C0473237 Monitoring 
   uloric C2683462 Monitoring 
   hernia repairs C0019328 Monitoring 
   risk for GI bleed C3251812 Monitoring 
   chronic productive cough C0742859 Monitoring 
   Chronic osteoarthritis C0263778 Monitoring 
   GI cancers C0685938 Monitoring 
   do not drink C4087012 Monitoring 
   of acute infection C0155392 Monitoring 
   
low calcium levels in the 
blood C0020598 Monitoring 
   food intake C0013470 Monitoring 
   gallstones or pancreatitis C0521614 Monitoring 
   infection bacterial infection C0004623 Monitoring 
   scapular C0223628 Monitoring 
   in the chest C1253943 Monitoring 
   MRSA pneumonia C1142536 Monitoring 
   Renal colic C0152169 Monitoring 
   obs C2986870 Monitoring 
   wound complications C1096106 Monitoring 
   Coughing up phlegm C1536391 Monitoring 
   check weight C2712830 Monitoring 
   chronic bronchiectasis C0741793 Monitoring 
147 
 
   chronic fevers C0743971 Monitoring 
   ulceration or erosions C4055054 Monitoring 
   MRSA skin infection C0343401 Monitoring 
   or damage C1301684 Monitoring 
   Cecal polyps C1112566 Monitoring 
   disc disease C0012619 Monitoring 
   infection the skin C1142269 Monitoring 
   cecal volvulus C0238047 Monitoring 
   Calcified coronary artery C0742825 Monitoring 
   abscess cavity C0333372 Monitoring 
   hepatic abscess C0023885 Monitoring 
   Suicidal intent C0582496 Monitoring 
   
effusion or pericardial 
effusion C0031039 Monitoring 
   Chronic gouty arthritis C0268108 Monitoring 
   inflammation prostate C0033581 Monitoring 
   infected tunneled C3161243 Monitoring 
   
choledocholithiasis or 
acute obstruction C3649781 Monitoring 
   chronic in C0153912 Monitoring 
   chronically ill appearing C2051413 Monitoring 
   groin abscess C0263109 Monitoring 
   after weight loss C2129177 Monitoring 
   Incarcerated ventral hernia C0311269 Monitoring 
   
Diverticulosis without 
acute diverticulitis C0149653 Monitoring 
   prostate hyperplasia C2937421 Monitoring 
   chronic medical C0425066 Monitoring 
   vascular disease C0042373 Monitoring 
   inflammation around C0031099 Monitoring 
   varicella zoster infection C0586989 Monitoring 
   chronic depressive C0581391 Monitoring 
   vascular stenosis C0679403 Monitoring 
   subdural empyema C0038539 Monitoring 
   bone flap C1266913 Monitoring 
   Retention cysts C0035281 Monitoring 
   chronic musculoskeletal C0746683 Monitoring 
   chronic recurrent C0410422 Monitoring 
   Colloid cyst C0333157 Monitoring 
   Chronic sequela C2198003 Monitoring 
   vascular malformation C0158570 Monitoring 
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   colon perforation C0347646 Monitoring 
   Chronic rib C0844663 Monitoring 
   
Chronic cardiopulmonary 
disease C0238074 Monitoring 
   Allergic C0700624 Monitoring 
   Chronic head C0558154 Monitoring 
   
Chronic hepatitis C virus 
infection C0524910 Monitoring 
   volume blood loss C4265180 Monitoring 
   Chronic anxiety C0581386 Monitoring 
   fluid weight C3484207 Monitoring 
   around his wounds C2129888 Monitoring 
   dry mouth C0043352 Monitoring 
   inflammation/abscess C3513855 Monitoring 
   intermittent cough C2077828 Monitoring 
   blurry vision C0344232 Monitoring 
   risk of kidney disease C3697935 Monitoring 
   Chronic foot ulcer C0744178 Monitoring 
   chronic muscle cramping C0746672 Monitoring 
   acute flare C4042866 Monitoring 
   thyroid cysts C0162299 Monitoring 
   
Coarse vascular 
calcifications C1268677 Monitoring 
   infection but C2749557 Monitoring 
   vitamin K intake C2317598 Monitoring 
   seasonal allergic rhinitis C0018621 Monitoring 
   obstructing hernia C0156140 Monitoring 
   chronic fungal C0396046 Monitoring 
   swelling of legs C0581394 Monitoring 
   chronic ankle C0410419 Monitoring 
   Chronic hand C0264045 Monitoring 
   dysphonia C1527344 Monitoring 
   Chronic wrist C0564827 Monitoring 
   Colocutaneous fistula C0341377 Monitoring 
   recent wound infection C2169571 Monitoring 
   BONE INFECTION C2242472 Monitoring 
   drink juice C2136335 Monitoring 
   Septic pulmonary emboli C0333222 Monitoring 
   stump healed C1398427 Monitoring 
   Chronic pulmonary fibrosis C0340126 Monitoring 
   ischemic vascular C0235490 Monitoring 
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   head trauma C0018674 Monitoring 
   tingling in the hand C4084744 Monitoring 
   
chronic iron deficiency 
anemia C0740989 Monitoring 
   pancreatic pseudocyst C0030299 Monitoring 
   bright C0423899 Monitoring 
   urethral stricture disease C0041974 Monitoring 
   biliary sludge C0282074 Monitoring 
   hematuria or C0475537 Monitoring 
   
adenocarcinoma of the 
prostate C0007112 Monitoring 
   LVAD C0181598 Monitoring 
   ulcers or skin C0455787 Monitoring 
   drastic C0743236 Monitoring 
   arsenic levels C0373548 Monitoring 
   infection damage C1411542 Monitoring 
   
chronic inflammatory 
bowel C0267374 Monitoring 
   infectious colitis C0277524 Monitoring 
   as much as C1879743 Monitoring 
   nonocclusive C0266061 Monitoring 
   Purposeful C1285529 Monitoring 
   blastic pelvic C2021201 Monitoring 
   cervical spinal cord lesion C0730136 Monitoring 
   chronic pains C0150055 Monitoring 
   chronic dyspnea C1388883 Monitoring 
   intestinal metaplasia C0334037 Monitoring 
   Acute blood loss anemia C0154298 Monitoring 
   
Chronic mesenteric 
ischemia C0311262 Monitoring 
   hepatocellular disease C0023895 Monitoring 
   steatosis C0152254 Monitoring 
   chronic active ileitis C0745221 Monitoring 
   infection or hernia C4049327 Monitoring 
   chronic psychosis C0221764 Monitoring 
   increased weight gain C0000765 Monitoring 
   swelling and C0455933 Monitoring 
   inflammation of the liver C0019158 Monitoring 
   Chronic dermatitis C0262975 Monitoring 
   insignificant C3898757 Monitoring 
   brawny edema C0333248 Monitoring 
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   Papillary thyroid cancer C0238463 Monitoring 
   Xerosis of skin C0263465 Monitoring 
   gonococcal infection C0018081 Monitoring 
   chronic hypernatremia C0268012 Monitoring 
   Metastatic prostate cancer C0936223 Monitoring 
   infected coronary C2049798 Monitoring 
   prosthetic infection C0349726 Monitoring 
   truncal ataxia C0427190 Monitoring 
   GI: liver disease C0017183 Monitoring 
   
invasive pneumococcal 
disease C1320214 Monitoring 
   not drink C0564343 Monitoring 
   gouty C0003868 Monitoring 
   Thyroid C0040132 Monitoring 
   urinary leakage C3897214 Monitoring 
   chronic moderate C0267386 Monitoring 
   UK C0077769 Monitoring 
   weight loss after gastric C2126001 Monitoring 
   Integumentary: skin lesion C0191447 Monitoring 
   A fib C0004238 Monitoring 
   scarring to the flanks C2037960 Monitoring 
   
Staphylococcus aureus 
bacteremia C1142423 Monitoring 
   High cardiac output C0085128 Monitoring 
   Alopecia areata C0002171 Monitoring 
   kidney transplant C0022671 Monitoring 
   salivary stones C0036091 Monitoring 
   neoplasm of the lung C0024121 Monitoring 
   or erosions C1540849 Monitoring 
   infection prophylaxis C0877629 Monitoring 
   Not eating C0418837 Monitoring 
   alcohol intake C0001948 Monitoring 
   chronic uveitis C1510449 Monitoring 
   Psoriatic plaques C0920235 Monitoring 
   chronic hemolytic anemia C0271904 Monitoring 
   murmur as child C0746654 Monitoring 
   possibly C0332149 Monitoring 
   osteoarthritis flare C3544322 Monitoring 
   toenail infection C0749565 Monitoring 
   
Seronegative rheumatoid 
arthritis C0409652 Monitoring 
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   infections or stomatitis C1398444 Monitoring 
   Worse after C0241739 Monitoring 
   attacks C0004063 Monitoring 
   risk of heart disease C1277690 Monitoring 
   cyst rupture C0333140 Monitoring 
   myeloid leukemia C0023470 Monitoring 
   ulcerations or rashes C0744159 Monitoring 
   
inflammation without any 
intestinal C3889047 Monitoring 
   aneurysm dissection C0002949 Monitoring 
   Chronic daily headache C0752147 Monitoring 
   visual C0234621 Monitoring 
   msk C1420279 Monitoring 
   panic C0030318 Monitoring 
   abd C0449202 Monitoring 
   metaplasia C0025568 Monitoring 
   glycogen storage disease C0017919 Monitoring 
   ovarian simple cyst C0237010 Monitoring 
   Periumbilical hernia C0747528 Monitoring 
   chronic Hep C0524909 Monitoring 
   not be safe C0581563 Monitoring 
   Paresthesia of skin C0235046 Monitoring 
   heat as C1820546 Monitoring 
   chronically draining wound C0750432 Monitoring 
   yellow sputum C0457096 Monitoring 
   chest or abdominal C0846687 Monitoring 
   nails C0027342 Monitoring 
   Black lung C0003165 Monitoring 
   clavicular fracture C0159658 Monitoring 
   splenic granulomas C1535984 Monitoring 
   
Chronic kidney disease 
mineral bone disease C4076240 Monitoring 
   increased fluid intake C0426596 Monitoring 
   infected mastoid C1096736 Monitoring 
   away C0425139 Monitoring 
   viral infection C0042769 Monitoring 
   diverticular disease C1510475 Monitoring 
   added C0002395 Monitoring 
   
symptomatic urinary tract 
infection C0749968 Monitoring 
   degenerative changes C0011164 Monitoring 
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   helped C1269765 Monitoring 
   Gastric erosions C0341177 Monitoring 
   gastric C1704242 Monitoring 
   erosions C0333307 Monitoring 
   liver biopsy C0193388 Monitoring 
   pneumoperitoneum C0032320 Monitoring 
   sickle cell C0221283 Monitoring 
   sickle cell disease C0002895 Monitoring 
   Beta Thalassemia C0005283 Monitoring 
   sickle beta thalassemia C0221019 Monitoring 
   Cod Liver Oil OIL C0009213 Monitoring 
   under the nails C0474374 Monitoring 
   enterovirus types C0376325 Monitoring 
   under C0542339 Monitoring 
   Perforated appendicitis C0854119 Monitoring 
   omental adhesions C0267781 Monitoring 
   Alcoholic liver disease C0023896 Monitoring 
   squamous cell carcinoma C0149782 Monitoring 
   stage liver disease C0745744 Monitoring 
   inherited renal disease C0403547 Monitoring 
   promote weight loss C2584720 Monitoring 
   started as C0474365 Monitoring 
   weight loss surgery C1456587 Monitoring 
   chronic jaw C0266964 Monitoring 
   burgdorferi antibodies C0368786 Monitoring 
   chronic ear infections C0743359 Monitoring 
   or signs of infection C2191772 Monitoring 
   Bone marrow edema C0948162 Monitoring 
   localized infections C0016397 Monitoring 
   retrobulbar hemorrhage C0302497 Monitoring 
   gum infection C0744403 Monitoring 
   
diverticulosis or 
diverticulitis C0679411 Monitoring 
   salt intake C0489767 Monitoring 
   skin tears C0877377 Monitoring 
   
Chronic intermittent 
diarrhea C0743174 Monitoring 
   gastric reflux C0558176 Monitoring 
   vascular damage C1389629 Monitoring 
   chronic stage IV C0854804 Monitoring 
   Incision site C0449681 Monitoring 
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   looks C0233426 Monitoring 
   bone fractures C0016658 Monitoring 
   renal as C0403448 Monitoring 
   Necrotic pancreatitis C0267941 Monitoring 
   chronic hydronephrosis C1405879 Monitoring 
   chronic hypocalcemia C0033806 Monitoring 
   foods C0016452 Monitoring 
   Squamous cell skin cancer C0553723 Monitoring 
   loss was C2018719 Monitoring 
   inflammation of duodenum C0013298 Monitoring 
   stones or masses C1714971 Monitoring 
   trigeminal neuralgia C0040997 Monitoring 
   
arteriosclerotic vascular 
disease C0003850 Monitoring 
   ureteral stent C0183518 Monitoring 
   chronic myeloid C0023473 Monitoring 
   inflammation no skin C3873446 Monitoring 
   gastric hyperplastic polyp C0878649 Monitoring 
   suture in the skin C0191408 Monitoring 
   Atrophic vaginal C0221392 Monitoring 
   Urticaria C0042109 Monitoring 
   chronic lumbar back C0741393 Monitoring 
   tingling in the arm C2116338 Monitoring 
   
Metastatic renal cell 
carcinoma C0278678 Monitoring 
   incision made C2034895 Monitoring 
   chronic drainage C0748721 Monitoring 
   wound open C0332798 Monitoring 
   thrombus C0087086 Monitoring 
   rectal cancer C0007113 Monitoring 
   radiation cystitis C0156270 Monitoring 
   Radiation proctitis C0400827 Monitoring 
   Mitral valve endocarditis C0746604 Monitoring 
   pacer C3890506 Monitoring 
   superficial wound infection C0406104 Monitoring 
   central line infection C1096243 Monitoring 
   risk of vascular disease C2584745 Monitoring 
   infection if C2051616 Monitoring 
   HBV Infection C3854623 Monitoring 
   synovial cysts C0085648 Monitoring 
   Heberden nodes C0018862 Monitoring 
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   chronic sacroiliac C0948612 Monitoring 
   Short term memory loss C0701811 Monitoring 
   scrotal infections C1299539 Monitoring 
   crusting of healed skin C2231982 Monitoring 
   scrotal skin C0222198 Monitoring 
   Splenic laceration C0347636 Monitoring 
   infected inguinal C0919796 Monitoring 
   enterocutaneous fistula C0341318 Monitoring 
   hernia mesh repair C0519122 Monitoring 
   infection of the sacrum C0410371 Monitoring 
   rectal perforation C0341402 Monitoring 
   glottic gap C2138972 Monitoring 
   chronic respiratory C0264220 Monitoring 
   lupus flares C4054590 Monitoring 
   SLE flare C1735608 Monitoring 
   fluid thrill no ascites C0437004 Monitoring 
   chronic dental caries C0266852 Monitoring 
   Scrotal C0036471 Monitoring 
   heart attack or C2926099 Monitoring 
   cold sores C0019345 Monitoring 
   drink extra C1170830 Monitoring 
   necrosis C0027540 Monitoring 
   Abdominal Adhesions C0549357 Monitoring 
   
Protracted upper 
respiratory infection C2133965 Monitoring 
   chronic rash C3806538 Monitoring 
   asthmatic bronchitis C1319018 Monitoring 
   
Degenerative 
spondylolisthesis C0264184 Monitoring 
   falls or any C2707943 Monitoring 
   stone like C1823135 Monitoring 
   hernia as C0267713 Monitoring 
   or myalgias C0410002 Monitoring 
   
RLE toe touch weight 
bearing C2149821 Monitoring 
   Refused weight loss C2169617 Monitoring 
   attempting weight loss C2046395 Monitoring 
   Chronic anal fissure C0349071 Monitoring 
   nicotine C0028040 Monitoring 
   rashes or C0011974 Monitoring 
   importance of weight C1705104 Monitoring 
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   Malignant neoplasm C0006826 Monitoring 
   chronic infiltrates C0021376 Monitoring 
   
Thyrotoxicosis without 
thyroid storm C2873871 Monitoring 
   or fevers C0275976 Monitoring 
   backup C1552560 Monitoring 
   chronic erythema C1265577 Monitoring 
   over C0020505 Monitoring 
   Antrochoanal polyp C0008298 Monitoring 
   fluid collection C0394552 Monitoring 
   scarring or old C0404534 Monitoring 
   such an C1548400 Monitoring 
   aspiration pneumonia C0032290 Monitoring 
   meningeal cysts C0347534 Monitoring 
   Pituitary Neoplasm C0032019 Monitoring 
   Chronic nausea C0746779 Monitoring 
   Over weight C0497406 Monitoring 
   chronic severe C0267387 Monitoring 
   uncal herniation C0393985 Monitoring 
   in weight gain C1398625 Monitoring 
   pulmonary vascular disease C0020542 Monitoring 
   likelihood C0033204 Monitoring 
   recheck C0745623 Monitoring 
   Acute pulmonary edema C0155919 Monitoring 
   intra C0347985 Monitoring 
   Perianal fistula C0267561 Monitoring 
   tics C0040188 Monitoring 
   chronic Q fever C1443892 Monitoring 
   psoas muscle C0085221 Monitoring 
   spine infections C0748912 Monitoring 
   Pancreatic cysts C0030283 Monitoring 
   Central C0205099 Monitoring 
   incision drainage C0152277 Monitoring 
   kidney stones and weight C2109384 Monitoring 
   Regaining C0730881 Monitoring 
   Anaplastic astrocytoma C0334579 Monitoring 
   Nonmelanoma skin C0699893 Monitoring 
   or sexual C1527307 Monitoring 
   reaction units C1975995 Monitoring 
   heat C0018837 Monitoring 
   erythematosus C0409974 Monitoring 
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   Ulcerations are drying C0747964 Monitoring 
   Chronic pulmonary edema C0264518 Monitoring 
   lifts weight C0043095 Monitoring 
   T levels C1278066 Monitoring 
   hepatitis infection C1112211 Monitoring 
   dysphagia and weight loss C3277224 Monitoring 
   rectal colon polyp C0742670 Monitoring 
   holes or tears C1883270 Monitoring 
   incision skin C0191279 Monitoring 
   fiber intake C1821272 Monitoring 
   eating fish C3671189 Monitoring 
   prostate or urothelial C1514430 Monitoring 
   incision wounds C0000925 Monitoring 
   narcotic dependence C1527402 Monitoring 
   polyp in the sigmoid C0742699 Monitoring 
   chronic sacral C2919335 Monitoring 
   Blood C0005767 Monitoring 
   coccygeal decubitus ulcer C2728301 Monitoring 
   infected sacral C3648743 Monitoring 
   sacral decubitus C0558159 Monitoring 
   chronic pancreatitis as C0940977 Monitoring 
   Infected cyst C1142249 Monitoring 
   pelvic fluid collections C1697454 Monitoring 
   erythema of the skin C0241365 Monitoring 
   hernia or reflux C1268942 Monitoring 
   nasal bleeds C0014591 Monitoring 
   chronic pyelonephritis C0085697 Monitoring 
   Postmenopausal bone loss C0029458 Monitoring 
   not always C2749261 Monitoring 
   chronic mucosal C1290074 Monitoring 
   Chronic resp C0421217 Monitoring 
   pleural thickening C0264545 Monitoring 
   within 48 hours C0150946 Monitoring 
   chronic strain C2063696 Monitoring 
   airway obstruction C0001883 Monitoring 
   Rectourethral Fistula C0268875 Monitoring 
   above C1282910 Monitoring 
   oxalate stones C0428457 Monitoring 
   fevers or skin rashes C0847014 Monitoring 
   infection signs of infection C2225262 Monitoring 
   infection after dog bite C0850850 Monitoring 
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   nephrolithiasis C0392525 Monitoring 
   after starting C1552564 Monitoring 
   profile C1721540 Monitoring 
   his C0019602 Monitoring 
   chronic inf C0155397 Monitoring 
   rust colored sputum C0748946 Monitoring 
   pus drainage C0748194 Monitoring 
   red meat intake C0556202 Monitoring 
   Blanching C0948786 Monitoring 
   lose consciousness C2057717 Monitoring 
   choking C0008301 Monitoring 
   barrier laser barrier laser C0302718 Monitoring 
   stone extraction C0883371 Monitoring 
   chronic allergies C0740905 Monitoring 
   chronic blood disorder C1275398 Monitoring 
   symptomatic infections C0864665 Monitoring 
   Renal arterial thrombosis C0340608 Monitoring 
   cold or heat intolerance C0424798 Monitoring 
   much C0205393 Monitoring 
   chronic ruq C0262419 Monitoring 
   Calcitonin C0006668 Monitoring 
   electrolyte abnormalities C0151613 Monitoring 
   paraumbilical hernia C0019311 Monitoring 
   
Mediastinal 
lymphadenopathy C0520743 Monitoring 
   septic arthritis C0003869 Monitoring 
   increased weight or edema C0743393 Monitoring 
   low C0205251 Monitoring 
   during this C3827541 Monitoring 
   swelling in the knee C0240130 Monitoring 
   chronic thromboembolic C2363973 Monitoring 
   discuss weight loss C1535374 Monitoring 
   under chin C0448809 Monitoring 
   hallux C0018534 Monitoring 
   as blood loss C0516480 Monitoring 
   stone surgeries C0401239 Monitoring 
   
Cryptogenic organizing 
pneumonia C0242770 Monitoring 
   simple liver cyst C2887948 Monitoring 
   yellow fever C0043395 Monitoring 
   anaphylactic reaction to C0344159 Monitoring 
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   Monocryl C0381197 Monitoring 
   allergic conjunctivitis C0009766 Monitoring 
   hyperplasia of tongue C0024421 Monitoring 
   biliary obstruction C0400979 Monitoring 
   NUT ALLERGY C0577620 Monitoring 
   to the flanks C2032306 Monitoring 
   chronic basilar fibrosis C0334133 Monitoring 
   chronic lung fibrosis C0264526 Monitoring 
   leukemoid reaction C0023501 Monitoring 
   Tornwaldt cyst C0264294 Monitoring 
   nasal bone fractures C0339848 Monitoring 
   Chronic nasal bone C1290184 Monitoring 
   Not checking blood sugars C2136219 Monitoring 
   night C0240526 Monitoring 
   groin nodes C0857362 Monitoring 
   vulvar cancer C0375071 Monitoring 
   chronic mental C0683405 Monitoring 
   came C0960273 Monitoring 
   
Anomalous pulmonary 
venous drainage C0265916 Monitoring 
   Pseudomonas infection C0033817 Monitoring 
   nervous system infection C0007684 Monitoring 
   Hepatitis diagnostic C0770872 Monitoring 
   do not see any C3639726 Monitoring 
   muscle spasms C0037763 Monitoring 
   potassium in the blood C0020461 Monitoring 
   spondylitic C0263853 Monitoring 
   Midline abd hernia C0750176 Monitoring 
   GI C0521362 Monitoring 
   orthopnea C0085619 Monitoring 
   Chronic Lymphoma C2063391 Monitoring 
   infected bursa C1290161 Monitoring 
   he C1418983 Monitoring 
   Chronic Pansinusitis C0155827 Monitoring 
   infection because C0034386 Monitoring 
   infected intra C0270179 Monitoring 
   
Drainage of abdominal 
abscess C0405771 Monitoring 
   Recurrent hernia C0281961 Monitoring 
   no signs of infection C3693702 Monitoring 
   Deg C2348088 Monitoring 
159 
 
   Acne scarring C0423783 Monitoring 
   ruptured aneurysms C0162869 Monitoring 
   
invasive pulmonary fungal 
infection C1262313 Monitoring 
   photosensitivity reaction C0162830 Monitoring 
   Invasive pulmonary C0276653 Monitoring 
   aspergillus infection C0851807 Monitoring 
   or recurrent hernia C1835116 Monitoring 
   cerebellar infarcts C0236073 Monitoring 
   rectal adenocarcinoma C0149978 Monitoring 
   gastric antral vascular C0267211 Monitoring 
   good C0205170 Monitoring 
   stent C0038257 Monitoring 
   infrarenal C0226025 Monitoring 
   Prostate carcinoma C0600139 Monitoring 
   desmoplastic reaction C1511789 Monitoring 
   biliary stones C0008350 Monitoring 
   Chronic hyponatremia C0268007 Monitoring 
   
Incarcerated umbilical 
hernia C0700253 Monitoring 
   
infarction within the 
vascular C0011263 Monitoring 
   heart burns C0018834 Monitoring 
   bone disease C0005940 Monitoring 
   myeloma FISH C2210831 Monitoring 
   internal hemorrhoid C0265034 Monitoring 
   ulcerations or wounds C0460766 Monitoring 
   
significant coronary artery 
disease C1299434 Monitoring 
   leiomyoma or benign C0023267 Monitoring 
   daytime somnolence C2219848 Monitoring 
   weight loss was weight C0750414 Monitoring 
   stone heart C2938932 Monitoring 
   lying C0600261 Monitoring 
   risk of kidney injury C0582456 Monitoring 
   Ruptured aortic aneurysm C0265010 Monitoring 
   chronic sinus disease C0748720 Monitoring 
   Chronic pelvic abscess C0269024 Monitoring 
   metastatic rectal cancer C0861772 Monitoring 
   infection or granulomatous C1610637 Monitoring 
   becomes C0429569 Monitoring 
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   tinea infection C0040247 Monitoring 
   HBV C0019169 Monitoring 
   instead of C0425956 Monitoring 
   Chronic frontal sinusitis C0008683 Monitoring 
   Breast neoplasm C1458155 Monitoring 
   
Papillary serous 
endometrial C0854924 Monitoring 
   papillary serous C0334358 Monitoring 
   pancreatic duct dilatation C0400535 Monitoring 
   diverticular abscess C0581275 Monitoring 
   concerning weight C2034380 Monitoring 
   emesis C0042963 Monitoring 
   
recent intentional weight 
loss C2169614 Monitoring 
   px C0332132 Monitoring 
   meningitis C0025285 Monitoring 
   leakage C0015376 Monitoring 
   bile leak C0400997 Monitoring 
   
Idiopathic pulmonary 
fibrosis C0085786 Monitoring 
   Fatty liver disease C0341447 Monitoring 
   chronic therapy C0749634 Monitoring 
   Malignant neoplasm of C0153340 Monitoring 
   splenic calcifications C1404059 Monitoring 
   smoking history C1519384 Monitoring 
   coughing or deep breath C1276787 Monitoring 
   tibial C0040184 Monitoring 
   PICC line C0179740 Monitoring 
   chronic cellulitis C0544781 Monitoring 
   limited weight bearing C2080837 Monitoring 
   esophageal strictures C0014866 Monitoring 
   chest wall infection C0438341 Monitoring 
   breast skin thickening C1268720 Monitoring 
   Latent syphilis C0039133 Monitoring 
   herniorraphy C0458169 Monitoring 
   Indirect inguinal hernia C0019296 Monitoring 
   
hemorrhage or vascular 
anomaly C0519029 Monitoring 
   pelvic fractures C0149531 Monitoring 
   hip abscess C0263120 Monitoring 
   endemic C0243130 Monitoring 
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fungal pulmonary 
infections C0024116 Monitoring 
   fevers or sweats C0038992 Monitoring 
   scrotal hernia C0019319 Monitoring 
   meniscal tears C0238218 Monitoring 
   smoking or risky behavior C1519383 Monitoring 
   Esophageal ulcers C0151970 Monitoring 
   nasal spray C0461725 Monitoring 
   Passing flatus C0016204 Monitoring 
   
chronic granulomatous 
disease C0018203 Monitoring 
   
chronic diabetic 
neuropathy C0393830 Monitoring 
   breaks in the skin C3842551 Monitoring 
   Hyperplasia of the breast C0741698 Monitoring 
   breast disease C0006145 Monitoring 
   subsegmental pulmonary C0503868 Monitoring 
   fragment these stones C0400630 Monitoring 
   IgA C0020835 Monitoring 
   ULCER RECTAL C0400839 Monitoring 
   gluteal C1550262 Monitoring 
   left inguinal hernia C0262537 Monitoring 
   incision hernia C0176963 Monitoring 
   sleep apnea C0037315 Monitoring 
   
kidney stones were uric 
acid stones C2109383 Monitoring 
   heaviest C2711761 Monitoring 
   ect C0013806 Monitoring 
   further C1517331 Monitoring 
   bowel or vascular C0400883 Monitoring 
   risk sexual behavior C1261242 Monitoring 
   chronically dry skin C2074685 Monitoring 
   Epidural abscess C0270629 Monitoring 
   Perianal skin tag C0521605 Monitoring 
   infection abd C0438343 Monitoring 
   flare up C3830105 Monitoring 
   pleural effusion C0032227 Monitoring 
   pulmonary process C0748169 Monitoring 
   chronic pancolitis C2711681 Monitoring 
   peripelvic cysts C0866184 Monitoring 
   resolution of chest C2318026 Monitoring 
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   ulcer arthritis C1388566 Monitoring 
   chronic occipital C0744647 Monitoring 
   infected arthroplasty C0410808 Monitoring 
   Infection of implant C0405488 Monitoring 
   chronic atypical C1292772 Monitoring 
   lung induced lung disease C0599154 Monitoring 
   erythema around C2071472 Monitoring 
   Chronic Leukemia C1279296 Monitoring 
   requiring wound C0744501 Monitoring 
   infection related C0085073 Monitoring 
   insufficency C0349073 Monitoring 
   
olfactory groove 
meningioma C1335107 Monitoring 
   Gastric mucosal atrophy C0597736 Monitoring 
   radiotracer C0597354 Monitoring 
   breakthrough C0444503 Monitoring 
   or ischemia C0745412 Monitoring 
   site healed C2197765 Monitoring 
   collateral venous C0265074 Monitoring 
   or colon cancer C0009375 Monitoring 
   Forehead laceration C0561236 Monitoring 
   ureteral reflux C0042580 Monitoring 
   anxiety C0003467 Monitoring 
   CaOx stones C1147841 Monitoring 
   this C1080058 Monitoring 
   rheumatoid arthritis C0003873 Monitoring 
   lifelong C4274169 Monitoring 
   allergic fungal C1827192 Monitoring 
   Reflux kidney C2123534 Monitoring 
   poisoning as blood C0036690 Monitoring 
   CrCL C1846718 Monitoring 
   Ulcers in colon C0267491 Monitoring 
   eating food because it C3275021 Monitoring 
   Extraction of kidney stone C0162428 Monitoring 
   back discomfort C0235706 Monitoring 
   dysplasia C0334044 Monitoring 
   refusal to bear weight C4054081 Monitoring 
   lymphangitis C0024225 Monitoring 
   striae in the skin C0152459 Monitoring 
   Watches C0043012 Monitoring 
   again C0723612 Monitoring 
163 
 
   ulcers or infection C1407931 Monitoring 
   chronic health C0559278 Monitoring 
   chronic fractures C2712806 Monitoring 
   it was C4086960 Monitoring 
   esophageal spasms C0014863 Monitoring 
   PDT C0175486 Monitoring 
   inflammation of the blood C0042384 Monitoring 
   oliguria C0028961 Monitoring 
   infection/abscess C0400889 Monitoring 
   steatohepatitis C2711227 Monitoring 
   started C0439659 Monitoring 
   around C0750503 Monitoring 
   Infected sexual C0036916 Monitoring 
   Expected weight gain C2233528 Monitoring 
   raise blood C0235416 Monitoring 
   reaction to C0013182 Monitoring 
   swelling of nasal C0581927 Monitoring 
   formed stools C2128963 Monitoring 
   swelling or chest C0347940 Monitoring 
   
inflammation from 
rheumatoid C0333423 Monitoring 
   cholestatic liver disease C0860204 Monitoring 
   stone pancreatitis C0440736 Monitoring 
   planned weight loss C1814869 Monitoring 
   radiation esophagitis C0238113 Monitoring 
   myalgia C0231528 Monitoring 
   respiratory distress C0476273 Monitoring 
   chronic allergic sinusitis C0748727 Monitoring 
   
Klebsiella pneumoniae line 
infection C0948802 Monitoring 
   pneumoniae line infection C0729704 Monitoring 
   
recent upper respiratory 
infection C2169609 Monitoring 
   stage III lung cancer C0862847 Monitoring 
   infective endocarditis C1541923 Monitoring 
   inflammation is C2678093 Monitoring 
   pelvic hematoma C0475319 Monitoring 
   Gastric outlet obstruction C0162651 Monitoring 
   pancreatic adenocarcinoma C0281361 Monitoring 
   induration under the wound C2116826 Monitoring 
   port site infection C4054168 Monitoring 
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   anorexia weight loss C0426583 Monitoring 
   thrill in vascular C0241658 Monitoring 
   
interstitial pulmonary 
edema C0748120 Monitoring 
   inguinal lymphadenopathy C0578736 Monitoring 
   Nonalcoholic fatty liver C0400966 Monitoring 
   hereditary C0439660 Monitoring 
   promote weight weight C2584705 Monitoring 
   swelling of feet C0574002 Monitoring 
   in the transplant C2170316 Monitoring 
   stent thrombosis C3897493 Monitoring 
   stones blood in urine C0455909 Monitoring 
   myofascial C0262941 Monitoring 
   salmonella infection C0036117 Monitoring 
   intake and weight C4263181 Monitoring 
   
squamous intraepithelial 
lesion C0333873 Monitoring 
   Nasal abscess C0264263 Monitoring 
   tenderness C0234233 Monitoring 
   infection in C0003204 Monitoring 
   mechanical neck C3877575 Monitoring 
   Migraine headaches C0149931 Monitoring 
   submucosal C1515025 Monitoring 
   ordered as C0508364 Monitoring 
   cysts C0010709 Monitoring 
   berry aneurysms C0005136 Monitoring 
   gas C0017110 Monitoring 
   calf C0230445 Monitoring 
   senile dementia C0011268 Monitoring 
   coughing up green sputum C2126217 Monitoring 
   carbohydrate intake C0489461 Monitoring 
   stabbing C0418391 Monitoring 
   Anion gap acidosis C0860062 Monitoring 
   Well healed knee wound C2142391 Monitoring 
   chronic lung infection C3163798 Monitoring 
   mycobacterium infection C0026918 Monitoring 
   desmoid tumor C0079218 Monitoring 
   distal ureteral stone C2006154 Monitoring 
   No known liver disease C3280432 Monitoring 
   PI C0031939 Monitoring 
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stopped drinking soft 
drinks C0425321 Monitoring 
   fatty liver C0015695 Monitoring 
   insult C0598698 Monitoring 
   ASCVD C3665365 Monitoring 
   ulceration as C0509790 Monitoring 
   home C0442519 Monitoring 
   Chronic hyperkalemia C0268023 Monitoring 
   Chronic spinal C3697550 Monitoring 
   feelings C1527305 Monitoring 
   Breast implants C0179412 Monitoring 
   ideally weight C0421272 Monitoring 
   variceal or GI hemorrhage C0333106 Monitoring 
   therapy given C3699632 Monitoring 
   venous disease C0235522 Monitoring 
   chronic intractable C0476481 Monitoring 
   saddle anesthesia C0179052 Monitoring 
   Chronic pruritus C0748035 Monitoring 
   radiation fibrosis C2350622 Monitoring 
   Not drinking much water C2077403 Monitoring 
   chest weight C0179897 Monitoring 
   significant C0750502 Monitoring 
   chronic vessel C3275069 Monitoring 
   recommend weight C3853327 Monitoring 
   Warm skin C0235218 Monitoring 
   parallel C0233174 Monitoring 
   family weight C2203029 Monitoring 
   dz C0062886 Monitoring 
   
Helicobacter pylori 
infection C0850666 Monitoring 
   ileitis C0020877 Monitoring 
   chronic gallbladder C1391788 Monitoring 
   
chronicity organizing 
pneumonia C4039254 Monitoring 
   chronic radiation proctitis C0400829 Monitoring 
   sarcoid C0036202 Monitoring 
   profound vision loss C3276857 Monitoring 
   hypopituitarism C0020635 Monitoring 
   chronic rotator cuff C0186620 Monitoring 
   kidney cancer C0740457 Monitoring 
   perforated sigmoid colon C4041049 Monitoring 
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decompensation of liver 
disease C4075847 Monitoring 
   given C1442162 Monitoring 
   Cirrhosis of the liver C0023890 Monitoring 
   
Bleeding internal 
hemorrhoids C0265036 Monitoring 
   under live fluoroscopy C0846072 Monitoring 
   dry rales C0859999 Monitoring 
   chronic diverticulitis C0859969 Monitoring 
   bowel dilatation C3280831 Monitoring 
   swelling or skin C0281982 Monitoring 
   
Mucinous cystic pancreatic 
neoplasm C1518872 Monitoring 
   ureteral strictures C3887590 Monitoring 
   does not C1299585 Monitoring 
   wound continues to bleed C0241742 Monitoring 
   Sessile colon polyp C0940597 Monitoring 
   
Histoplasma capsulatum 
infection C0153261 Monitoring 
   infected chest seroma C3805093 Monitoring 
   jaundice or C0474426 Monitoring 
   lose weight to C0231247 Monitoring 
   Allergic sinusitis C0748726 Monitoring 
   septated renal cyst C0237039 Monitoring 
   ulcers or reflux C0362009 Monitoring 
   orthopedic C0029355 Monitoring 
   infection drainage C0559642 Monitoring 
   Contradictory C4061957 Monitoring 
   cardiac chest C0190043 Monitoring 
   chronic metabolic alkalosis C0740894 Monitoring 
   
Diverticulosis in the 
sigmoid colon C0012818 Monitoring 
   radiation colitis C0341339 Monitoring 
   Staph aureus infection C0748791 Monitoring 
   skin ulcerations C0037299 Monitoring 
   fluid retention C0268000 Monitoring 
   gun shot wound C0043252 Monitoring 
   infected toes C0555972 Monitoring 
   kappa light chain myeloma C1532715 Monitoring 
   Metab C0025519 Monitoring 
   infection or ocular C0015403 Monitoring 
   remnant thyroid C0266285 Monitoring 
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   chest C0817096 Monitoring 
   staples in the skin C1139841 Monitoring 
   ataxia C0004134 Monitoring 
   ulceration under C0585371 Monitoring 
   
Postinflammatory 
pulmonary fibrosis C0175999 Monitoring 
   Exophytic right renal cyst C4229072 Monitoring 
   sustain weight loss C4062926 Monitoring 
   Klatskin tumor C0206702 Monitoring 
   Pneumobilia C1739097 Monitoring 
   accidental overdose C0151821 Monitoring 
   suicidal behavior C1760428 Monitoring 
   central retinal C0858623 Monitoring 
   flank C0230171 Monitoring 
   Biliary strictures C0597984 Monitoring 
   infection process C0596824 Monitoring 
   second vascular C0751414 Monitoring 
   sigmoid polyp C0877441 Monitoring 
   bone metastasis C0153690 Monitoring 
   Chronic interstitial cystitis C0600040 Monitoring 
   
oligoarticular rheumatoid 
arthritis C0157917 Monitoring 
   drip C0452837 Monitoring 
   Wound as C0270118 Monitoring 
   planned vascular C4265958 Monitoring 
   trying to drink C3641816 Monitoring 
   perioral numbness C0221730 Monitoring 
   cyanosis C0010520 Monitoring 
   perineural cysts C0520720 Monitoring 
   soft tissue infection C0149778 Monitoring 
   weight as C0513476 Monitoring 
   MAI pulmonary infection C0026916 Monitoring 
   swelling no C0577599 Monitoring 
   ulcers or venous stasis C0042344 Monitoring 
   apneic C0003578 Monitoring 
   burst C0439818 Monitoring 
   Chronic non C0342087 Monitoring 
   Flash pulmonary edema C1168329 Monitoring 
   choking on foods C0417813 Monitoring 
   pelvicaliectasis C2242514 Monitoring 
   talking to friends C3161682 Monitoring 
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   but not as C4036134 Monitoring 
   
Oral herpes simplex 
infection C0341012 Monitoring 
   Allergic asthma C0155877 Monitoring 
   burden C2828008 Monitoring 
   chronic diffuse C0343880 Monitoring 
   intracerebral hematoma C0021870 Monitoring 
   tears as C1385905 Monitoring 
   interstitial pneumonia C0206061 Monitoring 
   Panic disorder C0030319 Monitoring 
   radicular lumbar C1405960 Monitoring 
   hip osteoarthritis C0029410 Monitoring 
   HDV C0011220 Monitoring 
   resolution C0300132 Monitoring 
   splenomegaly C0038002 Monitoring 
   20lb C3364556 Monitoring 
   labia majora C0227760 Monitoring 
   ductal epithelium C1512086 Monitoring 
   aortic atherosclerosis C0155733 Monitoring 
   vaginal itching C0042256 Monitoring 
   role in preventing C0814407 Monitoring 
   skin wound not healed C2039198 Monitoring 
   thyroid nodules C0040137 Monitoring 
   papilloma virus infection C0343641 Monitoring 
   lose weight after weight C2219985 Monitoring 
   praised C0557963 Monitoring 
   chronic cervical C0269062 Monitoring 
   Prostate hypertrophy C1739363 Monitoring 
   CVA tenderness C0235634 Monitoring 
   just C0442728 Monitoring 
   Cardiac anomaly C0018798 Monitoring 
   raise red C0427458 Monitoring 
   blastic C1378512 Monitoring 
   calcium levels in the blood C0729820 Monitoring 
   mucosal thickening C3686502 Monitoring 
   dry skin C0151908 Monitoring 
   Mono C0021345 Monitoring 
   radiopaque C2930749 Monitoring 
   stone passage C2035063 Monitoring 
   knee discomfort C0745538 Monitoring 
   as these C1956388 Monitoring 
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   Hemangioma of liver C0238246 Monitoring 
   bladder infections C0600041 Monitoring 
   chronic healed C2368046 Monitoring 
   hepatic metastasis C0494165 Monitoring 
   other viral infection C0343538 Monitoring 
   abuse related C1550478 Monitoring 
   diff weight bearing C0563568 Monitoring 
   Urate Nephropathy C2955673 Monitoring 
   Lumbar disc disease C0221775 Monitoring 
   
Thrombosis of 
arteriovenous fistula C0340909 Monitoring 
   gastric variceal bleed C0267209 Monitoring 
   
viral upper respiratory 
infection C0009443 Monitoring 
   skin thickening C0241165 Monitoring 
   dark red blood C2129029 Monitoring 
   opf C0658189 Monitoring 
   abominal C3391308 Monitoring 
   healed scars C0008767 Monitoring 
   airway infection C4228019 Monitoring 
   infection of the larynx C1400586 Monitoring 
   infected site C0578491 Monitoring 
   digital rectal C1384593 Monitoring 
   Osteoarthritis of hands C0263746 Monitoring 
   hematoma in the groin C0585249 Monitoring 
   papilledema or retinal C0339604 Monitoring 
   Crohn disease C0010346 Monitoring 
   
Osteomyelitis versus 
abscess C0264053 Monitoring 
   after vascular C1392823 Monitoring 
   lobar pneumonia or C1535472 Monitoring 
   bleeding skin C0574741 Monitoring 
   fungal lung infection C0151874 Monitoring 
   chronic control C1171182 Monitoring 
   shadowing C0332554 Monitoring 
   sludge C0750852 Monitoring 
   CBD C0006863 Monitoring 
   better C0332272 Monitoring 
   
responsive pulmonary 
process C0871261 Monitoring 
   after weight gain C2126003 Monitoring 
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   some vascular disease C3549710 Monitoring 
   Acinetobacter infection C0001139 Monitoring 
   refresh tears C2962648 Monitoring 
   hemmorhoids C0723400 Monitoring 
   chronic hemorrhoids C0744804 Monitoring 
   chronic wound healing C3879688 Monitoring 
   arachnoid cyst C0078981 Monitoring 
   testicular C0205070 Monitoring 
   serous serous drainage C1822295 Monitoring 
   BKA C1426785 Monitoring 
   chronic pericardial effusion C1850039 Monitoring 
   spread of disease C3697425 Monitoring 
   chronic throat C0155825 Monitoring 
   under the tongue C1636188 Monitoring 
   urination after C1821649 Monitoring 
   chronic arm C0158382 Monitoring 
   chronic D Diff infection C2074980 Monitoring 
   scleroderma GI disease C0011644 Monitoring 
   abscess in the stoma C1142179 Monitoring 
   sclerodactyly C0150988 Monitoring 
   
symptomatic vascular 
disease C2936329 Monitoring 
   Pill esophagitis C0267099 Monitoring 
   laceration C0043246 Monitoring 
   tinea cruris C1384589 Monitoring 
   Parastomal hernia C0341539 Monitoring 
   tinea pedis infection C0744135 Monitoring 
   chronic feet C1276133 Monitoring 
   bloating or C0946092 Monitoring 
   RUQ C0439734 Monitoring 
   Chronic eczema C0263222 Monitoring 
   
eczema versus fungal 
infection C1322253 Monitoring 
   hemorrhoid C0019112 Monitoring 
   dystonic movements C0013421 Monitoring 
   Sulfa caused vaginal C1591349 Monitoring 
   went away C2169390 Monitoring 
   in the skin C0262988 Monitoring 
   wants weight C0421273 Monitoring 
   bacteruria C0262380 Monitoring 
   Sigmoid volvulus C0149863 Monitoring 
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   infection or stasis C1407921 Monitoring 
   tooth loss C0080233 Monitoring 
   related blood C1266852 Monitoring 
   infection status C0517627 Monitoring 
   solid C0205208 Monitoring 
   stable chest pains C0742297 Monitoring 
   risk of prostate cancer C1954276 Monitoring 
   inflammation warmth C2087495 Monitoring 
   maceration of the skin C0558143 Monitoring 
   
Chronic idiopathic 
constipation C0267509 Monitoring 
   
Retroperitoneal 
lymphadenopathy C0748390 Monitoring 
   refused C1705116 Monitoring 
   NASH induced liver C3869479 Monitoring 
   coughing up yellow sputum C2126216 Monitoring 
   Gastric diverticulum C0038355 Monitoring 
   containing inguinal hernia C3809861 Monitoring 
   chronic Lyme disease C2063079 Monitoring 
   was C1421478 Monitoring 
   recurrent epistaxis C3809715 Monitoring 
   renal findings C0426703 Monitoring 
   chondrocalcinosis C0553730 Monitoring 
   
Abdominal aortic 
atherosclerosis C0398356 Monitoring 
   chronic stomach C0341172 Monitoring 
   stasis edema C1135352 Monitoring 
   stool blood C1321898 Monitoring 
   line complications C1275741 Monitoring 
   flush skin C0016382 Monitoring 
   for liver disease C2584636 Monitoring 
   arterial inflow C0449613 Monitoring 
   about these C3898970 Monitoring 
   Chronic plaque C0406317 Monitoring 
   bloating after dairy food C2198704 Monitoring 
   stone not C0940852 Monitoring 
   stone nephrolithiasis C1578933 Monitoring 
   levels in the blood C0428249 Monitoring 
   chronic scar C3258142 Monitoring 
   Wound cellulitis C0406832 Monitoring 
   Moyamoya C0026654 Monitoring 
172 
 
   
intracranial vascular 
disease C0007820 Monitoring 
   blood in the stool C3843741 Monitoring 
   a weight C0745275 Monitoring 
   blanching of skin C0277941 Monitoring 
   photosensitivity of the skin C0349506 Monitoring 
   serious C0205404 Monitoring 
   chronic liver injury C2242584 Monitoring 
   do still C3173472 Monitoring 
   liver damage C0151763 Monitoring 
   weight loss management C0884421 Monitoring 
   Unspecified hernia repair C0198552 Monitoring 
   undergone C3829754 Monitoring 
   subcutaneous abscess C0241266 Monitoring 
   Basal cell skin cancer C0751676 Monitoring 
   profound weight loss C1848641 Monitoring 
   compartment syndrome C0009492 Monitoring 
   increased vascular C0232341 Monitoring 
   remaining C1527428 Monitoring 
   or supporting C0409089 Monitoring 
   microlithiasis C0333027 Monitoring 
   hereditary pancreatitis C0238339 Monitoring 
   groin C0018246 Monitoring 
   Cryptococcal infection C0740272 Monitoring 
   Wound care as C0811367 Monitoring 
   tracheoesophageal fistula C0040588 Monitoring 
   Scrotal cellulitis C0268927 Monitoring 
   chronic neutropenia C0746882 Monitoring 
   risk for liver disease C1281905 Monitoring 
   bridging fibrosis C0334160 Monitoring 
   small vessel disease C2733158 Monitoring 
   cauda equina C0007458 Monitoring 
   
meningitis or systemic 
infection C0729584 Monitoring 
   prandial C0376674 Monitoring 
   sternal wound infection C2729214 Monitoring 
   
Anticardiolipin antibody 
syndrome C1608418 Monitoring 
   within the skin C2234621 Monitoring 
   Blackout spell C0312422 Monitoring 
   Antral polyps C0264239 Monitoring 
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   ulceration not C1720140 Monitoring 
   spigelian hernia C0392508 Monitoring 
   Infected finger C0555974 Monitoring 
   air C0001861 Monitoring 
   mantle cell lymphoma C0334634 Monitoring 
   vascular abnormalities C0241657 Monitoring 
   
chronic sinopulmonary 
infection C1846546 Monitoring 
   vitiligo C0042900 Monitoring 
   as it would be C3641844 Monitoring 
   chronic pedal edema C0747319 Monitoring 
   OA knee C0409959 Monitoring 
   airway disease C0699949 Monitoring 
   Drainage Of Skin Abscess C0370367 Monitoring 
   cystic liver disease C0158683 Monitoring 
   infection or purulent C1535040 Monitoring 
   indwelling C0439848 Monitoring 
   muscle damage C0410158 Monitoring 
   Submental island flap C0440834 Monitoring 
   infection after C0393390 Monitoring 
   thing C1551338 Monitoring 
   before C0332152 Monitoring 
   clammy skin C0392162 Monitoring 
   chronic epistaxis C1739141 Monitoring 
   vascular event C0038454 Monitoring 
   vomiting or weight loss C2169616 Monitoring 
   Acute respiratory infection C0339901 Monitoring 
   chronic pericarditis C0265143 Monitoring 
   
pseudomonas urinary tract 
infections C0577710 Monitoring 
   cerebral vascular C0007787 Monitoring 
   Amyloid C0002716 Monitoring 
   remnant C3272697 Monitoring 
   adjuvant radiation therapy C1706721 Monitoring 
   fun C2700434 Monitoring 
   
Subcapsular renal 
hematoma C3897450 Monitoring 
   fill C1708059 Monitoring 
   groin wound C1402898 Monitoring 
   choroid plexus papilloma C0205770 Monitoring 
   inflammatory arthritis C0003864 Monitoring 
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   Not falls C0575123 Monitoring 
   
under fluoroscopic 
guidance C2321778 Monitoring 
   rectal exam C0199900 Monitoring 
   Moisturize C0868994 Monitoring 
   hypervolemia C0546817 Monitoring 
   unexpected C4055646 Monitoring 
   colonic lipoma C0940607 Monitoring 
   or septic arthritis C1692886 Monitoring 
   gap C0061928 Monitoring 
   gained much weight C3175834 Monitoring 
   breath away C3154057 Monitoring 
   stone retinal C0154854 Monitoring 
   deposition of crystals C0442844 Monitoring 
   chronic angle C0154947 Monitoring 
   Not taking oxycodone as C3898453 Monitoring 
   tubular C0332208 Monitoring 
   compression C0728907 Monitoring 
   dyspnea C0013404 Monitoring 
   salivary gland infection C0392318 Monitoring 
   polyp in the cecum C0742570 Monitoring 
   relief of bladder C0401615 Monitoring 
   found C0150312 Monitoring 
   massive blood loss C0333279 Monitoring 
   
chronic shoulder 
dislocation C1403308 Monitoring 
   Chronic right vision loss C3275688 Monitoring 
   comfort C1331418 Monitoring 
   rectal tumor C0034885 Monitoring 
   staghorn calculus C0333014 Monitoring 
   exertion or chest C0232288 Monitoring 
   vascular dementia C0011269 Monitoring 
   chronic fatigue C0518656 Monitoring 
   nylon in the skin C0856559 Monitoring 
   wound necrosis C1096115 Monitoring 
   fat or weight C0521974 Monitoring 
   lumbosacral radiculopathy C0154738 Monitoring 
   Prostate tenderness C0240813 Monitoring 
   papillary C0205312 Monitoring 
   Discolored skin C0151907 Monitoring 
   instability C1444783 Monitoring 
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   urinary stones C0042018 Monitoring 
   Biliary stent C0183512 Monitoring 
   fibroids or endometrial C1536487 Monitoring 
   Thyromegaly C0018021 Monitoring 
   left axillary abscess C4280975 Monitoring 
   
Stocking distribution 
sensory loss C0277852 Monitoring 
   polyarticular C0240789 Monitoring 
   appendicitis C0003615 Monitoring 
   bladder spasm C0426390 Monitoring 
   vental incisional hernia C1532116 Monitoring 
   always C1549493 Monitoring 
   nocturia C0028734 Monitoring 
   Chronic dysuria C0743334 Monitoring 
   colloid nodule C0342117 Monitoring 
   purpuric skin rash C0151882 Monitoring 
   swelling in stump C0740962 Monitoring 
   bowel within the hernia C1394743 Monitoring 
   ulcerations dry skin C3494913 Monitoring 
   without parastomal hernia C3264414 Monitoring 
   retinal detachment C0035305 Monitoring 
   
management of kidney 
disease C1515005 Monitoring 
   ulcer bleed C0333291 Monitoring 
   Pharyngocutaneous fistula C0396009 Monitoring 
   urination difficulty C0241705 Monitoring 
   as C0162635 Monitoring 
   osler nodes C0240608 Monitoring 
   inflammation in the C0004690 Monitoring 
   raise uric acid C0857189 Monitoring 
   retroperitoneal abscess C0237962 Monitoring 
   graft thrombosis C0919939 Monitoring 
   pelvic infections C0030790 Monitoring 
   vulvar infection C1400809 Monitoring 
   reducible central hernia C1265757 Monitoring 
   coughing or chest C0876765 Monitoring 
   chronic urate nephropathy C0268769 Monitoring 
   swelling tenderness C2055675 Monitoring 
   obstructive coronary artery C0546319 Monitoring 
   blood or blood C0371802 Monitoring 
   infected vascular graft C0340896 Monitoring 
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   pacing C0562458 Monitoring 
   chronic infundibular C0395990 Monitoring 
   nocardia infection C0028242 Monitoring 
   chronic effusions C0031144 Monitoring 
   gastric perforation C0235884 Monitoring 
   
drainage of retroperitoneal 
abscess C0342976 Monitoring 
   Peritoneal abscess C0267756 Monitoring 
   Wound related C2597978 Monitoring 
   infected dialysis C1400574 Monitoring 
   stump infection C0392042 Monitoring 
   bowel ischemia C2004435 Monitoring 
   Sickle Cell Trait C0037054 Monitoring 
   focal atelectasis C0264496 Monitoring 
   Splenic abscess C0272412 Monitoring 
   yellow nasal C2203645 Monitoring 
   debris C0440266 Monitoring 
   infection being C1855452 Monitoring 
   inflammation or erosions C0333357 Monitoring 
   any C1552551 Monitoring 
   dermoid cyst C0011649 Monitoring 
   bladded C0156265 Monitoring 
   swelling rectal C0848365 Monitoring 
   stool as C0423599 Monitoring 
   inflammation without C0155354 Monitoring 
   infection given ascites C0919899 Monitoring 
   Esophageal erosions C0341117 Monitoring 
   Abscess drain C0333371 Monitoring 
   intra abdominal abscess C0243001 Monitoring 
   anastomotic leak C0919691 Monitoring 
   RLQ abd abscess C0750795 Monitoring 
   Neck strain C0262573 Monitoring 
   gal C1704676 Monitoring 
   pseudoaneurysm C1510412 Monitoring 
   infected AV fistula C0741319 Monitoring 
   
cervical or inguinal 
lymphadenopathy C1850027 Monitoring 
   phrenic nerve palsy C1442879 Monitoring 
   Behcet disease C0004943 Monitoring 
   slurred speech C0234518 Monitoring 
   stones calcium C0797811 Monitoring 
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   stones within the bladder C0005683 Monitoring 
   wound abscess C0406105 Monitoring 
   infected renal cyst C0403383 Monitoring 
   suspect infection C0744970 Monitoring 
   Mycoplasma infection C0026936 Monitoring 
   palpitation or chest C0030252 Monitoring 
   risky C0871885 Monitoring 
   pelvic lymphadenopathy C1264124 Monitoring 
   
Locally advanced prostate 
cancer C0677984 Monitoring 
   Aortobiiliac C0918078 Monitoring 
   metastatic disease C2939420 Monitoring 
   wound of skin debridement C0191342 Monitoring 
   controlling weight C0920298 Monitoring 
   hemorrhoid bleeding C0265031 Monitoring 
   hepatic ascites C0401037 Monitoring 
   kinking within the catheter C3665945 Monitoring 
   humoral rejection C1608974 Monitoring 
   Nail fungal infection C0040261 Monitoring 
   cellulitis infections C0743758 Monitoring 
   
intellectual developmental 
delay C1408678 Monitoring 
   
Risk for hepatocellular 
carcinoma C1862761 Monitoring 
   penile C0030851 Monitoring 
   in liver disease C0393841 Monitoring 
   bleeding after C0156406 Monitoring 
   interstitium C2328510 Monitoring 
   white C0043157 Monitoring 
   basal ganglia C0004781 Monitoring 
   ankle wound C1396654 Monitoring 
   pulmonary granulomas C0235557 Monitoring 
   constitutional symptoms C0009812 Monitoring 
   Prostate Weight C2142671 Monitoring 
   chronic smoker C0848477 Monitoring 
   or choking C0546947 Monitoring 
   yellow nodule under skin C2126329 Monitoring 
   
risk for cardiovascular 
events C1273410 Monitoring 
   uric acid levels in the blood C0373739 Monitoring 
   Dyspepsia C0013395 Monitoring 
178 
 
   Unprovoked C0541789 Monitoring 
   
low likelihood coronary 
artery disease C3463819 Monitoring 
   Carotid atherosclerosis C0577631 Monitoring 
   Chronic plantar fasciitis C1136148 Monitoring 
   inguinal hernia repair mesh C0405615 Monitoring 
   chronic malnutrition C0746367 Monitoring 
   Ewing sarcoma C0553580 Monitoring 
   biventricular heart C0685095 Monitoring 
   head fractures C0744604 Monitoring 
   stone attacks C3267184 Monitoring 
   
chronic recurrent 
pancreatitis C2074913 Monitoring 
   subcutaneous nodules C0151811 Monitoring 
   foot infection C0555973 Monitoring 
   Cystoid macular edema C0024440 Monitoring 
   wound discharge C0406834 Monitoring 
   
chronic degenerative disk 
disease C0685106 Monitoring 
   probe C0182400 Monitoring 
   chronic heart C0175708 Monitoring 
   chronic relapsing C0278787 Monitoring 
   defers C0205421 Monitoring 
   soda C0683086 Monitoring 
   VRE urinary tract infection C2368066 Monitoring 
   Cardiac arrhythmias C0003811 Monitoring 
   chronic knee arthralgias C0741218 Monitoring 
   exit site C0449669 Monitoring 
   Focal calcifications C1265880 Monitoring 
   chronic coronary C1533195 Monitoring 
   Chronic leukopenia C0745710 Monitoring 
   Anemia of renal disease C0472713 Monitoring 
   vomiting or C1822400 Monitoring 
   discuss weight C0419897 Monitoring 
   infection or abscess C1542840 Monitoring 
   rectus sheath hematoma C0238408 Monitoring 
   or epidural abscess C2875032 Monitoring 
   chronic mouth C0281800 Monitoring 
   edema or chest C2732581 Monitoring 
   bowel volvulus C0042961 Monitoring 
   requiring skin graft C0748750 Monitoring 
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   Acinetobacter Pneumonia C2063075 Monitoring 
   subclavian vein thrombosis C0749087 Monitoring 
   acute pancreatitis C0001339 Monitoring 
   Hemorrhagic renal cyst C1168323 Monitoring 
   Integrity C0443238 Monitoring 
   facial tic C0338467 Monitoring 
   IgE C0020846 Monitoring 
   C infections C0010414 Monitoring 
   continued loss C2749246 Monitoring 
   intertriginous C0205268 Monitoring 
   headaches or C0239885 Monitoring 
   gastric dilatation C0038353 Monitoring 
   swelling not C2184237 Monitoring 
   
Metastatic gastric 
adenocarcinoma C3160888 Monitoring 
   chronic dilatation C1265762 Monitoring 
   outpt C0551586 Monitoring 
   Congenital vascular disease C1275966 Monitoring 
   flaxseed oil C0023754 Monitoring 
   Psuedomonas C3460694 Monitoring 
   breast swelling C0006152 Monitoring 
   pneumocystis pneumonia C1535939 Monitoring 
   chronic pancytopenia C0747203 Monitoring 
   
incarcerated inguinal 
hernia C0740375 Monitoring 
   fingernail fungal infection C0744036 Monitoring 
   compression fracture C0521169 Monitoring 
   spicy food intake C0559575 Monitoring 
   stiffness in any joints C0162298 Monitoring 
   Subaortic stenosis C0340375 Monitoring 
   
Unprotected sexual 
intercourse C1578545 Monitoring 
   bread intake C0556171 Monitoring 
   Sessile polyp C0522621 Monitoring 
   shooting pains C0278146 Monitoring 
   Peripheral edema C0085649 Monitoring 
   pulmonary infiltrates C0235896 Monitoring 
   raise arm C0231810 Monitoring 
   tendon tears C0850773 Monitoring 
   or vascular lesion C0423793 Monitoring 
   atrophic skin C0151514 Monitoring 
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   chronic urethritis C0150001 Monitoring 
   Kaposi sarcoma C0036220 Monitoring 
   Hydrops of gallbladder C0152445 Monitoring 
   
Nontraumatic subdural 
hemorrhage C0265080 Monitoring 
   chronic graft C0301948 Monitoring 
   Chronic eustachian tube C0155430 Monitoring 
   crohns colitis C0156147 Monitoring 
   chronic active colitis C2826588 Monitoring 
   misunderstood C4061919 Monitoring 
   arthritic pains C0857177 Monitoring 
   chronic systemic C1290611 Monitoring 
   chronic suprapubic C0749927 Monitoring 
   chronic flank C2074632 Monitoring 
   bladder irritation C2945586 Monitoring 
   healed fractures C0162542 Monitoring 
   
hydronephrosis or renal 
calculus C1391794 Monitoring 
 
Medication Other 
C0020740 Ibuprofen Intervening joint C0022417 Intervening 
C0002144 allopurinol Intervening renal C0022646 Intervening 
C0699241 Nitrostat Intervening vitamin C0042890 Intervening 
C0025810 Methylphenidate Intervening Hepatitis C C0019196 Intervening 
C0056732 Cyclobenzaprine Intervening chest C0817096 Intervening 
C0024002 Lorazepam Intervening sildenafil C0529793 Intervening 
C0002658 Amphetamines Intervening Neosporin C0068536 Intervening 
C0040207 TICLOPIDINE Intervening Torsemide C0076840 Intervening 
C0020404 hydroxyzine Intervening Vitamin C C0003968 Intervening 
C0033405 promethazine Intervening adjuvant C1522673 Intervening 
C0146011 tizanidine Intervening claritin C0701055 Intervening 
C0053799 Bisoprolol Intervening macrobid C0591750 Intervening 
C0025242 Memantine Intervening blood uric acid C0373739 Intervening 
C0010980 Dapsone Intervening attack of gout C2712871 Intervening 
C0730920 Thymoglobulin Intervening Ventolin C0033744 Intervening 
C0663448 Viagra Intervening groin C0018246 Intervening 
C0008783 Cimetidine Intervening vitamin D C0042866 Intervening 
C0053229 Benzonatate Intervening Multivit C0301532 Intervening 
C0124498 Kayexalate Intervening stores C1698986 Intervening 
C0025376 Meperidine Intervening David C3809991 Intervening 
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C0699177 Plaquenil Intervening blood C0005767 Intervening 
C0033429 Propafenone Intervening Flecainide C0016229 Intervening 
C0021246 indomethacin Intervening insomnia C0917801 Intervening 
C0015772 Felodipine Intervening hep C C2148557 Intervening 
C0033228 Fenofibrate Intervening 
evaluation of 
chest C0742295 Intervening 
C1170736 zetia Intervening Betamethasone C0005308 Intervening 
C1579314 DtaP Intervening Accolate C0526502 Intervening 
C0053091 benazepril Intervening aleve C0718343 Intervening 
C0720193 Enbrel Intervening renal toxins C0597372 Intervening 
C0072973 Ramipril Intervening 
vitamin D 
levels C0428586 Intervening 
C0012522 diphenhydramine Intervening blastomycosis C0005716 Intervening 
C0064636 lamotrigine Intervening renal c C0439042 Intervening 
C0069751 oxcarbazepine Intervening 
Hypophosphate
mia C0085682 Intervening 
C0033209 probenecid Intervening twice C1948050 Intervening 
C0025872 metronidazole Intervening Synthroid C0728762 Intervening 
C0526512 Synercid Intervening Atarax C0684229 Intervening 
C0279284 Doxil Intervening stomach C0038351 Intervening 
C0034259 Pyridium Intervening toxins C0040549 Intervening 
C1170407 mucinex Intervening insipidus C0011848 Intervening 
C0699770 Proventil Intervening 
heart and 
kidney C0155602 Intervening 
C1570232 Lyrica Intervening 
vitamin K 
levels C0443768 Intervening 
C1636686 byetta Intervening 
Hepatitis C 
liver C1391577 Intervening 
C0162723 zyrtec Intervening melatonin C0025219 Intervening 
C0002403 amantadine Intervening assays C1510438 Intervening 
C0596004 Hyoscyamine Intervening sickle C C0019034 Intervening 
C0087119 Elavil Intervening 
FOSAMPREN
AVIR C1176315 Intervening 
C0595425 Zanaflex Intervening pian C0043388 Intervening 
C1505021 Cymbalta Intervening Pramoxine C0071810 Intervening 
C0030049 oxycodone Intervening Psycho C0871175 Intervening 
C0700003 Lopid Intervening Gallstones C0242216 Intervening 
C0032143 TPA Intervening vitamin B C0042849 Intervening 
C1996201 Actonel Intervening intertrigo C0021807 Intervening 
C0071097 pioglitazone Intervening APAP C0000970 Intervening 
C0721436 Lotensin Intervening divalproex C0042291 Intervening 
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C0040610 Tramadol Intervening blood levels C0151539 Intervening 
C0004745 Barbiturates Intervening danazol C0010961 Intervening 
C2137913 
joint 
corticosteroid Intervening lupus C0024131 Intervening 
C0592245 valtrex Intervening joint discomfort C3544124 Intervening 
C0593507 advil Intervening joint dis C0022408 Intervening 
C0700727 Sudafed Intervening repeat C0205341 Intervening 
C0001617 corticosteroid Intervening stomach upset C0235309 Intervening 
C1174784 Ranexa Intervening Robert C0331964 Intervening 
C1170019 Abilify Intervening Hep C RNA C0973340 Intervening 
C0068334 Nabumetone Intervening PMR C0032533 Intervening 
C0536495 Moxifloxacin Intervening joint pains C0003862 Intervening 
C0728767 Marinol Intervening upset C3887804 Intervening 
C0700517 Keflex Intervening attack C0004063 Intervening 
C0876139 Protonix Intervening aphonia C0003564 Intervening 
C0033148 Primidone Intervening hemostat C0019120 Intervening 
C0591237 Casodex Intervening joint c C0408229 Intervening 
C0876226 Zyvox Intervening LVAD C0181598 Intervening 
C0663241 Linezolid Intervening gloves C0441051 Intervening 
C0249529 febuxostat Intervening backup C1552560 Intervening 
C0936278 vistaril Intervening Tracy C3391642 Intervening 
C0010137 Cortisone Intervening sarcoid C0036202 Intervening 
C0687812 
allopurinol 
100mg Intervening treatement C0741107 Intervening 
C0012093 Dicloxacillin Intervening propylthiouracil C0033511 Intervening 
C0127096 Maxzide Intervening    
C0009316 COLISTIN Intervening    
C0305648 Citrucel Intervening    
C0216784 Valsartan Intervening    
C0249458 valACYclovir Intervening    
C0350186 TNG Intervening    
C0008294 Chlorthalidone Intervening    
C1528494 truvada Intervening    
C0066685 Moexipril Intervening    
C0592157 Tagamet Intervening    
C0701009 bumex Intervening    
C0064238 kaopectate Intervening    
C0015620 famotidine Intervening    
C0875968 Avelox Intervening    
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C0701281 Biaxin Intervening    
C0592168 Tenormin Intervening    
C0002645 amox Intervening    
C0700187 macrodantin Intervening    
C0700016 Mysoline Intervening    
C0075870 tazobactam Intervening    
C0051696 amlodipine Intervening    
C0678162 pulmicort Intervening    
C0723893 Tricor Intervening    
C0013881 Librium Intervening    
C1527845 Vytorin Intervening    
C0876218 Xopenex Intervening    
C0024027 lovastatin Intervening    
C0012125 Dicyclomine Intervening    
C0069177 NyQuil Intervening    
C0594040 Nasacort Intervening    
C0022209 Isoniazid Intervening    
C0034261 pyridostigmine Intervening    
C0730987 Exelon Intervening    
C0282386 levofloxacin Intervening    
C1110594 Allegra Intervening    
C0380393 ziprasidone Intervening    
C0878174 Arimidex Intervening    
C0075632 SUMAtriptan Intervening    
C0053526 Bethanechol Intervening    
C0013085 Doxepin Intervening    
C0700023 bentyl Intervening    
C0038425 
STREPTOMYCI
N Intervening    
C0593342 Requip Intervening    
C0719197 ceftin Intervening    
C0016365 fluoxetine Intervening    
C0591139 Bactrim Intervening    
C1122245 benicar Intervening    
C0876060 Keppra Intervening    
C1330412 Namenda Intervening    
C0707987 Claritin 10mg Intervening    
C0027358 Naloxone Intervening    
C0060282 FeSO4 Intervening    
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C1702177 Januvia Intervening    
C0720403 Feosol Intervening    
C0700798 indocin Intervening    
C0007555 cefotetan Intervening    
C0699932 Senokot Intervening    
C0017696 Glucan Intervening    
C0878061 Altace Intervening    
C0111046 creon Intervening    
C0022860 labetalol Intervening    
C0014695 Ergocalciferol Intervening    
C0040805 Trazodone Intervening    
C0290795 Adderall Intervening    
C0031379 Phenazopyridine Intervening    
C0723743 Tiazac Intervening    
C0666743 infliximab Intervening    
C0012091 diclofenac Intervening    
C1174767 Fosrenol Intervening    
C0061851 ondansetron Intervening    
C0876768 Vioxx Intervening    
C0483244 anusol Intervening    
C0040165 levothyroxine Intervening    
C0721044 Imitrex Intervening    
C0004482 azathioprine Intervening    
C0718244 Actigall Intervening    
C0733842 Stelazine Intervening    
C1170286 Forteo Intervening    
C0722336 Oscal Intervening    
C1170079 Avodart Intervening    
C1174734 Uroxatral Intervening    
C0700899 benadryl Intervening    
C0064113 itraconazole Intervening    
C0722138 asprin Intervening    
C0699439 Nizoral Intervening    
C0210355 Arthrotec Intervening    
C0003289 antidepressants Intervening    
C0069805 oxybutynin Intervening    
C0701348 Femara Intervening    
C0698978 Plaquenil 200mg Intervening    
C0042553 Versed Intervening    
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C0244821 Ropinirole Intervening    
C0699547 Azulfidine Intervening    
C0019139 LMWH Intervening    
C0253563 eptifibatide Intervening    
C0011812 
Dextroamphetam
ine Intervening    
C1170699 Ultracet Intervening    
C0723012 remicade Intervening    
C0016277 Fluconazole Intervening    
C0939692 DuoNebs Intervening    
C0028833 Octreotide Intervening    
C0165921 Entacapone Intervening    
C0078844 Zonisamide Intervening    
C0292855 zestoretic Intervening    
C0720318 evista Intervening    
C0674427 Sustiva Intervening    
C0700524 amoxil Intervening    
C0974285 
amlodipine 
10mg Intervening    
C0030863 Pentamidine Intervening    
C0070895 foscarnet Intervening    
C1098320 Olmesartan Intervening    
C1631198 Florastor Intervening    
C0014563 EPINEPHrine Intervening    
C0875967 Avandia Intervening    
C0699065 Thorazine Intervening    
C0939530 Welchol Intervening    
C0033798 
PSEUDOEPHE
DRINE Intervening    
C0718644 arava Intervening    
C0965129 Rosuvastatin Intervening    
C0246689 Repaglinide Intervening    
C0289313 Rosiglitazone Intervening    
C0701094 Darvon Intervening    
C0876064 lantus Intervening    
C0057144 daptomycin Intervening    
C0875952 Aciphex Intervening    
C0700017 Naprosyn Intervening    
C0073374 Rifaximin Intervening    
C0009279 colestipol Intervening    
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C0003138 Antacid Intervening    
C0876173 tamiflu Intervening    
C0687813 
Allopurinol 
300mg Intervening    
C0591292 Corgard Intervening    
C1101609 viread Intervening    
C0004599 bacitracin Intervening    
C0008273 Chlorothiazide Intervening    
C1314782 Levemir Intervening    
C0538927 Celecoxib Intervening    
C0591275 Cogentin Intervening    
C0728743 Cefzil Intervening    
C0123931 irinotecan Intervening    
C0085795 amphotericin Intervening    
C0069717 oxaliplatin Intervening    
C0728751 Betapace Intervening    
C0981097 vitamin C 500mg Intervening    
C0721298 lamisil Intervening    
C0690835 Torsemide 10mg Intervening    
C1698963 Sutent Intervening    
C0042397 vasopressors Intervening    
C0070384 Percodan Intervening    
C0006462 busPIRone Intervening    
C0678117 Sandostatin Intervening    
C1602236 ferrex Intervening    
C0701331 Relafen Intervening    
C0595301 Avapro Intervening    
C0939412 Novolog Intervening    
C0014964 Ethambutol Intervening    
C0722882 Provigil Intervening    
C3215523 vitamin D pill Intervening    
C1418193 OTC Intervening    
C1145759 atazanavir Intervening    
C1516119 Sorafenib Intervening    
C0702216 Soma Intervening    
C1579761 Lunesta Intervening    
C0699926 Robaxin Intervening    
C0732355 Rituxan Intervening    
C0594492 Nasonex Intervening    
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C0689174 Ibuprofen 600mg Intervening    
C0718711 Atacand Intervening    
C0290883 Anastrozole Intervening    
C1724016 Atripla Intervening    
C0689206 
indomethacin 
50mg Intervening    
C0020336 
hydroxychloroqu
ine Intervening    
C1450020 levothyrox Intervening    
C0733418 Ticlid Intervening    
C0037688 Sorbitol Intervening    
C0700712 Micronase Intervening    
C0017628 glyBURIDE Intervening    
C1174890 levitra Intervening    
C0171023 Olanzapine Intervening    
C0795227 
allopurinol 
500mg Intervening    
C0003360 antihistamine Intervening    
C0678171 Pentasa Intervening    
C0036557 sedatives Intervening    
C0026078 Midodrine Intervening    
C0591055 Aldomet Intervening    
C0688870 flecainide 100mg Intervening    
C1577528 Nifedical Intervening    
C0699595 Septra Intervening    
C1260298 tigecycline Intervening    
C0591224 Capoten Intervening    
C0701890 Duricef Intervening    
C0762662 Rofecoxib Intervening    
C0001367 Acyclovir Intervening    
C0699279 imuran Intervening    
C0007713 Cepacol Intervening    
C0936148 Posaconazole Intervening    
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